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Summary 
Recently, it was shown that the NS-segment of the avian influenza virus strain 
A/Goose/Guangdong/1/1996 (GD, H5N1) promotes replication and increases 
pathogenicity of the strictly avian strain A/FPV/Rostock/34 (FPV, H7N1) in 
mammalian cells and mice, whereas the NS-segment of A/Mallard/NL/12/2000 (MA, 
H7N3) impaired FPV replication in mammalian cells. The NS1 proteins of GD and Ma 
differ only by eight amino acids. Nevertheless, the critical genetic differences were 
not yet identified. In this report, I demonstrate that the specific amino acid changes 
D74N and/or P3S+R41K+D74N in the NS1-MA protein are sufficient to allow 
mammalian adaption of avian influenza viruses. They lead to enhanced virus 
propagation in mammalian cells and increased plaque size, suggesting shorter 
replication cycles. On a molecular level, I show the importance of these specific 
residues for strongly enhanced mRNA production as well as viral protein production 
in mammalian cells. At the same time this adaptive changes are not disadvantageous 
in avian cells. My study suggests that the D74N and/or P3S+R41K+D74N 
substitutions are involved in the temperature adaptation of the polymerase of avian 
influenza virus from birds to mammals. They also confer the ability to the otherwise 
strictly avian influenza virus to replicate in mice and cause disease. Global gene 
expression of mammalian A549 cells upon infection with FPV harboring NS-MA 
(FPV-NSMA) or with  FPV harboring NS-MA mutants (FPV-NSMA_D74N and FPV-NSMA_ 
P3S+R41K+D74N) viruses are qualitatively similar in the activation of biological host 
inflammatory response including type I interferon (IFN) and chemokine signaling, 
However, in comparison to FPV-NSMA virus infected cells, the mutants NS1-MAD74N 
and/or NS1-MAP3S+R41K+D74N elicit a quantitatively weaker host inflammatory response 
of type I interferon (IFN) and pro-inflammatory cytokine/chemokine response. This 
points to a reduced innate immune response, which is correlated with increased viral 
replication competence. Together, these adaptive mutations in the NS1 protein seem 
to allow to establish successful infections in mammalian cells. 
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Zusammenfassung 
Vor kurzem konnten wir zeigen, dass das NS-Segment des Influenza-Virus 
A/Goose/Guangdong/1/1996 (GD, H5N1) sowohl die Replikation von 
A/FPV/Rostock/34 (FPV, H7N3) in Säugerzellen und Mäusen begünstigt wie auch 
dessen Pathogenität in eben diesen erhöht. Im Gegensatz dazu beeinflusst das NS-
Segment von A/Mallard/NL/12/2000  (MA, H7N3) die FPV Replikation in 
Säugerzellen negativ. Die NS1-Proteine von GD und MA unterscheiden sich in nur 
acht Aminosäuren. Jedoch wurden bisher die verantwortlichen Aminosäuren für 
diesen funktionellen Unterschied nicht identifiziert. In dieser Arbeit zeige ich, dass die 
spezifischen Aminosäure-Änderungen D74N und/oder P3S+R41K+D74N im NS1-MA 
Protein ausreichen, um eine Adaption des Virus an Säugerzellen zu ermöglichen.  So 
führen sie zu einer gesteigerten Virus-Replikation und größeren Plaques in 
Säugerzellen, was einen kürzeren Replikationszyklus nahe legt. Auf molekularer 
Ebene zeige ich, dass diese Aminosäure-Änderungen zu einer stark vermehrten 
mRNA Produktion wie auch zu einer gesteigerten Protein-Synthese in Säugerzellen 
führen, während diese Adaptionen jedoch keine Replikations-Nachteile in 
Vogelzellen zeigen. Meine Studie zeigt auch, dass die Mutationen D74N und/oder 
P3S+R41K+D74N eine Rolle in der Temperatur-Adaption der Polymerasen von 
Vogelgrippe-Viren an Säuger spielen. Außerdem ermöglichen sie originär strikt 
aviären Vogelgrippe-Viren, sich in Mäusen zu vermehren und sie erkranken zu 
lassen. Die Gesamtgenexpression in infizierten Säugerzellen ist zwischen Wildtyp 
und mutiertem Virus qualitativ ähnlich, insbesondere im Hinblick auf die fast 
identischen Immunantworten durch Typ1 Interferon (IFN) und Cytokine/Chemokine. 
Eine Infektion von FPV, welches das NS1-MA mit den Mutationen D74N und/oder 
P3S+R41K+D74N besitzt, löst aber im Vergleich zum NS1-MA Wildtyp eine 
quantitativ schwächere Immunantwort insbesondere bezogen auf Typ1 Interferon 
(IFN) und pro-entzündliche Cytokine/Chemokine aus. Dies ist ein Hinweis auf eine 
wahrscheinlich weniger starke humorale Immunantwort, die mit einer verbesserten 
Virus-Replikation einhergeht. Zusammengefasst erlauben o.g. adaptive Mutationen 
des NS1-Proteins es, aviären Influenza-Viren eine erfolgreiche Infektion in 
Säugerzellen zu etablieren. 
 
 
                                                                                                                                    List of Publications 
 
XII 
 
List of Publications 
 
1. Kanrai P, Mostafa A, Madhugiri R, Lechner M, Wilk E, Schughart K, Ziebuhr J, 
and Pleschka S. Novel residues in avian influenza virus NS1 protein enhance 
polymerase activity and virulence in mammalian host. (Submited) 
 
2. Kanrai P, Madhugiri R, Mostafa A, Lechner M, Wilhelm J, Ziebuhr J, and 
Pleschka S. Cellular transcription profile response to infection of different NS 
gene reassortant of avian influenza viruses in mammalian host.  
(Manuscript preparation) 
 
3. Mostafa A, Kanrai P, Ziebuhr J and Pleschka P. The PB1 Segment of 2009 
pandemic influenza virus confers efficient replication of different influenza 
vaccine strains in cell cultures and embryonated eggs.  
(Manuscript preparation) 
 
4. Mostafa A, Kanrai P, Petersen H, Ibrahim S, Rautenschlein S, Pleschka S. 
Efficient Generation of Recombinant Influenza A Viruses Employing a New 
Approach to Overcome the Genetic Instability of HA Segments. PLoS One. 
2015 Jan 23;10(1). 
 
5. Krumbholz A, Lange J, Sauerbrei A, Groth M, Platzer M, Kanrai P, Pleschka 
S, Scholtissek C, Büttner M, Dürrwald R, Zell R. (2014). Origin of the 
European avian-like swine influenza viruses.  J Gen Virol. 2014 Nov; 95 (Pt 
11):2372-6. 
 
6. Groth M, Lange J, Kanrai P, Pleschka S, Scholtissek C, Krumbholz A, Platzer 
M, Sauerbrei A, Zell R. 2014. The genome of an influenza virus from a pilot 
whale: relation to influenza viruses of gulls and marine mammals. Infect Genet 
Evol. 2014 Jun; 24:183-6. 
 
7. Lange J, Groth M, Kanrai P, Pleschka S, Scholtissek C, Dürrwald R, Platzer 
M, Sauerbrei A, Zell R.2014.  Circulation of classical swine influenza virus in 
Europe between the wars. Arch Virol. 2014 Jun; 159 (6):1467-73. 
 
8. Mostafa A, Kanrai P, Ziebuhr J, Pleschka S. 2013. Improved dual promotor-
driven reverse genetics system for influenza viruses. J Virol Methods. 2013 
Nov193 (2):603-10. 
 
 
                                                                                                                                                Introduction 
 
1 
 
Chapter 1 
Introduction 
1.1 Influenza A viruses 
Influenza is considered to be one of the life-threatening infectious diseases. In many 
countries seasonal influenza affects annually up to 40% of the population and 
500000 people die from it worldwide every year. Occasionally, influenza affects 20-
40% of the world’s population in a single year. Such unpredictable influenza 
“pandemics” (global increases in incidence) occurred three times in the 20th century: 
1918-1919, 1957-1958, and 1968. The 1918 ("Spanish flu") pandemic was the most 
severe, and is estimated to have clinically affected ~500 million people and caused 
>40 million deaths [1]. The pandemics of 1957 ("Asian flu") and 1968 ("Hong Kong 
flu") had much lower, but still significant mortality rates [2]. New highly-virulent 
influenza strains can arise unexpectedly to cause world-wide pandemics with 
markedly increased morbidity and mortality, such as the “avian flu” in 1997 and 
“swine flu” in 2009 [3]. 
 
Influenza viruses were first isolated as the causative agent of influenza in 1933 by 
Wilson Smith. They belong to the Orthomyxoviridae family and are divided into three 
genera, namely influenza A, B and C viruses. The genera can be distinguished by 
their Haemagglutinin (HA) and neuraminidase (NA) protein antigens [4]. Influenza A 
and B viruses can cause major outbreaks and severe disease, whereas influenza C 
viruses are mostly responsible for sporadic upper respiratory tract illness in children. 
It is believed that most mammalian influenza A viruses are derived from an avian, 
which circulates in wild aquatic birds [5]. The influenza B and C viruses diverged from 
the influenza A virus lineage several centuries ago and adapted to infect humans 
only. In contrast, influenza A viruses can infect a wide range of species (Fig. 1.1), 
including non-human primates, pigs, horses, cats, seals, whales and minks. 
 
Influenza A viruses are divided into subtypes, based on the nature of their surface 
glycoproteins, HA and NA [6]. There are 16 different HAs and nine NAs which are 
distinguishable serologically, i.e. antibodies to one virus subtype do not react with 
another. All virus subtypes appear to circulate in aquatic birds [7]. Only some of 
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these subtypes have been identified in humans, specifically the H1N1, H2N2 and 
H3N2 viruses, corresponding to the three major pandemics of the last century. 
During recent outbreaks of highly pathogenic avian influenza (HPAI), there have 
been occasional transmissions of H5N1, H7N7 and H9N2 viruses to humans [8, 9]. 
There are no influenza B virus subtypes. The B virus primarily infects humans, 
although it has also been isolated from seals [5]. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1 Host range of influenza A viruses. Wild water birds represent the natural reservoir of influenza A 
viruses, from which they can be transmitted to a wide variety of other hosts, including horses, cats, dogs, whales, 
seals, wild flying birds, chicken, pigs, and humans. Only recently, influenza A virus has also been detected in 
bats, although the origin is unclear. (Adapted from Manz et al [10]) 
 
1.1.1 Morphology and genome structure of influenza A virus 
Influenza A virus virion consists of a lipid envelope that is derived from the host 
cellular membrane during the budding process. They are generally spherical or 
elliptical in shape, ranging from approximately 80–120 nm in diameter and are 
occasionally filamentous, reaching more than 20 μm in length. However, they take on 
an irregular shape, a characteristic dependent upon the viral strain, as well as the cell 
type used for propagation [10]. The influenza A virus genome consists of eight RNA 
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segments, and encodes at least 10 well-described proteins (Fig. 1.2). Furthermore, 
there are a growing number of newly identified proteins encoded by certain strains of 
influenza A virus, including PB1-F2 [11], PB1-N4 [12], PA-X [13], N-truncated PAs 
[14], M42 [15] and NS3 [16], which are generated by various co-transcriptional or co-
translational strategies. The 10 common viral proteins are expressed in all influenza 
A viruses, and are functionally essential for a complete infection cycle in immuno-
competent hosts. The HA protein present on the surface of the virion, and recognizes 
sialic acid on the surface of host cells [17]. After binding, virus particles are 
endocytosed, and the lowering of the pH, caused by subsequent endosome 
maturation, triggers a conformational change in HA resulting in fusion of the 
endosome and virion membranes. The viral M2 protein (matrix 2) functions as an ion 
channel to further lower the pH of the virus particle, thereby aiding in the dissociation 
of the M1 protein (matrix 1) virion ‘shell’ such that the eight vRNPs (NP 
[nucleoprotein]-coated and polymerase complex (PB1, PA, and PB2)-bound viral 
RNAs) (Fig. 1.3) are released into the cytosol [18]. The vRNPs are then transported 
into the cell nucleus where accessory cellular components essential for influenza 
viral replication and transcription are located. After genome replication, transcription 
and protein synthesis, NEP (nuclear export protein) and M1 act to transport newly 
synthesized vRNPs out of the nucleus, into the cytoplasm and to the plasma 
membrane, where assembly of progeny virions take place. At these area, several 
viral proteins contribute to budding, including M1 and M2. Finally, NA acts to remove 
sialic acid from glycoproteins in both the viral and cell membranes, thereby 
preventing interaction between HA and host cell receptors, and thus, ensuring 
release of new infectious virus particles [6]. NS1 (nonstructural protein 1) acts within 
the infected cell to counteract innate host-cell defense systems, including interferon 
(IFN), that may otherwise limit efficient virus replication [19]. A schematic 
representation of the influenza A virus particle together with its RNA segments and 
encoded proteins is shown in Fig. 1.2. 
 
 
 
 
 
 
                                                                                                                                                Introduction 
 
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2 The influenza virus virion. The eight viral RNA segments were separated by electrophoresis (left). The 
corresponding gene products and their localization within the virus particle are depicted on the right. The non-
structural virus protein, the NS1, is only found inside infected cells. (Adapted from Ludwig et al. [20]) 
 
 
 
 
 
Fig. 1.3 The influenza virus RNP structure. The NP (blue) is associated with (-) sense single-stranded RNA 
(black line), and the three subunits of RNA-dependent RNA-polymerase (RDRP): PB1 (yellow), PB2 (orange) and 
PA (green), which bind at a short duplex region of the vRNA. (Adapted from Portela and Digard [21]) 
 
1.1.2 Propagation and genome replication of influenza A virus 
1.1.2.1 Replication cycle –virus entry 
The initial step of the viral entry process is the attachment of influenza A virus (IAV) 
to the host cell. The primary receptor for IAV is sialic acid and this receptor is 
recognized and bound by the viral membrane protein HA [23]. Sialic acid is the distal 
residue in oligosaccharide chains of N- and O-linked glycoproteins and lipids. Often, 
sialic acid is attached to the underlying galactose by α-2,3 or α-2,6 linkages. This 
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linkage is the resulting structural consequences influence how well IAV can bind to its 
receptor. 
HA is a multifunctional protein mediating virus attachment and fusion. There are 18 
different HA subtypes known, of which 16 circulate in waterfowl and two (H17 and 
H18) have been isolated from bats [24, 25]. Of note, H17 and H18 do not bind to 
sialic acid; the receptor for these viruses is not yet known [26, 27]. HA is expressed 
as a trimer on the virion surface. The stalk region of HA connects HA to the virion 
envelope by a short hydrophobic sequence [28]. This region is predominate 
glycosylated on conserved epitopes, which appear to be required for the stability and 
structure of the molecule [29]. The globular head is also glycosylated, but the 
glycosylation pattern and its type can be highly variable in different HA subtypes. The 
receptor-binding pocket (RBP) is located on the distal end of the HA trimer at the 
globular head (Fig. 1.5a) and is highly conserved among different HA subtypes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.4 The Replication cycle of influenza virus. It begins with binding of the HA-spike to sialic-acid containing 
receptors on the cell surface. The virion is then taken up into the cell through endocytosis. The RNPs are 
released into the cell cytoplasm after fusion between the viral and the endosomal membrane, and then 
transported into the nucleus, where transcription and replication of the viral RNA takes place. Viral mRNA is 
exported to the cytoplasm and translated into viral proteins. Some replicative proteins (i.e. NP, PB1, PB2 and PA) 
are transported back to the nucleus and continue the viral genome replication. Viral surface-glycoproteins (i.e. HA 
and NA) are transported to the cell surface. Late during virus replication cycle, vRNPs are exported out of the 
nucleus and packed and progeny virions are then released from the membrane by budding. (Adapted from 
Pleschka [22]) 
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Mutations in residues of the RBP and those in close proximity can drastically alter the 
receptor specificity of HA [30, 31]. Sialic acid has been shown to occupy the whole 
RBP and to be the major point of contact between the virus and the cell [32]. The 
interaction between sialic acid and HA is believed to be of low affinity. To increase 
the overall strength of the interaction, multiple HA molecules are used to bind to 
several glycoproteins, resulting in high-avidity binding to the cell surface [33]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.5 Structure of HA. (A) Structure of the HA of IAV A/SouthCarolina/1918 based on the results of Gamblin 
et al. (2004) [34] [Protein Data Bank (PDB) accession no. 1RUZ]. The trimeric complex of HA is shown with one 
monomer highlighted in colour. HA1 is depicted in red, HA2 in blue and the RBP in green. (B) The pre- and post-
fusion conformations of HA are shown (Bullough et al. 1994 [35]; PDB accession no. 1HTM). For the post-fusion 
conformation, only the structure of the part represented in blue could be resolved. HA1 was not included in the 
structure and is modelled according to Edinger et al. [23]. 
 
1.1.2.2 Replication cycle – viral mRNA synthesis 
After entry into the nucleus, transcription and replication of the influenza virus 
genome depends on viral polymerase activity, together with cellular co-factors. 
Influenza A virus RNA synthesis requires four proteins, which together with viral 
RNA, which make up the functional RNP: NP, PA, PB1 and PB2 [36]. Genomic viral 
RNA (vRNA) has conserved sequences at the 5' and 3' termini that share some 
sequence complementarity [37].  A high degree of conservation at the 3' ends as well 
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as at the 5' ends was observed among the genome segments of each virus and 
among the segments of the three different virus types. A uridine-rich region was 
observed from positions 17 through 22 at the 5' end of each segment. Moreover, the 
conserved 3' and 5'-terminal sequences showed partial and inverted 
complementarity. This feature results in very similar sequences at the 3' ends of the 
plus and minus strand RNAs and may also enable single-strand RNAs of influenza 
virus to form "panhandle" structures. Inverted complementary repeats may play an 
important role in initiation of viral RNA replication [37, 38]. Each vRNA is 
encapsidated by NP, and is associated with a single heterotrimeric polymerase 
complex. The incoming RNP (i.e. from the virion) is all that is required to transcribe 
mRNA, as long as an appropriate 5' host-derived capped RNA is available [39]. 
 
During mRNA synthesis (Fig. 1.6), the polymerase (via PB1) binds to the 5' end of 
the vRNA segment and thereby stimulates the cap-binding activity of PB2, which 
allows the polymerase to bind host-cell mRNAs produced as RNA polymerase II 
transcripts [40]. Subsequent interaction of the 3' end of the vRNA template with the 
viral polymerase triggers cleavage of the host-cell mRNA by PB1 and PA [41, 42], 
thus retaining the 5'- methylated host cap structure together with 9-15 cellular mRNA 
nucleotides. Viral capped mRNAs are protected from cleavage when they interact 
with the viral polymerase [40]. The cleaved host cap structure acts as a primer for 
viral transcription initiation by PB1 [43], which is enhanced by the physical interaction 
of PB2 with the cap structure. Addition of ribonucleotides (elongation) occurs 
according to the viral template (vRNA), and at some point PB2 dissociates from the 
cap [21]. 
 
Synthesis of viral mRNA terminates at a stretch of uridine (U) residues ~15-22 
nucleotides from the 5' end of the vRNA, where steric hindrance of the viral 
polymerase probably causes it to reiteratively copy the poly(U) tract (“stutter”) 
resulting in the generation of a poly(A) tail [21] (Fig. 1.6). It is unclear what role, if 
any, is played by the PA polymerase subunit in viral mRNA synthesis, although it 
may contribute to the nuclear localization of PB1, as well as efficient endonuclease 
activity and/or elongation [41, 44]. Although pre-mRNAs of most eukaryotic cells are 
fully spliced (i.e. introns removed) in order to generate functionally mature mRNAs, 
only two influenza A virus mRNAs require splicing: NS1 and M1. Additionally, unlike 
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complete cellular mRNA splicing, the splicing of viral NS1 and M1 mRNAs (to 
produce NEP and M2 mRNAs, respectively) appears to be regulated such that 
spliced mRNA is only ~10% that of unspliced mRNA [39]. M1 mRNA splicing is 
controlled by both the viral polymerase and cellular splicing factors, such as the 
serine/arginine-rich splicing factor SF2/ASF [45]. Splicing of NS1 mRNA to produce 
NEP mRNA can be regulated by the NS1 protein itself [46]. It is not exactly clear how 
viral mRNAs (both spliced and un-spliced) can specifically leave the nucleus to be 
translated into protein, particularly as NS1 has been reported to block the nucleo-
cytoplasmic transport of cellular mRNAs [47]. 
 
1.1.2.3 Replication cycle – viral genome replication 
The replication of genomic virion RNA (vRNA) occurs in two stages: the initial 
synthesis of “template” RNA that is complementary to full-length vRNA (i.e. a 
positive-sense strand: cRNA), and the subsequent copying of cRNA into new vRNAs 
(reviewed in [43] and [21]) (Fig. 1.6). Although viral mRNAs and cRNAs are both 
positive-sense, mRNA cannot act as a replicative intermediate in the formation of 
new vRNAs as it has a 5' host-derived cap and is truncated relative to the full-length 
genomic segments. Thus, the viral polymerase initiates cRNA synthesis in a cap-
independent manner, and must “read-through” the polyadenylation signal at the 5' 
end of vRNA [48]. Additionally, cRNA (but not mRNA) is encapsidated by NP. Unlike 
mRNA transcription, the incoming viral RNP alone is insufficient to stimulate cRNA 
synthesis and evidence suggests that an initial round of mRNA and protein synthesis 
is necessary prior to initiation of cRNA synthesis [42]. 
 
It is not clear what viral components constitute the replication polymerase complex. 
Soluble viral NP appears to be a major factor regulating replication, and its 
involvement would correlate with the requirement for de novo protein synthesis. 
Soluble NP may simply act in a concentration-dependent manner (i.e. stabilising 
cRNA transcripts when high enough levels of NP protein are available by modifying 
the transcription template [40] or by directly modifying polymerase function (i.e. 
“switching” protein-protein interactions between NP and PB1/PB2 in order to favour a 
replication polymerase over a transcription polymerase) [49]. Additionally, all three 
polymerase subunits (PA, PB1, PB2) are required for efficient cRNA synthesis [50], 
and it is possible that PA acts in a proteolytic manner to clip components of the 
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transcription polymerase, and thus convert it into a replication polymerase [51]. 
Possible roles of numerous host-cell proteins (including hCLE, HSP90 and 
UAP56/BAT1; a DEAD-box ATP-dependent RNA helicase) in viral RNA synthesis 
have not been fully clarified [52]. Both PA and soluble NP are important for the 
synthesis of vRNA from cRNA [53]. The binding of NP to nascent viral RNA may be 
facilitated by UAP56 and Tat-SF1, which proposed to act as chaperones for NP [54, 
55]. NS1 protein has also been suggested to be an additional cofactor that directly 
interacts with the viral replication polymerase complex and affects accumulation of 
vRNA, but not cRNA [56]. Intriguingly, vRNA only appears to be synthesised at sites 
of insoluble “nuclear matrix” within the nucleus, whilst both mRNA and cRNA 
synthesis is detectable in both soluble and insoluble nuclear fractions [57]. 
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Fig. 1.6 Models for the transcription and replication of the influenza virus vRNP. In a vRNP the viral 
polymerase, consisting of the PB1, PB2 and PA subunits, is bound to the partially complementary 5’ and 3’ 
termini of a vRNA segment. The oligomeric nucleoprotein that associates with the rest of the vRNA is not shown 
for simplicity. (i) Transcription is initiated by PB2 binding to the 5’ cap structure of host pre-mRNA followed by 
endonucleolytic cleavage of the host pre-mRNA by PA. (ii) The 3’ end of the capped RNA primer is positioned in 
the active site of PB1, along with the 3’ end of the vRNA template, to allow transcription initiation to take place. 
(iii) Once the 3’ end of vRNA has been copied it re-binds the polymerase, a process possibly facilitated by base-
pairing between the vRNA termini. (iv) As elongation proceeds the vRNA template is threaded through the active 
site of PB1 eventually leading to polyadenylation by repeated copying of the U sequence near the 5’ end of the 
vRNA template, due to steric hindrance caused by the vRNA 5’ end remaining bound to the transcribing 
polymerase. The 5’ cap of mRNA is released from PB2 and is bound by the cellular nuclear cap-binding complex 
(CBC) triggering the recruitment of cellular factors for mRNP assembly. (v) Replication of vRNA into cRNA is 
shown as proposed in the trans-acting polymerase model, but note that alternative models involving a cis-acting 
polymerase in vRNA→cRNA replication have also been proposed (see text for details). According to the trans-
acting polymerase model, the 3’ end of the vRNA template is released from the vRNP-associated polymerase by 
an unknown mechanism that allows it to bind to a trans-acting RNA polymerase. Replication is initiated by the 
binding of the trans-acting polymerase to GTP, directed by the penultimate residue in the vRNA 3‘-terminus, and 
the generation of pppApG (not shown) to be elongated by the trans-acting polymerase. (vi) Once the 3’ end of 
vRNA has been copied it re-binds the vRNP-associated polymerase while the 5’ end of the newly synthesized 
cRNA binds to the trans-acting polymerase. (vii) As elongation proceeds the 5’ end of vRNA template needs to be 
released by the vRNA-associated polymerase to allow the trans-acting polymerase to read through the U 
sequence near the 5’ end of vRNA to generate a full-length, run-off copy of vRNA. After the 5 ́ end of vRNA has 
been copied it re-binds the vRNP-associated polymerase while the 3’ end of the newly synthesized cRNA binds to 
the trans-acting polymerase, which becomes part of the cRNP complex. Co-replicational encapsidation of cRNA 
with NP is not shown for simplicity. (Diagrams modified from Fodor  [42]) 
 
1.1.2.4 Replication cycle – viral genome translation 
Influenza virus mRNAs are translated by the host cell translation machinery, 
including several cellular translation factors such as eIF4A (eukaryotic initiation 
factor-4A), eIF4E and eIF4G interact with viral mRNAs and/or polymerase complexes 
[58]. Upon IAV infection, host cell protein synthesis is limited, and IAV mRNAs are 
preferentially translated [59]. In particular, ‘cap-snatching’ may deplete newly 
synthesized, nuclear mRNAs of their cap structures, resulting in their rapid 
degradation before nuclear export and translation. In addition, the interaction of NS1 
with the cellular PABII (poly(A)-binding protein II) [60] and CPSF (cleavage and 
polyade-nylation specificity factor) proteins [61], and the interaction of the viral 
polymerase complex with the C-terminal domain of the largest subunit of cellular 
DNA-dependant RNA polymerase II (Pol II) [62] may contribute to the inhibition of 
host mRNA synthesis (reviewed in [63]). After their synthesis in the cytoplasm, the 
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viral polymerase subunit proteins and NP are imported into the nucleus via their 
nuclear localization signals [64] to catalyse the replication and transcription of vRNA. 
In addition, the M1 [65], NEP/NS2 [66] and NS1 [19] proteins are imported into the 
nucleus to execute their roles in vRNP nuclear export (M1 and NEP/NS2) or the 
processing and export of cellular and viral mRNAs (NS1) (reviewed in [19]). 
 
1.1.2.5 Replication cycle – packaging and budding 
There are two models for the packaging of a segmented, monocompartment 
genome. In a random model, a mechanism exists to distinguish pieces of the viral 
genome from cellular RNA and non-genomic viral RNAs and incorporate them into 
virions, but has no way of distinguishing between different segments (Fig. 1.7a). 
Under this hypothesize, a fully infectious virion would acquire a complete genome 
purely through chance, which the probability of success being increased by 
packaging more segments than the minimum required for a complete genome [67]. 
Infectious bursal disease virus, with a two segment double-stranded (ds)RNA 
genome, may provide an example of such a strategy, as distinct populations of 
virions with increasing numbers of segments and specific infectivities can be isolated 
[68]. Conversely, in a specific packaging model, a mechanism ensures that one copy 
of each different segment is specifically selected during viral assembly (Fig. 1.7b) 
[69]. The dsRNA bacteriophage Φ6 is a good example of this strategy as a specific 
packaging mechanism has been demonstrated for its three segments and the 
particle. PFU ratio of the virus is close to 1 [70]. These models represent the extreme 
cases of segment-specificity and absolutely no specificity in the former case and 
unfailingly rigorous selection in the latter. The extent to which packaging of the 
influenza A genome is in fact segment-specific has been debated, and evidence for 
varying degrees of segment-specificity has been presented. 
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Fig. 1.7 Models of influenza virus particle assembly and genome packaging. The eight individual segments 
(differentiated by colour) are replicated independently in the nucleus before being exported to the cytoplasm and 
migrating to the apical plasma membrane. There, they interact with other viral structural proteins and new virus 
particles formed by budding. (a) The random model for genome packaging proposes that more than eight RNPs 
are incorporated in a segment non-specific manner such that a reasonable proportion of virions contain at least 
one copy of each segment. (b) The specific model proposes that unique segment-specific packaging signals 
operate to form a defined array of eight RNPs containing one copy of each segment. (c) A negatively stained EM 
section through an A/PuertoRico/8/34 (H1N1) influenza virion showing the distinctive 7+1 array of RNPs 
(appearing as dots in transverse section). (Diagrams modified from Hutchinson, et al. [53]) 
 
1.1.3 Host adaptation and transmission of influenza A viruses in mammals 
Following the initial and sporadic emergence in humans of highly pathogenic avian 
H5N1 influenza A viruses in Hong Kong in 1997, I have come to realize the potential 
for avian influenza A viruses to be transmitted directly from birds to humans. 
Understanding the basic viral and cellular mechanisms that contribute to infection of 
mammalian species with avian influenza viruses is essential for developing 
prevention and control measures against possible future human pandemics. Multiple 
physical and functional cellular barriers can restrict influenza A virus infection in a 
new host species, including the cell membrane, the nuclear envelope, the nuclear 
environment and innate antiviral responses. In this report, I summarize current 
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knowledge on viral and host factors required for avian H5N1 influenza A viruses to 
successfully establish infections in mammalian cells.  
 
1.1.3.1 Crossing the Plasma Membrane 
The plasma membrane is the first cellular barrier that protects a host cell from virus 
infection. IAV must recognize specific receptors (sialic acids) in order to begin the 
infection of a cell [71]. There are two major types of linkages between 
sialyloligosaccharides (SAs) and galactose (Gal): SA-α2,6-Gal and SA-α2,3-Gal [71]. 
The HA proteins of human influenza viruses preferentially bind the SA-α2,6-Gal 
linkage, while the HA proteins of avian influenza virus have a higher affinity for SA-
α2,3-Gal [72]. Thus, the tissue distribution of different sialic acid linkages is a major 
factor in determining the sites of initial virus infection and replication. SA-α2,3-Gal is 
abundantly expressed on avian intestinal and respiratory epithelial cells, but is only 
expressed in the lower, and not upper respiratory tracts of humans [73]. SA-α2,6-Gal 
is mainly distributed on human airway epithelial cells of the upper respiratory tract, 
but can be detected in the respiratory and intestinal tracts of several avian species 
[73]. Avian influenza viruses, including H5N1, recognize SA-α2,3-Gal as their 
receptors and efficiently target and replicate in the intestinal tracts of birds, but not in 
the upper respiratory tracts of humans. Nevertheless, efficient virus replication in the 
human upper respiratory tract would be more likely to result in aerosol-mediated 
human-to-human transmission. In this regard, the avian-origin HA proteins from the 
1918, 1957 and 1968 human pandemic strains all recognized the SA-α2,6-Gal 
receptors [74, 75]. This may suggest that these HA proteins had switched their sialic-
acid binding specificity at some point during their adaptation to humans [74]. Thus, it 
is believed that avian H5N1 viruses would also have to change their receptor binding 
preference from SA-α2,3-Gal to SA-α2,6-Gal in order to infect humans and transmit 
efficiently. Current human infections with H5N1 viruses that target SA-α2,3-Gal may 
lead to virus replication in the lower respiratory tracts of humans, thereby causing 
severe lung damage and disease. It cannot be excluded that such SA-α2,3-Gal-
targeted viruses could also transmit between humans.  
 
In recent years, it has become increasingly apparent that a number of mutations in 
HA and NA, that would require change their receptor binding preference from SA-
α2,3-Gal to SA-α2,6-Gal. (See table 1.1) 
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Table 1.1 Amino acid mutation involved in receptor binding preference from SA-α2,3-
Gal to SA-α2,6-Gal 
 
Protein Mutation Adaptive mechanism Reference 
HA N154S Increase α2,6 binding [76] 
 A158T Decrease α2,3 binding [77] 
 N182K Increase α2,6 binding [77] 
 Q192R Increase α2,6 binding [77] 
 Q222L Increase α2,6 binding [76] 
 S223N Increase α2,6 binding [76] 
 G224S Increase α2,6 binding [76] 
 Q226L Increase α2,6 binding [71, 74] 
 S227N 
Increase α2,6 binding and decrease 
α2,3 binding 
[78] 
 G228S Increase α2,6 binding [79] 
NA Deletion in stalk 
Functional balance with H5N1 by 
decreasing enzyme activity of H5N1 
[80, 81] 
 
 
1.1.3.2 Polymerase complex 
Viral RNA polymerase is crucial for avian influenza viruses, since these polymerases 
have relatively poor activity in mammalian cells. Several amino-acid substitutions in 
the ribonucleoprotein complex are known to contribute to the host-range restriction of 
influenza viruses and increase replication in the mammalian host. High virus 
replication in the upper respiratory tract is critical for airborne transmission since 
decreased replication abolished airborne transmission between mammals [82]. In the 
study of Herfst et al. [83], the airborne-transmissible H5N1 virus possessed the 
E627K amino-acid substitution in PB2. However, it has yet to be elucidated if this 
residue is crucial for airborne transmission and whether it can be substituted by 
functionally equivalent mutations. The airborne-transmissible H5N1 viruses of Herfst 
et al. [83] possess several additional substitutions in the polymerase genes, which 
may have contributed to airborne transmission. A K627E substitution was found to 
reduce transmission in a direct contact transmission model for the highly pathogenic 
avian influenza (HPAI) H5N1 virus. Introduction of D701N in combination with the 
K627E substitution resulted in more efficient transmission in mammals, a phenotype 
more similar to that of the wild type viruses, suggesting that this residue can 
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compensate for the absence of 627K [84]. In the context of a human H3N2 virus, 
introduction of K627E resulted in less efficient transmission in guinea pigs [84]. 
Studies on the A(H1N1)pdm09 virus demonstrated that this virus was transmitted 
efficiently via the airborne route between ferrets [85]. Nevertheless, acquisition of the 
D701N substitution in A(H1N1)pdm09 virus resulted in more severe disease and 
increased transmission [86]. These data indicate that amino-acid positions 627 and 
701 in PB2 are critical determinants of airborne transmission between mammals in 
diverse virus backgrounds. There is also evidence that the PB1 gene from an avian 
source promotes avian polymerase activity in mammalian cells [87]. Two mutations in 
PB1 (473V and 598P) were identified as increasing the polymerase activity of viruses 
carrying PB2 627E in mammalian cells [88]. More recently, it was found that 
mutations in NEP are also involved in host adaptation. The adaptive mutation M16I 
(and others) in the NEP proteins of certain human H5N1 isolates can increase the 
relatively low polymerase activity of avian viruses in mammalian cells [89]. These 
NEP mutations are more common in human H5N1 isolates carrying the PB2 627E 
mutation than in human H5N1 viruses possessing PB2 627K, which suggests that 
NEP can act as an important determinant of host adaptation by promoting efficient 
polymerase activity in human cells. Summary of mutations which are involved in 
increased polymerase activity and show in Table 1.2. 
 
Table 1.2 Amino acid mutations involved in increased polymerase activity 
 
Protein Mutation Adaptive mechanism Reference 
PB1 L473V 
Increase polymerase activity of 
H5N1 and 2009pH1N1 
[88] 
 L598P 
Increase polymerase activity of 
H5N1 
[88] 
PB2 Q591K 
Increase polymerase activity of 
H5N1 and 2009pH1N1 
[90] 
 E627K 
Increase polymerase activity of 
H5N1 
[84, 91] 
 D701N 
Increase polymerase activity of 
H5N1 and H7N7 
[92] 
NEP M16I 
Increase polymerase activity of 
H5N1 
[93] 
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1.1.3.3 Reassortment 
Previously, it was believed that avian influenza viruses may not cause the next 
influenza pandemic directly, as pigs were considered a necessary intermediate host 
to facilitate reassortment between avian, swine and human influenza viruses. In 
addition, pigs were thought to serve as a critical host for initial mammalian 
adaptation. However, the role of pigs as mixing vessel for avian and human influenza 
viruses may not be unique, as humans can be infected with avian influenza viruses 
directly from an avian reservoir. Reassortment of the H5N1 virus with contemporary 
human influenza viruses did not easily yield an airborne-transmissible virus between 
mammals [94]. However, more recently, it was shown that several reassortant H5N1 
virus variants were transmitted via the airborne route between guinea pigs [95]. This 
H5 virus, which revealed dual specificity for avian and human receptors, required the 
PA and NS genes of the A(H1N1)pdm09 virus to acquire airborne transmissibility 
between guinea pigs. In addition, the NP, M and NA genes from A(H1N1)pdm09 
virus were important to enhance airborne transmissibility between mammals. These 
results appear to be in contrast to the study of Imai et al. [96] in which a reassortant 
virus with a mutant H5 HA with human receptor specificity in a A(H1N1)pdm09 virus 
backbone failed to transmit via the airborne route between ferrets. This difference 
may be explained by the use of different lineages of H5 HAs. In addition, it is unclear 
how the guinea pig and ferret models compare with respect to H5 virus transmission 
studies. However, as mentioned above, the avian-human reassortant influenza virus 
in the study of Imai et al. [96] transmitted via the airborne route after passaging in 
ferrets, when a few additional genetic changes in HA were acquired. These two 
studies thus demonstrated that different airborne-transmissible H5N1 strains can 
emerge upon reassortment between human and avian influenza viruses, as was 
previously also shown for avian H9N2 virus. 
 
Fortunately, at present, reassortment of avian H5, H7 and H9 viruses with 
contemporary human influenza viruses has not been detected in nature. This may in 
part be explained by the relatively low number of human cases of avian influenza 
virus infections, and the low probability of double infections with human influenza 
viruses in a single host. In addition, influenza viruses have to infect the same cell, 
and similar timing of infection is necessary to initiate gene reassortment. However, 
co-infections of avian and human influenza viruses in humans or pigs may provide 
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new opportunities for reassortment, and evidence from pandemics of the last century 
indicates that the likelihood of such reassortment is not negligible. 
The emergence of the A(H1N1)pdm09 virus demonstrated that pigs can be the direct 
source of pandemic influenza. Reassortment was responsible for the unique 
constellation of virus genes, which was shown to be a critical determinant of airborne 
transmission between ferrets [85], in particular the Eurasian swine-origin gene 
segments [97]. The emergence of H1N2 and H3N2 swine viruses underlines that 
swine populations should be monitored closely for the emergence of influenza 
viruses with pandemic potential. When the airborne transmissibility of these viruses 
was assessed, the H1N2 virus acquired substitutions in HA (D222G) and NA 
(S315N) during a single ferret passage that resulted in airborne transmission among 
ferrets. Reverse genetics studies further indicated that these amino-acid substitutions 
contributed substantially to the airborne transmissibility [98]. The viral RNA 
polymerase was also shown to promote airborne transmission [99]. Moreover, four 
swine H3N2v viruses, collected from 2009 until 2011, also possessed the capacity to 
spread between cohoused ferrets, and the 2010 and 2011 H3N2 viruses transmitted 
efficiently to naive ferrets via the airborne route [100]. These findings support the 
continuous threat of swine influenza viruses to humans, and the need for continued 
surveillance. 
 
1.1.3.4 Unknown determinants of transmission 
The role of other viral proteins in airborne transmission has so far remained elusive. 
The study of Zhang et al. [95] demonstrated that the PA, NS, M, NA and NP genes 
are important to confer airborne transmission; however, the key amino-acid 
substitutions remain unknown. In addition, it has been suggested that H5N1 viruses 
that acquire a long stalk NA through reassortment may be more likely to be 
transmitted among humans [101]. Although it is known that influenza virus 
morphology affects virus production, the relative contribution of spherical and more 
elongated versions of influenza virus to transmission is still unclear. Early work 
showed that most influenza virus strains isolated from humans are predominantly 
filamentous and, upon continued passage in egg or tissue culture, adopt a more 
spherical morphology, which correlated with increased virus titers [102]. It is possible 
that increased levels of influenza virus production by spherical strains will results in 
more efficient influenza virus transmission [97]. The contribution of substitutions in 
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the M gene segment on virus morphology and transmission warrants further 
investigation. 
 
1.2 The non-structural (NS1) protein 
NS1 protein is widely regarded as a multifunctional virulence factor, and is expressed 
at high levels in virus-infected cells [19]. It is not a structural component of the virion 
[103]. During infection, NS1 performs a plethora of activities that each contribute to 
efficient virus replication: Temporal regulation of viral RNA synthesis [104], 
enhancement of viral mRNA translation [58], regulation of virus particle 
morphogenesis [46], and suppression of the host immune/apoptotic responses [47] 
The protein-protein and protein-RNA interactions that mediate these functions are 
detailed below.  
 
Fig. 1.8 Generation of the NS1 and nuclear export protein (NEP) mRNAs of the influenza A virus. The intact 
NS gene is represented as a white box flanked by black squares that represent the non-coding regions of the 
gene. Thin lines at the ends of the mRNAs represent untranslated regions. The 5' cap structures (black circles) 
and poly(A) tails in the mRNAs are shown. The open reading frame of the NS1 protein is represented as a gray 
box. The specific NEP open reading frame is shown as a hatched box. The NEP mRNA derived from the NS gene 
is a spliced product of the NS1 mRNA, as indicated by the V-shaped line. Reproduced from Garcia-Sastre et al. 
[103] 
 
1.2.1 Synthesis of NS1 protein 
The smallest genomic segment of influenza A virus (segment 8) is transcribed into 
two separate mRNAs, which encode the non-structural (NS1) and nuclear export 
(NEP) viral polypeptides [19] (Fig 1.8). A co-linear mRNA transcript directly codes for 
NS1, whilst NEP is translated from spliced mRNA [19]. Both mRNA species share a 
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56-nucleotide viral leader sequence, which contains the AUG initiation codon and 
encodes nine N-terminal amino acid residues common to NS1 and NEP [105]. 
Removal of the 473-nucleotide intron in order to form NEP mRNA means that after 
the 9 shared residues, translation of NEP continues in the +1 ORF relative to NS 
[106]. Thus, after the splicing site, the NS1 and NEP ORFs overlap by the equivalent 
of ~70 residues [106]. In infected cells, the steady-state amount of spliced NEP 
mRNA is only ~10% that of unspliced NS1 mRNA [107]. 
 
1.2.2 Sub-cellular localization of NS1 protein 
The sub-cellular localization of NS1 protein appears to be dependent on several 
factors, including virus strain, expression level of NS1, cell-type used, state of cell-
polarity and time post-infection [108]. Experimental detection of NS1 within cells is 
also determined by the fixation procedure used, as some fixatives (such as acetone) 
have been suggested to preferentially extract small proteins like NS1 from the 
cytoplasm [109]. At early work identified the NS1 protein in crystalline cytoplasmic 
inclusions that could be isolated from cells late in infection. NS1 proteins contain one 
or two nuclear localisation sequences (NLSs; NLS1 and NLS2), which mediate their 
active nuclear import via binding to cellular importin α-molecules [110]. As such, 
translocation of NS1 from cytoplasmic ribosomes to the nucleus is thought to be 
extremely rapid. NLS1 in NS1 is monopartite, and involves arginine-35, arginine-38, 
and lysine-41, residues also involved in dsRNA-binding [110]. This NLS is well-
conserved among all known influenza A virus NS1 proteins [110]. In contrast, the 
bipartite NLS2 comprises specific amino-acids at the C-terminus of only some NS1 
proteins (lysine-219, arginine-220, arginine-231 and arginine-232) [110]. 
 
Concurrent with NLS2 is a functional nucleolar localization signal (NoLS), which 
requires additional basic residues (usually arginine and lysine, respectively) at 
positions 224 and 229 [110]. Thus, although the NS1 proteins of most strains appear 
predominantly nuclear during virus infection, only a subset that contain a functional 
NoLS localise into nucleoli [110]. The nucleolar function of NS1 is unknown, however 
a mutant influenza A virus (A/Udorn/72 strain) expressing a truncated NS1 protein 
unable to localise into nucleoli was not attenuated for replication under tissue-culture 
conditions [110]. Therefore, it has been suggested that any nucleolar function of NS1 
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may only be necessary for the in vivo pathogenesis of some viruses [110]. As NLS2 
is absent from the majority of pathogenic and non-pathogenic influenza A virus 
strains, it is difficult to ascribe a critical function to this sequence with regards viral 
replication/pathogenesis. Thus, many regulatory signals are responsible for the 
varied distribution of NS1 during infection (i.e. nuclear, nucleolar or cytoplasmic). 
Such varied localizations presumably contribute to the reported ability of NS1 to 
perform a number of different functions as detailed below (Fig 1.9). 
 
 
 
Fig. 1.9 Linear schematic of the NS1 domain layout and interactions. NS1 (yellow) can be divided into four 
distinct regions: the N-terminal RNA-binding domain (RBD), the linker region (LR), the effector domain (ED) and 
the C-terminal ‘tail’ (CTT). Interaction sites for NS1 to form homo-multimers are present in both the RBD 
(triangular cut-outs) and ED (W187). Both the LR and the CTT vary in length among strains: the longest total NS1 
length reported is 237 aa, but 230 residues are common. NS1 interacts with many viral and cellular factors during 
infection, and some well-described examples are indicated: red-coloured factors are targeted by NS1 to inhibit 
cellular antiviral defences, while green-coloured factors are stimulated by NS1 to enhance virus replication (RIG-I, 
retinoic acid inducible gene I; DDX21, DEAD box helicase 21; TRIM25, tripartite motif containing 25; PKR, double 
stranded RNA activated protein kinase; PABII, poly(A) binding protein II; PAF1, RNA polymerase II associated 
factor; PABI, poly(A) binding protein I; eIF4GI, eukaryotic translation initiation factor 4 gamma, 1; Pol, 
polymerase). (Adapted from Hale BG [111]) 
 
1.2.3 NS1 and viral RNA synthesis 
The NS1 protein has been reported to control the temporal synthesis of both viral 
mRNAs and vRNAs [56]. The highly conserved (>95%) isoleucine-123 and 
methionine-124 residues in the C-terminal effector domain of NS1 have been 
implicated in this activity as the substitution of these two residues for alanine resulted 
in the increased synthesis of all viral mRNAs and vRNAs early in infection [104]. In 
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particular, both HA and M1 (usually only synthesised in the “late” phase of infection) 
were synthesised “early” in the context of a mutant virus encoding NS1 with amino-
acid substitutions at isoleucine-123 and methionine-124 [104]. The mechanism by 
which NS1 might regulate switches in viral vRNA, mRNA, and protein synthesis is 
unclear, but is not thought to involve PKR, a cellular protein bound by NS1 that can 
regulate translation (see below) [104]. One possibility is that NS1 functionally 
interacts with the viral polymerase complex to affect these processes [57].  
 
1.2.4 NS1 and viral mRNA translation 
As an RNA-binding protein, NS1 has been shown to interact in vitro with a variety of 
RNA species: dsRNA [112], viral genomic RNA [113], viral mRNA [59], poly(A)-
containing RNAs [114] and snRNAs (small nuclear RNAs) derived from the U6 
promoter [115]. As described below, the interactions of NS1 with putative viral 
dsRNA, viral genomic RNA and cellular poly(A)-containing RNAs (as well as the 
cellular proteins that may bind these ligands) likely play predominant roles in 
countering the host antiviral response [116]. Moreover, the possible interaction of 
NS1 with the 5’UTR (untranslated region) of viral mRNAs [59] has been linked to the 
ability of NS1 to directly enhance the translation initiation of viral mRNAs [117]. 
 
Other than possibly binding the 5’UTR of viral mRNAs, NS1-mediated enhancement 
of viral protein synthesis may also require its interaction with host-cell proteins. NS1 
can form an RNA-protein complex consisting of the eukaryotic translation initiation 
factor eIF4GI, poly(A)-binding protein I (PABI) and viral mRNAs [58, 118]. The RNA-
independent binding of NS1 to eIF4GI requires the N-terminal 113 residues of NS1 
[118], whilst the RNA-independent interaction with PABI requires residues in the N-
terminal 81 amino acids of NS1 [58]. Thus, mutant NS1 proteins unable to bind 
eIF4GI are also defective in enhancing viral mRNA translation [117]. 
 
In addition, NS1 interacts with hStaufen, a dsRNA-and tubulin-binding protein that is 
related to PKR [119]. The interaction is independent of RNA and appears to be 
mediated by the C-terminal effector domain of NS1 and the dsRNA-binding domains 
of hStaufen [119]. It has been speculated that the interaction between NS1 and 
hStaufen may also promote efficient protein synthesis from viral mRNAs [119]. 
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Indeed, a proportion of both NS1 and hStaufen has been found to co-fractionate with 
cytoplasmic polysomes in influenza A virus infected cells [117]. Thus, in order to 
promote efficient viral protein synthesis, NS1 may interact with cellular hStaufen, 
eIF4GI and PABI to specifically recruit viral mRNAs to multi-protein translation-
initiation complexes. The additional contribution of NS1 to viral protein synthesis by 
inhibiting PKR is discussed below. 
 
1.2.5 NS1 and the host immune response  
The innate interferon (IFN) response of the host-cell is a potent antiviral mechanism 
that can limit the replication and spread of viruses (reviewed in [120]). IFNs (such as 
IFNα or IFNβ) are soluble cytokines synthesised by cells in response to viral 
infection. Secreted IFNs act in both an autocrine and paracrine fashion to upregulate 
>300 genes and thereby induce an “antiviral state” within target host cells. 
 
A number of studies have demonstrated, at the molecular level, how NS1 functions to 
limit both the production and downstream effects of IFN. As described below, it is 
becoming increasingly apparent that the mechanisms by which NS1 achieves this 
are likely to be strain and/or cell-type specific [121, 122]. 
 
1.2.5.1 Limitation of IFN production by NS1 
Studies on the NS1 protein of influenza PR8 (H1N1) virus show that it can 
specifically prevent dsRNA-and virus-mediated activation of the transcription factors 
interferon regulatory factor-3 (IRF-3), NFκB and c-Jun/ATF-2, and thus limit induction 
of IFNβ [123]. This inhibition appears to occur pre-transcriptionally, and has been 
attributed to two residues in the dimerised RNA-binding domain of PR8/NS1: 
arginine-38 and lysine-41, which both mediate efficient RNA-binding [124]. 
Furthermore, recent work indicates that the mechanism of IFN inhibition may actually 
involve PR8/NS1 forming a complex with retinoic acid-inducible gene product I (RIG-
I) [116]. Studies using the human H3N2 virus A/Udorn/72 (Ud) have revealed that 
Ud/NS1 can limit IFNβ induction by preventing the global post-transcriptional 
processing of cellular pre mRNAs [125]. For this, the C-terminal effector domain of 
Ud/NS1 binds directly to two zinc-finger regions in the 30 kDa subunit of cleavage 
and polyadenylation specificity factor (CPSF30) and also binds poly(A)-binding 
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protein II (PABII) [126]. NS1 binding to CPSF30 prevents the cellular protein from 
binding pre-mRNAs, thus inhibiting the correct cleavage and polyadenylation of host 
mRNAs [127]. NS1 binding to PABII is thought to block the nuclear export of mRNAs 
that might partially escape from the inhibition of 3'-end formation [128]. Retention of 
cellular pre-mRNAs within the nucleus of infected cells usually leads to their rapid 
degradation. 
 
1.2.5.2 Inhibition of host-cell mRNA processing by NS1 
It has been shown that the NS1 can also form a complex with components of the 
mRNA nuclear export machinery: NXF1, p15, Rae1, E1B-AP5 and to some extent 
Nup98 [47]. The complex formation between NS1 and NXF1, Rae1, and E1B-AP5 
requires residues in both the RNA-binding and C-terminal effector domains of NS1, 
whilst the interaction with p15 appears to be mediated solely by the C-terminal 
effector domain [47]. In addition to inhibiting the 3'-end processing of host-cell pre-
mRNAs (and thereby mRNA export) by binding CPSF30 and PABII, NS1 can act 
directly at the level of nuclear mRNA export transporters in order to prevent host 
protein synthesis. 
 
Yeast two-hybrid studies also identified a novel ~70 kDa NS1-binding protein 
(subsequently termed NS1-BP) [129]. It has been proposed that the interaction 
between NS1 and NS1-BP may contribute towards the inhibition of host-cell mRNA 
processing, although a role for the interaction in regulating viral mRNA splicing 
cannot be ruled out [129]. 
 
1.2.5.3 Inhibition of IFN-inducible enzymes by NS1 
The ability of some NS1 proteins to efficiently limit IFN and tumor necrosis factor α 
(TNFα) stimulated gene expression, has a beneficial effect on virus replication and 
pathogenicity [122]. However, NS1 also specifically blocks the activation of two 
cytoplasmic IFN-inducible anti-viral proteins. Firstly, 2'-5'-oligoadenylate synthetases 
(2'-5'-OAS) is activated by double-stranded RNA (dsRNA) (a putative by-product of 
RNA virus replication) that acts as co-factor to activate 2'-5'-OAS, which is then able 
to polymerizeadenosine triphosphate (ATP) into 2'-5'-oligoadenylate (2'-5' oligo(A)) 
chains (reviewed in [19]). These 2'-5' oligo(A) chains in turn cause dimerisation and 
activation of the latent ribonuclease RNaseL that inhibits viral replication (translation) 
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by degrading single-stranded RNAs, such as mRNAs and ribosomal RNAs (reviewed 
in [19]. 
 
Secondly, dsRNA also activates protein kinase-R (PKR). PKR is activated by dsRNA. 
PKR can be activated by the protein PACT or by heparin. PKR contains an N-
terminal dsRNA binding domain (dsRBD) and a C-terminal kinase domain that gives 
pro-apoptotic functions. NS1 can binds to specific motifs within the N-terminal domain 
of PKR, and thereby releases its conformational induced auto inhibition of both 
cellular and viral protein synthesis (reviewed in [130]). PKR also play roles in 
upregulating gene expression of IFNβ from IRF-3 and NFκB responsive promoters 
(reviewed in [130]), and is involved in initiating the apoptotic response. Thus, it is 
beneficial for virus to block both 2'-5'-OAS and PKR as they play important roles in 
limiting virus replication. 
 
1.2.5.4 NS1 and the adaptive immune response 
Studies on human-derived primary dendritic cell (DCs) have revealed that the 
influenza A virus NS1 protein is able to prevent the correct maturation of DCs in 
response to virus infection, and thereby limits host T-cell activation [131]. Specifically, 
infection of DCs with PR8delNS1 virus (PR8 lacking the ability to express full-length 
NS1) leads to the secretion of higher amounts of IFNα, IFNβ, TNFα, and IL-6, as 
compared to the WT virus [131]. Expression of WT NS1 also specifically limited the 
virus-induced expression of several genes involved in DC maturation and migration, 
including: MHC, IL-8, IL-12, p35, IL-23, p19, IRF-7, RANTES, TRIF, MIP-1β and 
CCR7 [131]. Thus, DCs infected with influenza A viruses expressing WT NS1 are 
unable to mature, and thereby fail to stimulate the secretion of IFNγ from T-cells 
[131]. This effect of NS1 would clearly have a profound inhibitory effect on the 
adaptive immune response to infection. 
 
1.2.6 Effect of NS1 on other cell signaling pathways 
The NS1 proteins from five different human and avian influenza A virus strains can 
associate with NS1-I, a human protein highly homologous to the porcine 17β-
estradiol dehydrogenase precursor protein, which may mediate steroid hormone 
levels [132]. Although the function of this interaction is not well understood, 
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overexpression of NS1-I in 293 cells specifically reduces the expression of influenza 
A virus proteins, suggesting that NS1-I has antiviral activity that may be inhibited by 
NS1 [132]. Moreover, large-scale sequence analyses of avian influenza A viruses 
have also revealed two other putative protein binding motifs within NS1: a Src-
homology 3 (SH3) binding motif (residues 212-216) [133] and a PDZ domain ligand. 
These containing SH3 or PDZ domains often coordinate the assembly of a diverse 
array of localized signaling complexes. In vitro studies have shown that the PDZ 
domain ligand of highly pathogenic avian influenza virus NS1s (including those from 
H5N1 and 1918 strains) can bind over 30 different human PDZ-proteins [134]. 
 
1.2.7 NS1 and the host apoptotic response 
During infection, influenza A viruses induce cell death by both apoptosis [135] and 
necrosis [136]. Most infected cells undergo apoptosis by intrinsic mechanisms, 
however influenza A virus can induce apoptosis in neighbouring, uninfected cells by 
triggering the release of extracellular cytokines that act in a paracrine fashion [137]. 
The exact function of NS1 with regard to virus-induced apoptosis/cell-death is 
unclear, and may be dependent upon specific host-cell factors or virus strains. For 
example, Ud/NS1 on its own appears to be extremely toxic to MDCK cells, but not in 
HeLa cells [138] and Ud/NS1 (but not PR8/NS1) inhibits the processing of cellular 
pre-mRNAs, a process likely to be toxic to the cell [139]. However, in the context of 
virus infection, NS1 appears to have anti-apoptotic functions, which have been linked 
largely to its ability to limit the production and/or downstream effects of IFN [140]. As 
such, catalytically active PKR is reported to play an important role in influenza A 
virus-mediated induction of apoptosis [141], thus the direct binding and inhibition of 
PKR by NS1 may contribute to cell-death suppression [142]. The same may be true 
for the pro-apoptotic functions of 2'-5' OAS/RNaseL [143]. In addition, by limiting the 
production of IFN and other cytokines, NS1 might reduce paracrin-mediated 
(extrinsic) apoptosis induction in neighbouring uninfected cells [144]. Overall, there 
may be a temporal role for NS1 in contributing to both “early” (active) suppression of 
apoptosis, and “late” (toxic) induction cell-death during infection. 
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1.3 NS1 protein and host range 
During infection, the host innate immune response is elicited to counteract virus 
replication. Influenza A viruses limit this cellular defense mechanism in infected cells 
by producing the NS1 protein from genomic segment 8. In recent years, it has 
become increasingly apparent that a number of NS1 functions are virus strain-
specific. All NS1 proteins appear to bind and neutralize RIG-I ligands (such as 
5′triphosphated RNAs) as part of their antagonism of RIG-I signaling [63]. However, 
another mechanism by which NS1 proteins can inhibit RIG-I activation is by 
preventing the ubiquitination of RIG-I by both TRIM25 or Riplet ubiquitin E3 ligases 
and this function appears to vary between strains [64]. Studies suggest that an avian-
type H5N1 NS1, but not human/swine-type NS1s, can bind efficiently to chicken 
TRIM25 to suppress IFN production in chicken cells. In contrast, all NS1s tested so 
far (including avian, swine, and human) appear to interact with human TRIM25. 
Interestingly, the avian H5N1 NS1 protein used in the above study failed to interact 
with human Riplet, while human-type NS1 proteins bind human Riplet and inhibit its 
RIG-I activating function [64]. It remains to be determined precisely whether the 
various different NS1-TRIM25/Riplet binding specificities contribute to avian-
mammalian transmission. 
 
The interaction of NS1 with CPSF30 is also strain-dependent. The viruses isolated 
after 1998 carry out mutations residues 103 and 106 on NS1 of H5N1 viruses, which 
acquiring the ability to bind human CPSF30 and thereby better suppress the human 
IFN response [65].  
 
Sequence analyses have revealed several features of NS1 that are potentially 
relevant to host adaptation. Firstly, the NS1 gene can be divided into two major 
alleles: A and B [20]. Allele A NS1s are found in both avian and human viruses, while 
allele B NS1s are only found in avian viruses [67, 68]. Viruses with allele A NS1s 
appear to have a replication advantage over those with allele B NS1s in mammalian 
cells, suggesting that those avian H5N1 influenza viruses carrying allele A NS1 
genes may already have acquired functions adapted to replicate in mammals. In NS1 
feature revealed by sequencing is the presence of strong or weak PDZ-ligand 
domain consensus motifs located at the C-terminus of NS1. Such motifs have been 
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identified as virulence determinants [69]. NS1 proteins with avian-like PDZ-ligand 
domains (including H5N1) are associated with high virulence in mammals [70], which 
may result from binding of these ‘strong’ PDZ-ligand domains to several human PDZ-
containing proteins [73]. Therefore, it is possible that switching from avian-type 
(‘strong’) to human-type (‘weak’) PDZ-ligand domain motifs is required during full 
avian-to-mammal adaptation as a virus reaches equilibrium with its host and 
virulence is compromised. The C-terminus of NS1 is thought to be unstructured [74], 
and is highly variable in length between strains [68, 75]. Different variants may have 
different host-specific preferences relating to cellular binding partners, which will 
include cellular PDZ-domain containing proteins as well as other proteins. Whether 
the C-terminal length variability of NS1 proteins contributes to host adaptation 
remains to be thoroughly examined.  
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1.4 Aims 
Highly pathogenic avian influenza viruses (HPAIV) with reassorted NS segments 
from H5 (GD; A/Goose/Guangdong/1/1996) and H7 (A/Mallard/NL/12/2000) type 
avian virus strains placed in the genetic background of A/FPV/Rostock/34 HPAIV 
(FPV-H7N1) were generated by reverse genetics (FPV-NSGD and FPV-NSMA). 
Virological characterisation demonstrated that growth kinetics of the reassortant 
viruses differed from the wild type FPV and depended on cells of mammalian or 
avian origin. Surprisingly, molecular analysis revealed that the different reassortant 
NS segments were not only responsible for alterations in the anti-viral host response, 
but also affected viral genome replication and transcription. Polymerase 
reconstitution experiments demonstrated the effects on accumulation of viral RNA 
species depended on the specific NS-segment. IFN-beta expression and the 
induction of apoptosis were found to be inversely correlated with the magnitude of 
viral replication. Based on the above results, especially based on the fact that the 
NS-GD and NS-MA proteins only differ in eight amino acids, and NS-GD and NS-MA 
in the FPV genetic background lead to dramatically different propagation 
characteristics of reassortant viruses. I therefore aim to analyze which amino acids or 
which combination of amino acids are implicated in  
I. an effect on the viral polymerase regarding viral genome replication,  
transcription. 
II. viral propagation (growth rate) and transmission. 
III. the effect of the NS protein on the global of cellular transcription 
profile in mammalian host. 
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Chapter 2 
Materials and Methods 
2.1 Materials 
2.1.1 Instruments  
Abbocath-T (26Gx19mm)  Hospira 
Bio Imaging Analyzer (BAS 2000)     Fuji Film 
BioMax TranScreen HE Intensifying Screen   Kodak 
BioMax Cassette       Kodak 
Cell culture incubator      Heraeus; Nuaire 
Cell culture microscope      Hund 
Confocal laser scanning microscope (TCS SP5)  Leica 
Culture Hood (HB2448)      Heraeus 
Developing machine      Optimax, Protec 
Disposable Razor Med Comfort     AMPri GmbH 
Electrophoresis apparatus system Institute for Medical 
Virology 
Electrophoresis power supply (EPS500/400) Pharmacia 
ELISA reader (Type LP 400) Diagnostic Pasteur 
FACScan Becton Dickinson, USA 
Fine scale (Mettler PM460) Mettler Waagen GmbH 
Heat block        Jumotron 
LuminexTM Reader       Biorad 
Magnetic stirrer       IKA Labortechnik 
Megafuge 1.0 R       Heraeus 
Microwave oven       Quelle 
Mini centrifuge       Biofuge 13, Heraeus 
Neubauer chamber       Optik Labor 
Omincan 50        Braun Medical 
pH meter (Type 632)      Metrohm 
Shaker (Type 3013)       MSGV GmbH 
Scale (P1200)       Mettler 
Scanner Canonscan 9900F     Canon 
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SDS-PAGE gel system      Invitrogen, Germany 
Sonicator (Type HD70)      Bondelin Sonoplus 
Spectrophotometer (DU-70)     Beckman 
Sterile needles       BD Microlance 3 BD 
Syringe (microliter, serial 700)     Hamilton 
Syringe 20ml single use      Braun, Melsungen AG 
Tissue Ruptor       Qiagen 
Vortex (Vibrofix VF1)      IKA Labortechnik 
Water bath (SW-20C)      Julabo 
      
2.1.2 Reagents and general materials 
1 kb DNA ladder mix      PEQLAB 
10X restriction enzyme buffer 1, 2, 3 and 4   NEB 
10X AccuPrime Pfx DNA polymerase buffer   Invitrogen 
Acrylamide        Bio-Rad 
Ammonium persulfate (APS)     Serva 
AccuPrime dNTPs (3 mM)      Invitrogen 
Accutase        PAA 
Acetic acid        Roth 
Agar high-gel strength      Serva 
Agarose ultra pure       Roth 
Aprotinin        Roth 
β-mercaptoethanol (MetOH)     Roth 
Benzamidin        Sigma 
Blotting papers (GB004)      Scheicher & Schuell 
Bradford reagent       Bio-Rad 
Bromophenol blue       Merck 
Boric acid        Roth 
BSA (Solution, 30%)      MP Biomedicals 
BSA (Powder)       Roth 
Casein Bacto-Casitone      Difco Laboratories 
Chloroform        Roth 
Coomassie brilliant blue R 250     Merck 
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Cryotubes        Nunc 
Cuvette        Bio-Rad 
DAB Peroxidase substrate  
(3,3’-Diaminobenzidine)      Sigma 
DAPI (stock 1mg/ml)      Sigma 
DEAE Dextran (MW: 500,000)     Pharmacia Biotech 
1,4-Diazabicyclo 2,2,2octane (DABCO)   Merck 
Dimethylsulfoxid (DMSO)      Sigma  
1,4-Dithiothreit (C4H10O2S2) (DTT)    Roth 
DNA loading buffer (6X)      PeqLab 
Eppendorf tube       Eppendorf 
Ethanol (absolute)       Roth 
Ethidium bromide       Roche 
Ethylenediamine tetraacetic acid (EDTA)   Fluka 
Glycerol        Sigma 
Glycine        Roth 
Hydrochloride (HCl)       Roth 
Isopropanol        Roth 
Kodak® BioMax™ MS film (20cm×25 cm)   Sigma 
Leupeptin        Sigma 
Magnesium chloride (MgCl2)     Merck 
Microtiter plate (96 wells)      Greiner 
Mowiol 40 – 88       Aldrich 
Methanol        Roth 
Oxoid Agar        Oxoid 
Paraformaldehyde (PFA)      Merck 
Pefablock        Roth 
Peptone from meat trypsin-digested    Merck 
Potassium chloride (KCl)      Roth 
Precision Plus Protein Standards (All Blue)   Bio-Rad 
Potassium dihydrogen phosphate (KH2PO4)   Roth 
Propidium Iodide       Sigma 
PVDF-Membrane Immobilon-P transfer membrane  Millipore 
Rainbow marker       Amersham 
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Roti-Free, ready-to-use Stripping Buffer    Roth 
Scientific Imaging film BioMax MR    Kodak 
Sodium chloride (NaCl)      Roth 
Sodium dodecyl sulfate (SDS)     Merck 
Sodium-β-glycerophosphate     Sigma 
Sodium hydroxide (NaOH)      Merck 
Sodium hydrogen carbonate (NaHCO3)    Fluka 
Sodium orthovanadate      Sigma 
Sodium pyrophosphate      Sigma 
TEMED (N,N,N',N'-Tetramethyl-ethylene diamine)  Serva 
TLC plates (20 x 20 cm Silica gel 60)    Merck 
TranIT2020        Mirus 
Trypsin-EDTA (10X)      PAA 
Tris-HCl        Roth 
Triton X-100 (t-Octylphenoxypolyethoxyethanol)  Sigma 
Trizol Reagent       Invitrogen 
Tween 20        Roth 
Trypan blue        Gibco 
Urea         Sigma 
Whatman 3MM Paper      Schleicher & Schüll  
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2.1.3 Monoclonal and polyclonal antibodies 
  
Antibody Company Dilution 
Anti-flu A NP mouse 
monoclonal IgG 
SantaCruz Biotechnology 1:500 
Anti-flu A NS1 mouse 
monoclonal IgG 
SantaCruz Biotechnology 1:2000 
Anti-flu A GST-NS1 mouse 
monoclonal IgG 
Kind gift from Dr. T. Wolff, 
Berlin, Germany 
1:2000 
HRP conjugated goat anti-
mouse IgG 
SantaCruz Biotechnology 1:1000 
HRP conjugated goat anti-rabbit 
IgG 
SantaCruz Biotechnology 1:1000 
Anti-flu A NP (FPV) mouse 
(clone 1331) 
Biozol–Biodesign Internat. 1:5000 
Anti-influenza A PR/8/34 rabbit 
polyclonal IgG 
Biomol-US Biological 1:1000 
Alexa 594 anti-mouse Invitrogen 1:200 
Alexa 594 anti-rabbit Invitrogen 1:200 
 
2.1.4 Materials for cell culture 
 
Chicken Serum       Sigma 
Dulbecco's Modified Eagle's medium (DMEM)   Invitrogen 
Fetal calf serum (FCS)      PAN 
HIMF10        Invitrogen 
L-Glutamine 100X       Invitrogen 
Minimum Essential Media (MEM) (10X)     Invitrogen 
Penicillin-streptomycin solution (100X)    PAA 
TPCK-treated Trypsin (10X)      PAA 
Tissue culture dish       Becton Dickinson 
Tissue culture flask       Nunc 
Tryptose Phosphate Broth      Sigma 
Bovine Albumin (30% BSA)     PAA   
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2.1.5 Enzymes 
 
AccuPrime Pfx DNA Polymerase     Invitrogen 
GoTaq flexi DNA polymerase     Promega 
PlatinumR Pfx DNA polymerase     Invitrogen 
SuperScript TM III reverse transcriptase    Invitrogen 
T4 Ligase        NEB 
T4 polynuleotide kinase (10,000 units/ml)   NEB 
 
2.1.6 Kits   
 
AEC staining kit       Sigma 
Bradford Protein Assay Kit 
ECL (enhanced chemiluminescence) solution Kit  Amersham/GE 
High pure PCR product purification Kit    Roche 
In situ cell death detection Kit, fluorescein   Roche 
NucleoPond Xtra Maxi Kit for DNA plasmids prep  Macherey-Nagel 
pcDNATM 3.1 directional TOPO expression Kit   Invitrogen 
QIAprep Spin Miniprep Kit (250)     Qiagen 
QIAamp Viral RNA Mini Kit (250)     Qiagen 
Qiagen plasmid Maxi Kit      Qiagen 
Nucleotide removal Kit TOPO XL PCR cloning Kit  Qiagen 
Caspase-3 activity       Abcam 
Rapid DNA ligation Kit      Roche 
QuikChange® Site-Directed Mutagenesis Kit   Stratagene 
Human Interferon beta Kit      PBL Assay Science 
 
2.1.7 E. coli strain, recombinant viruses and cell lines 
 
E. coli strain 
XL1-Blue        Stratagene 
TOP 10        Invitrogen 
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Recombinant influenza viruses 
A/FPV/Rostock/34 (H7N1) (FPV-WT) Rescued at the Institute 
of Medical Virology, 
Giessen 
FPV-NSGD Rescued at the Institute 
of Medical Virology, 
Giessen 
FPV-NSMA Rescued at the Institute 
of Medical Virology, 
Giessen 
FPV-NSMA_P3S Rescued at the Institute 
of Medical Virology, 
Giessen 
FPV-NSMA_R41K Rescued at the Institute 
of Medical Virology, 
Giessen 
FPV-NSMA_D74N Rescued at the Institute 
of Medical Virology, 
Giessen 
FPV-NSMA_I98M Rescued at the Institute 
of Medical Virology, 
Giessen 
FPV-NSMA_D153S Rescued at the Institute 
of Medical Virology, 
Giessen 
FPV-NSMA_M166V Rescued at the Institute 
of Medical Virology, 
Giessen 
FPV-NSMA_P213S Rescued at the Institute 
of Medical Virology, 
Giessen 
FPV-NSMA_R224K Rescued at the Institute 
of Medical Virology, 
Giessen 
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FPV-NSMA_P3S+R41K Rescued at the Institute 
of Medical Virology, 
Giessen 
FPV-NSMA_P3S+R41K+D74N Rescued at the Institute 
of Medical Virology, 
Giessen 
FPV-NSMA_P3S+R41K+D74N+I98M Rescued at the Institute 
of Medical Virology, 
Giessen 
FPV-NSMA_P3S+R41K+D74N+I98M+D153S Rescued at the Institute 
of Medical Virology, 
Giessen 
FPV-NSMA_P3S+R41K+D74N+I98M+D153S+M166V Rescued at the Institute 
of Medical Virology, 
Giessen 
FPV-NSMA_P3S+R41K+D74N+I98M+D153S+M166V+P213S Rescued at the Institute 
of Medical Virology, 
Giessen 
FPV-NSMA_P3S+R41K+D74N+I98M+D153S+M166V+P213S+R224K Rescued at the Institute 
of Medical Virology, 
Giessen 
FPV-NSGD/MA Rescued at the Institute    
of Medical Virology, 
Giessen 
FPV-NSMA/GD Rescued at the Institute    
of Medical Virology, 
Giessen 
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Cell lines 
 
A549 (Human Alveoar Epithelial cells) ATCC 
MDCK-II (Madin-Darby canine kidney cells) Cell-collection of the 
Institute of Medical 
Virology, Giessen 
293T (Human embryonic kidney cells) Cell-collection of the 
Institute of Medical 
Virology, Giessen 
QT6 (quail fibroblast cells) Kind gift from the 
Institute for Virology, 
Marburg 
 
2.1.8 Plasmids 
 
pPolI-FPV-PB1 (A/FPV/Rostock/34 (H7N1)) Kind gift from the 
Institute for Virology, 
Marburg 
pPolI-FPV-PB2 (A/FPV/Rostock/34 (H7N1)) Kind gift from the 
Institute for Virology, 
Marburg 
pPolI-FPV-PA (A/FPV/Rostock/34 (H7N1)) Kind gift from the 
Institute for Virology, 
Marburg 
 
pPolI-NP (A/FPV/Rostock/34 (H7N1)) Kind gift from the 
Institute for Virology, 
Marburg 
pPolI-FPV-HA (A/FPV/Rostock/34 (H7N1)) Kind gift from the 
Institute for Virology, 
Marburg 
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pPolI-FPV-NA (A/FPV/Rostock/34 (H7N1)) Kind gift from the 
Institute for Virology, 
Marburg 
pPolI-FPV-M (A/FPV/Rostock/34 (H7N1)) Kind gift from the 
Institute for Virology, 
Marburg 
pPolI-FPV-NS (A/FPV/Rostock/34 (H7N1)) Kind gift from the 
Institute for Virology, 
Marburg 
pCI-GD-NS (A/Goose/Guangdong/1/96 (H5N1)) Kind gift from the 
Institute for Virology, 
Marburg 
pPolI-MA-NS (A/Mallard/NL/12/2000 (H7N3)) Kind gift from the 
Institute for Virology, 
Helsinki 
pPolI-Ma-NSGD/MA (A/Mallard/NL/12/2000 (H7N3)) Kind gift from the 
Institute for Virology, 
Helsinki 
pPolI-Ma-NSMA/GD (A/Mallard/NL/12/2000 (H7N3)) Kind gift from the 
Institute for Virology, 
Helsinki 
pHMG-PA (A/Puerto Rico/8/34(H1N1)) Kind gift from the 
Institute for Virology, 
Zurich 
pHMG-PB1 (A/Puerto Rico/8/34(H1N1)) Kind gift from the 
Institute for Virology, 
Zurich 
pHMG-PB2 (A/Puerto Rico/8/34(H1N1)) Kind gift from the 
Institute for Virology, 
Zurich 
pHMG-NP (A/Puerto Rico/8/34(H1N1)) Kind gift from the 
Institute for Virology, 
Zurich 
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pPolI-CAT-RT (Human Pol promoter) Kind gift from the 
department of 
microbiology, Mount 
Sinai School of 
Medicine,  New York 
pcDNA3.0-GD-NS1(A/Goose/Guangdong/1/96 (H5N1)) Constructed at the 
Institute of Medical 
Virology, Giessen 
pcDNA3.0-MA-NS1(A/Mallard/NL/12/2000 (H7N3)) Constructed at the 
Institute of Medical 
Virology, Giessen 
pcDNA3.0-MA-NS1D74N(A/Mallard/NL/12/2000 (H7N3)) Constructed at the 
Institute of Medical 
Virology, Giessen 
pcDNA3.0-MA-NS1P3S/R41K/D74N 
(A/Mallard/NL/12/2000 (H7N3)) Constructed at the 
Institute of Medical 
Virology, Giessen 
pcDNA3.1-FPV-NP (A/FPV/Rostock/34 (H7N1)) Constructed at the 
Institute of Medical 
Virology, Giessen 
pcDNA3.0-FPV-PB1(A/FPV/Rostock/34 (H7N1)) Constructed at the 
Institute of Medical 
Virology, Giessen 
pcDNA3.0-FPV-PB2(A/FPV/Rostock/34 (H7N1)) Constructed at the 
Institute of Medical 
Virology, Giessen 
pcDNA3.0-FPV-PA(A/FPV/Rostock/34 (H7N1)) Constructed at the 
Institute of Medical 
Virology, Giessen 
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2.1.9 Medias, buffers and solutions 
 
Avicel Medium (100 ml) 
10  ml   10X MEM 
33  ml   ddH2O 
1 ml   Penicillin/Strepromycin liquid (100X) 
1  ml   BSA solution (35%) 
50  ml   Avicell Stock (2.5%)  
1  ml   DEAE-Dextran (1%) 
4  ml   NaHCO3 (7.5%) 
 
Avicel Stock (2.5%) 
5  g   Avicel-Powder  
200  ml   ddH2O  
 
Cell culture medium for QT6 cells (500 ml) 
425  ml   HAM's-F10 media 
5  ml    Penicillin/Strepromycin liquid (100X) 
5  ml   L-Glutamine 
50  ml   Fetal Calf Serum (FCS) 
5  ml   Chicken Serum 
10  ml   Tryptose Phosphate Broth 
 
Cell fixing buffer (100 ml) 
95  ml   PBS++ 
4  ml   Formaldehyde (PFA) (37%) 
1  ml   Triton X-100 (t-Octylphenoxypolyethoxyethanol) 
 
DMEM/BA (500 ml) 
492  ml   DMEM 
5  ml   Penicillin/streptomycin (100X) 
3  ml   Bovine Albumin (BA) (30%) 
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2X DMEM/BA for Plaque-Assay (500 ml) 
100  ml    MEM (10X) 
10  ml    Penicillin/Streptomycin (100X) 
20  ml   NaHCO3 (7.5%) 
6  ml   Bovine Albumin (BA) (30%) 
354  ml   ddH2O 
 
Luria-Broth (LB) medium  
Extract of yeast powder (0.5%) (w/v) 
Peptone from meat trypsin-digested (1%) (w/v) 
adjust pH to 7.5 with NaOH and total volume to 1 L with ddH2O, autoclaved 
for plates, add agar high-gel strength (1.5%) (w/v), autoclaved 
 
Infection media (for MDCK, A549 and 293T) (100 ml) 
98.5  ml   DMEM (1X) 
1  ml   Penicillin/Strepromycin liquid (100X) 
500  ul   BSA (30%) 
 
Infection media (QT6) (100 ml) 
95.5  ml   HAM's-F10 media 
1  ml    Penicillin/Strepromycin liquid (100x) 
1  ml   L-Glutamine 
2  ml   Tryptose Phosphate Broth 
500  µl   BSA (30%) 
Mowiol mounting medium 
Mowiol 4-88 
Glycerol 
Tris-HCl (0.2 M, pH 8.5)  
DABCO (1,4-diazabicyclo-[2,2,2]-octane)  
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SDS-PAGE stacking gel (1 gel) 
2.9  ml   ddH2O 
1.25  ml   Tris-HCl, pH 6.8 (0.5 M) 
50  μl   SDS (10%) 
750  μl   Polyacrylamide (PAA) (30%) 
50  μl   APS (10%) 
4  μl   TEMED 
 
SDS-PAGE resolving gel (10%) (1 gel) 
4  ml   ddH2O 
2.5  ml   Tris-HCl, pH 8.8 (1.5 M) 
100  μl   SDS (10%) 
3.3  ml   Polyacrylamide (PAA) (30%) 
 
SM medium 
Gelatin (0.01%)  
NaCl 250 mM 
MgSO4 8.5 mM  
Tris–HCl 50 mM, pH 7.5 
 
SOC Medium 
Tryptone  (2%) (w/v) 
Yeast extract (0.5%) (w/v) 
NaCl 10 mM 
MaCl2 10 mM 
Glucose 20 mM 
Prepare a solution containing the first four reagents, sterilize at 121°C, then add 
sterile MgCl2 and Glucose 
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6%, 7M urea polyacrylamide gel 
21 g   Urea 
5  ml   10X TBE 
7.5  ml   Acrylamide (40%) 
Fill up the tube to 50ml with sterile water 
0.5  ml   APS (10%)   
0.05  ml   TEMED 
 
Blocking buffer and antibody diluting solution 
Non-fat dry milk (5%) (w/v) in 1XTBS-T (see below) 
 
Lysis buffer 
10 ml   TLB buffer (see TLB buffer) 
10  µl   Pefablock (200 mM) 
10  µl   Aprotinin (5 mg/ml) 
10  µl   Leupeptin (5 mg/ml) 
100  µl   Sodium orthovanadate (100 mM) 
50  µl   Benzamidine (1 M) 
 
1XPBS++ buffer (500 ml) 
495  ml   1XPBS (autoclaved) 
5  ml   Ca2+/Mg2+ solution (100X) 
 
PBS/Ca2+/Mg2+/BA/antibiotic (200ml) 
20  ml   10X PBS (see above) 
174.8  ml   ddH2O (sterile) 
2  ml    Penicillin/Streptomycin (100X) 
1.2  ml   BSA (30%) 
2  ml    Ca2+/Mg2+ (100X) 
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SDS-PAGE loading buffer (2X) (Laemmli Buffer) 
100  mM   Tris-HCl, pH 6.8 
200  mM   DTT (dithiothreitol) 
SDS (4%) 
Glycerol (20%) 
Bromophenol blue (0.2%) 
 
SDS-PAGE running buffer (5X) (1000 ml) 
1  g   SDS 
6  g   Tris-HCl 
28.8  g   Glycin 
adjust total volume to 1 L with ddH2O 
 
SDS-PAGE transfer buffer (1000 ml) 
5.8  g   Tris-HCl 
2.9  g   Glycin 
0.17  g   SDS 
200  ml   Methanol 
adjust to total volume to 1 L with ddH2O 
 
TAE buffer (10X) (1000 ml) 
48.5  g   Tris 
11.4  ml   Glacial acetic acid 
20  ml   0.5 M EDTA (pH 8.0) 
 
TAE buffer (1X) 
Dilute stock solution 10X (10:1) in ddH2O  
1XTAE buffer contain  
40  mM   Tris 
20  mM   Acetic acid 
1  mM   EDTA 
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TLB buffer 
20  mM   Tris-HCl, pH 7.4 
137  mM   NaCl 
Glycerol (10%) (v/v) 
Triton X-100 (1%) (v/v) 
2  mM   EDTA 
50  mM   Sodium-β-glycerophosphate 
20  mM   Sodiumpyrophosphate 
 
Tris-Buffered Saline (10X TBS) (1000 ml) 
24.2  g   Tris-HCl 
80  g   NaCl 
dissolve by adding 900 ml ddH2O 
adjust pH to 7.6 and total volume to 1 L with ddH2O 
 
TBS/Tween (0.05%) (1XTBS-T) (1000 ml) 
100  ml   10X TBS 
900  ml   ddH2O 
0.5  ml   Tween 20  
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2.2 Methods   
 
2.2.1 DNA cloning and sub-cloning 
2.2.1.1 Preparation of competent cells for DNA transformation 
10 l glycerol stock of Escherichia coli XL1-Blue (or DH5α) strain was transferred into 
10 ml LB medium. Cells were grown overnight at 37C on the incubator shaker with 
moderate shaking (200 rpm). 10 ml overnight culture was transferred into 1 L LB 
medium. Cells were grown for additional 3-4 h at 37C until the OD595 reached 0.5-
0.8. After cooling down on ice for 30 min, cells were transferred into four sterile 250 
ml centrifugation tubes and pelleted by centrifugation for 10 min at 10,000 rpm 
(Biofuge 13, 16,000 g), 4C. Then cells were sequentially resuspended in 500ml of 
chilled 1 mM HEPES (pH 7.0), pelleted again by centrifugation and resuspended in 
250 ml of chilled 1 mM HEPES (pH 7.0), pelleted by centrifugation again as above. 
The cells were resuspended in 50 ml chilled 10% glycerol in ddH2O, centrifuged 
again as above and resuspended in 2.5-3 ml 10% (v/v) glycerol. Competent cells 
were aliquoted in 100 l on ice. The tubes containing the competent cells were 
placed into fluid nitrogen to be frozen, and then stocked immediately at -70C.  
 
2.2.1.2 Transformation cells by heat sock 
10 µl of plasmid DNA (10 ng/µl) or 20 l of desalted ligation mixture was mixed in 100 
l of rapidly thawed competent cells by stirring gently with the pipette tip. After a short 
incubation in ice, a mixture of chemically competent bacteria and DNA is placed at 
42°C for 45 seconds (heat shock) and then placed back in ice. SOC media is added 
and the transformed cells are incubated at 37°C for 30 min with agitation, Afterward, 
the cells and SOC medium mixture was centrifuged shortly after incubation, then only 
100 µl medium was kept in the eppendorf tube, rest of supernatants were discarded. 
The cell pellet was resuspended in the 100 µl liquid as mentioned and spread onto a 
pre-warmed LB plate containing 100 µg/ml ampicillin. The plates were incubated 
overnight at 37C (plasmid transformed bacteria are selected on LB plates with 
ampicillin). After 16 h incubation, the single colony was picked and inoculated in LB 
medium with ampicillin and shaken overnight at 37°C. The bacteria culture was then 
used for preparing plasmid DNA and frozen glycerol stocks by mixing 850 µl bacteria 
culture with 150 µl autoclaved 100% glycerol. 
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2.2.1.3 Preparation of plasmid DNA 
Plasmid DNA maxi preparation was performed using QIAprep plasmid midi or maxi 
Kit. The culture of bacteria containing plasmids was grown in 100 ml of LB media 
overnight in 37°C incubator with shaking at 200 rpm. The bacteria were collected by 
centrifuging the overnight culture at 6,000 rpm (Beckman JA14, 7,500 g) and 4°C for 
15 min. Then after the bacterial pellet was resuspended in 10 ml of buffer P1 and 10 
ml buffer P2 was added. The whole mixture was mixed gently and incubated at room 
temperature for 5 min. 10 ml of chilled buffer P3 was added, mixed immediately and 
incubated on ice for 20 min. The mixture was centrifuged at 4,000 rpm (Megafuge 
1.0R, 5,400 g) for 30 min at 4°C. The supernatant was applied to an equilibrated 
QIAGEN-tip 500 and allowed to enter the resin by gravity flow. The QIAGEN-tip was 
washed twice with 30 ml buffer QC. DNA was eluted with 15 ml buffer QF. The DNA 
is precipitated by adding 0.7 volumes (10.5 ml) of isopropanol and centrifugation at 
12,000 rpm (Beckman JA20, 21,000 g) for 30 min at 4°C. The resulting pellet was 
washed twice with 70% ethanol and air-dried at room temperature. The pellet is then 
carefully resuspended in certain volume of TE buffer depending on the size of DNA 
pellet. The concentration of plasmid DNA was photometric measured and adjusted to 
1 µg/µl. The plasmid DNA can be stored at 4°C for a short time only or at -20°C over 
a longer period. 
 
2.2.1.4 Measurement of plasmid DNA concentration 
The DNA concentration is determined by using a picodrop (Xipha Biotech) at 
wavelength of 260 nm and 280 nm. The absorption of at 260 nm corresponds to the 
concentration of DNA and 280 is corresponds to the protein. First of all an 
appropriate DNA dilution (normally 1:10 or 1:100) was made, 5 µl of DNA suspension 
was transferred into a picodrop, which has been calibrated before to the solvent 
(either H2O or TE buffer). The absorbent ratio between 260/280 should lie in between 
1.8-2 to ensure high purity of DNA. 
2.2.1.5 Restriction endonuclease digestion 
Digestion of DNA with restriction endonuclease was performed by pipetting DNA 
sample, 10X restriction buffer, restriction enzyme, and distilled and deionized water 
(ddH2O) in a 1.5 ml eppendorf tube. The reaction mixture was incubated at the 
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recommended temperature (usually at 37°C). Normally 1 or 5 Units of restriction 
enzyme were used to digest 1 g DNA.  
2.2.1.6 Agarose gel electrophoresis 
The agarose (1-3%) was melted in 1X TAE buffer using a microwave oven, and 
cooled to about 55oC. Before the gel was poured into a casting platform, ethidium 
bromide (4 µl of 10 mg/ml in 100 ml solved agarose) was added. DNA samples were 
mixed with appropriate amount of 6X loading buffer before loaded into the wells. 
Normally, the gel was run with 100-120 V and 300-400 mA. DNA was visualized by 
placing gel on a UV light source and picture was photographed directly by a photo 
system. 
2.2.1.7 Preparation of DNA fragments 
DNA bands were excised from gel and subsequently purified with a High pure PCR 
product purification Kit (Roche). The preparation was performed according to the 
manufacturer’s instruction. After purification, 5 l of the purified DNA was run on 
agarose gel for determine the DNA amount for ligation.  
2.2.1.8 Ligation 
Ligations were done with a rapid DNA ligation Kit (Roche). Each 4 µl of linearized 
vector DNA and purified DNA fragment were used. The exact operation was 
performed according to the manufacturer’s instruction. The ligation products were 
purified with high pure PCR product purification Kit according to the manufacturer’s 
instruction, before they were used for heat shock transformation. 
 
2.2.2 QuikChange® Site-Directed Mutagenesis  
QuikChange® Site-Directed Mutagenesis is a four-step procedure (Fig. 2.1), and is 
used for introduction of point mutations, switching of amino acids, and deletion or 
insertion of amino acids residues. The method uses a double stranded DNA vector 
and two oligonucleotide primers containing the desired mutation. The primers are 
complementary to each other and to the double stranded template DNA. After 
denaturation of the vector DNA, the mutagenic primers anneal complementary to 
opposite strands of the vector. Elongation by Pfu DNA polymerase results in a 
mutated plasmid with staggered nicks. After the thermal cycling, the PCR product is 
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treated with DpnI endonuclease. DpnI has the target sequence 5’-Gm6ATC-3’, and is 
used to digest hemimethylated and methylated parental DNA, leaving the non-
methylated, newly synthesized DNA intact for further use. After DpnI treatment, the 
plasmids are transformed into competent E. coli XL blue, where the cells DNA repair 
machinery seals the nick.  
 
  
 
 
Fig. 2.1 An illustration of the four steps of the QuikChange® Site-Directed Mutagenesis protocol. In step 
one the plasmid is isolated for the mutagenesis reaction. Step two involves the mutagenic PCR. The third step is 
digestion of the template with DpnI, leaving only the mutated PCR products. The final step is transformation of the 
mutated plasmid. Figure from http://www.stratagene.com/manuals/200516.pdf. 
 
All the work was carried out as suggested by the QuikChange® Site-Directed 
Mutagenesis protocol, but with small alterations to the reaction mix, which was as 
follows:  
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2.2.2.1 Primers:  
All primers were designed by Primer X software (www.bioinfirmatics.org/primerx) 
 
2.2.2.2 Reaction mix 
0.5    μl   forward primer, 2.5 pmoles/μl 
0.5    μl   reverse primer, 2.5 pmoles/μl 
0.25  μl   40 mM dNTP mix, (10 mM each) 
1.25  μl   10X PfuUltra Buffer (contains Mg++) 
1.0   μl   Template DNA, 2 ng/μl 
0.25 μl   PfuUltra Hotstart (Stratagene) 
8.75  μl  Sterile H2O 
0.625 µl  DMSO 
8.125  μl   Total 
 
 
 
 
 
Primers  Sequence (5'->3') Tm (°C) 
P3S-F GACAAAGACATAATGGATTCCAACACGATAACCTCG 68,3 
P3S-R CGAGGTTATCGTGTTGGAATCCATTATGTCTTTGTC 68,3 
R41K-F CTCCGAAGAGACCAAAAGGCATTAAAGGGAAGAG 69,5 
R41K-R CTCTTCCCTTTAATGCCTTTTGGTCTCTTCGGAG 69,5 
D74N-F CTGAAGAGTGAAACAAATGAAAACCTCAAAATAG 63,4 
D74N-R CTATTTTGAGGTTTTCATTTGTTTCACTCTTCAG 63,4 
I98M-F GAGCATAGAGGAGATGAGCCGAGAATGGTAC 69,5 
I98M-R GTACCATTCTCGGCTCATCTCCTCTATGCTC 69,5 
D153S-F GAGGGCATTCACAGAAAGTGGTGCTATTGTGGCTG 71,8 
D153S-R CAGCCACAATAGCACCACTTTCTGTGAATGCCCTC 71,8 
D74N-WT-F GATTCTGGAGGAAGAATCCAATGAGGCACTTAAAATGAC 69,5 
D74N-WT-R GTCATTTTAAGTGCCTCATTGGATTCTTCCTCCAGAATC 69,5 
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2.2.2.3 PCR program setup for site directed mutagenesis 
1.  5 min, 95 °C 
2. Repeat 18X  (a) 50 s, 95 °C 
(b) 50 s, 60 °C 
(c) 1 min+1 min/1 kb template, 68 °C 
3.  7 min, 68 °C 
2.2.2.4 Control of amplification DNA by gel electrophoresis (1%) 
 For this assay, 50 ml of 1X TAE buffer was measured, 0.5 g of agarose powder 
weighed and microwaved for 2.5 minutes. The solution was then allowed to cool for a 
few minutes then 2 μl of Ethidium bromide was added. This solution was then poured 
in a gel plate and an 8 lane comb inserted in it to form the grooves/wells. The 
solution was then allowed to solidify at room temperature. The samples were then 
loaded at ran at 200 V in TAE buffer.  
2.2.2.5 Transformation of XL1-Blue competent cells  
XL1-Blue cells were obtained from Stratagene, 0.85 μl of the β-mercaptoethanol 
provided was then added to 50 μl of the cells, 1 μl of the DNA plasmid obtained after 
PCR quick change added, the tube was incubated on ice for 30 minutes, heat pulsed 
at 42 °C (water bath) for 45 seconds, incubated on ice for 2 minutes again, 0.5 ml 
SOC solution to the tube and then the tube incubated at 37 °C for 1 h (rotation speed 
200 rpm). After the incubation, 50 μl of the solution was applied to LB agar plate 
containing 250 mg/ml ampicillin. The plates were then incubated at 37 °C overnight. 
The next day, a single colony from an agar plate was picked up, added to a culture 
tube containing 5 ml LB media contain 250 mg/ml ampicillin added and allowed to 
rotate at 200 rpm at 37 °C overnight. The next day, the amplified DNA had to be 
extracted. 
 
2.2.3 Working with cell cultures 
2.2.3.1 Maintenance of mammalian and avian cell culture 
MDCK, A549 and 293T were maintained in Dulbecco modified Eagles medium 
(DMEM) containing phenol red as a pH-indicator, supplemented with 10% heat 
inactivated fetal calf serum (FCS) and Penicillin/Strepromycin (P/S). The cells were 
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incubated at 37°C with 5% CO2 and 95% humidity. They were routinely cultured to a 
100% confluence than passaged according to the need. QT6 were maintained in 
HAM's-F10 media containing 1% L-Glutamine, supplemented with 8% heat 
inactivated fetal calf serum (FCS), 2% Chicken Serum, 2% Tryptose phosphate broth 
and P/S. The cells were incubated at 37°C with 5% CO2 and 95% humidity. They 
were routinely cultured to a 100% confluence than passaged according to the need. 
2.2.3.2 Storage of cell cultures 
For freezing; cells were washed with 1X PBS and 5 ml of 1X trypsin-EDTA was then 
added. The cells were then incubated at 37°C with 5% CO2 and 95% humidity and 
left until cell detachment, after which 5ml complete media was added. Cell 
suspensions were then centrifuged at 1200 rpm, 4°C for 5 min. The cells pellet were 
gently resuspended with 1 ml freeze medium (90% complete DMEM and 10% 
DMSO) and transferred into cryotubes. These were set into a styropore box and left 
to freeze gradually in the -80°C freezer. The DMSO prevents ice crystal formation 
and allows the cells to remain intact. After 24 hours, cells were transferred into liquid 
nitrogen where they can be kept for a longer period of time. 
 
For thawing; cells were removed from liquid nitrogen and immediately transferred 
into a 37°C water bath until complete thawing. Cells were then resuspended carefully 
and transferred into a cell culture flask filled with complete DMEM (15 ml). After 24h 
cells were replaced with complete DMEM (15 ml) and continue culture until the cells 
have reached 100% confluence and should be passaged for further propagation. 
2.2.3.3 Infection of cells 
The virus inoculum was prepared by adding the according amount of virus stock to a 
certain volume of PBS/BA depending on the desired multiplicity of infection (moi) 
used for experiment. Confluent cells in 3.5 cm dishes were washed with 1x PBS++ 
and 500 µl of virus inoculum was laid on top of cell surface, rolling the plate to ensure 
the virus inoculum were equally distributed. The cells were further incubated at room 
temperature for 1 h, after which the inoculum was removed by aspiration, then wash 
the cell one time with 1X PBS, and 2ml of infection media was added. Cells were 
then further incubated at 37°C with 5% CO2 for the desired time points.  
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The calculation of moi was done as follows: 
 
2.2.3.4 Preparation of cell lysates for Western blot analysis 
At a certain time point after infection and/or treatment, cells (from 3.5 cm dishes) 
were washed with cold 1X PBS++. An extra 1 ml of cold 1X PBS++ was added to the 
cells with which they were scraped off and transferred into eppendorf tube. This was 
then centrifuged at 13000 rpm for 1 min and the cell pellet carefully resuspended in 
75 µl lysis buffer by pipetting up and down. The lysis was performed by incubating 
cells for 25-30 min on ice and vortexing at 5 min intervals. The lysed cells were then 
centrifuged at 13000 rpm, 4°C for 15 min. The supernatant was finally transferred 
into new eppendorf tube and stored at -70°C until further requirement. 
 
2.2.4 Cell viability (cytotoxicity) analysis 
In order to determine whether the concentration of inhibitors used for experiments 
would affect cell viability, MTT-assay was performed. This assays measure the 
activity of mitochondrial dehydrogenase in the living cells. 3-(4,5-dimethylthiazole-2-
yl)-2,5-diphenyl tetrazolium bromide (MTT) or (4-(3-(-iodophenyl)-2-(4-nitrophenyl)-
2H-5tetrazolio)-1,3-benzene disulfoonate) (WST-1) is taken up by cells and can be 
reduced either enzymatically (by mitochondrial dehydrogenase/reductase enzymes) 
or through direct interaction with NADH, which is reduced to NADPH. This reaction 
only takes place when enzymes are active in living cells and therefore conversion is 
directly related to number of viable cells and can be analyzed photometrically in an 
enzyme-linked immunosorbent assay (ELISA) reader. This reaction produces blue 
formazan crystals (MTT) in living cells. 
2.2.4.1 MTT-assay 
MDCK, A549, and QT6 cells were seeded in 96well cell culture plates (150 ul/well) 
and grown in complete DMEM media overnight at 37°C with 5% CO2 so that they 
were confluent on the day of the experiment. After addition of the inhibitors (mixed in 
DMEM/BA), cells were incubated further for 4, 6, 8, 10, 24 and 48 hours. Cell media 
1000 µl 
Virus titer [PFU] moi x cell amount in the culture 
X µl virus 
= 
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was then replaced with 150 µl of complete DMEM media and incubated for 1 h to 
allow for cell proliferation. 7 µl of 5mg/ml MTT stock (diluted in complete DMEM 
media) solution was diluted in 193 µl complete DMEM media (175 µg/ml final 
concentration) and added into each well after aspirating the old media. Cells were 
incubated for a further 90 min and subsequently fixed with 4% paraformaldehyde 
(PFA, in 1X PBS) at room temperature for 30 min. The fixing solution was aspirated 
and the plates were dried under the hood for 10-15 min. The tetrazolium crystal was 
dissolved by adding 200 µl of isopropanol to each well and the plates left shaking for 
10 min on a 96-well plate shaker. The plates were analyzed photometrically at 550 
nm excitation in an enzyme-linked immunosorbent assay (ELISA) reader. 
 
2.2.5 DNA-transfection of eukaryotic cell cultures 
2.2.5.1 Transfection of adherent 293T cells 
The day before transfection, 293T were split 1:2 into a new flask to promote cell 
growth. The next day the cells were seeded in 3.5 cm dishes to grow to 
approximately 90% confluence over night for the transfection. DNA and TranIT2020 
mix were prepared as follows: DNA (in µg) was diluted in OPTI-MEM reduced serum 
medium (final volume is 100 µl) and mixed gently. TranIT2020 (2 µl of TranIT2020 
per µg DNA) was mixed and diluted in OPTI-MEM (final volume is 100 µl), mixed 
gently and incubated for 5 min at room temperature. The diluted TranIT2020 was 
added to the tube containing the diluted DNA, then mixed gently and incubated for 45 
min at room temperature to allow forming of the DNA-TranIT2020 complexes. During 
complex formation, cells were washed with OPTI-MEM and refreshed with 800 μl of 
new medium without antibiotics (DMEM+10% FCS) was added. The DNA-Plus-
TranIT2020 Reagent complexes (total 200 µl volume) were added dropwise into the 
dish containing fresh medium. The cells were incubated at 37°C at 5% CO2 for 6 h. 
Thereafter, the media containing DNA-Plus-TranLT2020 Reagent complexes was 
removed and replaced with 2 ml of complete DMEM media. The cells were further 
incubated at 37°C at 5% CO2 for 24-48 h.  
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2.2.5.2 RNP reconstitution assay 
2.2.5.2.1 Transfection of adherent cells to performed CAT assay after RNP 
reconstitution  
1.2 µg of DNA mixture of four expression plasmids encoding the PB1, PB2, PA and 
NP proteins (in the ratio of 1:1:1:2) from FPV virus, and 2.0 µg of pPolI-CAT-RT 
(carrying the human pol-I-promoter), together with either empty vector pcDNA 3.0 
(4.0 µg) or pcDNA-NS1 (4.0 µg) from GD, MA, and MA mutant virus respectively 
were transfected according to section 2.2.5.1.  
 
2.2.5.2.2 Chloramphenicol Acetyl Transferase (CAT) assay  
The principle for CAT assay is shown in Fig 2.2. 
 
2.2.5.2.3 Preparation of cell extracts 
Cells were washed with 1X PBS++
 
scraped off in 500 μl 1X PBS++
 
and transferred into 
a new eppendorf tube (on ice). Cells were centrifuged at 3000 rpm in a 
microcentrifuge (Heraeus, Germany) at 4°C for 1 min. Pellet was resuspended in 100 
μl of 0.25 M Tris-HCl (pH-7.4). Resuspended pellet was incubated for 2 min in liquid 
nitrogen followed by 5 min incubation at 37°C in water bath. This process was 
repeated for two more times and cells were centrifuged at 3000 rpm for 1 min at 4°C. 
100 μl supernatant, which is the enzyme extract, was transferred into a new 
eppendorf tube on ice and was used for CAT assay (Invitrogen, USA) or was stored 
at -70°C. 
 
2.2.5.2.4 Determination of relative protein amount 
A 5 μl sample from the cell lysate was taken to measure the relative protein amount 
and mixed as followed: 
5 μl  Sample 
200  μl  Bradford protein buffer 
800  μl  ddH2O 
The relative concentration of protein was calculated by the measurement of the 
absorbance at the wavelength 595 nm in a DU-70 spectrophotometer (Beckman). 
According to the indicated absorbance, the protein concentration of different samples 
could be calculated by stand curve derived from BSA standards or compared 
between samples by normalizing the lowest concentration to 1. 
                                                                                                                              Materials and Methods 
 
56 
 
 
 
Fig. 2.2 The principle of CAT assay. CAT, a bacterial gene, which neutralizes the antibiotics chloramphenicol by 
acetylating the drug at one or two hydroxyl groups. Cell lysates containing CAT enzyme are simply incubated with 
the fluorescent substrate and acetyl-CoA at 37°C, ethyl acetate is added to terminate the reaction and to extract 
the fluorescent substrate and its acetylated derivatives, which are then resolved by thin layer chromatograph 
(TLC, Invitrogen). Brightly fluorescent, well-separated spots can be visualized with a hand-held UV lamp. To 
quantify CAT activity, a laser scanner typoon (GE healthcare) is used.  
 
2.2.5.2.5 Chloramphenicol reaction 
Running chamber was set up one day before Chloramphenicol reaction. 26 ml of 
methanol and 174 ml of chloroform (13:87) was mixed as running buffer, and then 
the running buffer was poured into the chamber and covered with a lid overnight to 
generate a stable air gas phase. 50 μl of each pre-diluted enzyme (1:10, 1:100 and 
1:1000) extract was incubated with 20 μl (4mM) AcCoA and 5 μl BODIPY 
(Invitrogen). Everything was mixed properly and this 75 μl reaction mixture was 
incubated at 37°C for two and a half hours in a water bath. Thereafter, 500 μl of ethyl 
acetate was added and mixed, the mixture was vortexed vigorously for 5 min and 
then centrifuged at 13000 rpm for another 5min resulting in two phases including the 
upper ethyl acetate layer (450 μl) and lower water layer. Ethyl acetate layer was 
transferred into new eppendorf tube (with holes made in the lid) and were vacuum 
dried with speed vac machine (Savant) for 25 min. 
 
2.2.5.2.6 Loading samples on TLC plate 
The dried pellet was dissolved with 20 μl ethyl acetate and was loaded in the form of 
little dots on TLC plate (Silica gel, Sigma Aldrich) with the help of air supply. Air 
supply helps minimizing spread of ethyl acetate on TLC plate during sample loading. 
The dots were loaded a little higher than the level of pre-equilibrated running buffer. 
% 
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TLC plate was plated into the running chamber in an inclined position. The spots 
migrated up by capillary action until the solvent reached the top of the TLC plate 
(around 30 min). Then it was stopped by removing the plate and allowing the plate to 
dry. Later, the products (acetylated chloramphenicol) and the unacetylated substrate 
were visualized as a light green colour spot on the chromatogram in UV-light (as Fig. 
2.3). The plates were scanned by Typhoon 9200 (GE Healthcare) and the spots were 
quantified and calculated (as Fig. 2.2) by GenQuant software (GE Healthcare).  
 
2.2.6 Generation, amplification and purification of NS reassortant of H7-type 
highly pathogenic avian influenza virus  
293T cells in 3.5 cm diameter dishes were transfected with 12 plasmids (5 µg DNA in 
total) according to section 2.2.5.1. For the generation of wt FPV, 1.2 μl (1 µg/μl) of 
the protein expression plasmids (pHMG-PB1, pHMG-PB2, pHMG-PA and pHMG-NP) 
were transfected in a ratio of 1:1:1:2 along with 3.8 μl (1 µg/μl) of the pol-I plasmids 
(pPol-I-FPV-PB1, FPV-PB2, FPV-PA, FPV-NP, FPV-HA, FPV-NA, FPV-M and FPV-
NS) in a ratio of 1:1:1:1:2:2:1:1. To generate the reassortant viruses carrying different 
NS segments (NS-GD, NS-MA and NS-MA mutants), the pPol-I-FPV-NS plasmid 
was substituted by the pPol-I-NS plasmids of NS-GD, MA and MA- mutants. At 24 h 
after transfection, the transfection mixture was removed and the cells were incubated 
with 2 ml of fresh medium. The harvested medium from transfected dishes was 
screened for rescued influenza virus by observation of cytopathic effect (CPE) and 
plaque assay on MDCK cells according to the section 2.2.7.1. The progeny viruses 
were amplified on MDCK cells in 75 mm flask and continued for 3 round of plaque 
purification according to the section 2.2.7.3. The purified viruses were then amplified 
and titrated on MDCK cells by foci assay according to section 2.2.7.2 and stored at -
70°C. The generation of all viruses was carried out using biosafety level 3 
procedures. 
 
2.2.7 Analysis of infectious virus titers  
2.2.7.1 Standard plaque assay 
MDCK cells were seeded on 3.5 cm dishes one day before and grew to 100% 
confluence. The cells were washed once with 1X PBS++, then 100 µl of virus dilution 
(10 time serial dilute) was laid on the cells. The cells were incubated at RT for 1 h. 
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During the incubation, 2 ml Oxoid (2%) agar was melted and incubated alongside at 
42°C in a water bath. DMEM medium was also incubated in a 37°C water bath. After 
one hour, the inoculum was removed from the dishes, 2 ml Oxoid (2%) agar was 
mixed with DMEM (and the other solutions, as described in section 2.1.9.). 2 ml 
mixture was given immediately to every plate using a sterile plastic pipette. When the 
agar became solid, the dishes were inversely laid in a 37°C, 5% CO2 humidified 
incubator. After 2 days plaques were seen on the dishes. The cells were fixed with 
3.7% formaldehyde for 1h at room temperature. Then the agar was removed from the 
dishes with a spatula. Cells were stained with 1.25% coomassie brilliant blue (1 
ml/3.5 cm plate) at room temperature for 5 min, and then the plates were washed 
gently with tab water. Plaques were counted at different dilutions and the total 
amount of plaques was calculated by the following formula: 
 
PFU/ml  number of plaques  volume factor  dilution factor 
 
Volume factor: PFU (Plaque forming unit) is related to 1 ml. If a dish was infected 
with 100 µl viral dilution solution, the factor is 10. 
2.2.7.2 Immunohistochemistry (Avicel Foci assay) 
Virus dilutions were made in the 96 well microtiter plates with U-form bottom. First 
180 µl of virus dilution solution was pipetted into each well and 20 µl of the virus 
stock was added into the wells of the first row. The virus dilution (200 µl) was mixed 
by up and down pipetting and 20 µl of it was transferred into wells of the second row. 
The same steps were repeated up to the last row (A-H) to get 10-1 to 10-8 dilution 
series. MDCK cells were seeded in 96-well plates and grown over night at 37°C with 
5% CO2 so that they were 90% confluent on the day of infection. The cells were 
washed once with 1X PBS++, then infected with 50 µl of virus dilution and incubated 
at room temperature for 1 h. Virus inoculum was aspirated and 150 µl Avicel media 
(See in section 2.1.9) was added into each well. The plate was placed at 37°C with 
5% CO2 for 30 or 48 h depending on the virus strain. After the incubation, avicel 
media was removed by aspiration. Cells were washed twice with 1X PBS++ and fixed, 
as well as permeabilized, with 330 µl/well of 4% PFA/1% TritonX-100 in 1X PBS++ 
overnight at 4°C or alternatively for 1 h at RT. Afterwards cells were washed and 
three times with 1X PBS/0.05% Tween20 and incubated with 50 µl of primary 
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antibody (anti NP-mAb, 1:6000 diluted in PBS++/3% BSA) for 1 h at room 
temperature. After aspirating the primary antibody dilution, cells were again washed 
three times with PBS/0.05% Tween20, followed by secondary antibody  incubation 
(Horse Radish Peroxidase (HRP)-conjugated anti mouse, 1:1000 diluted in 
PBS++/3% BSA) for 45 min at room temperature. Cells were washed and 40 µl of 
AEC staining Kit solution (section 2.1.10) was added into each well and placed at 
room temperature for 30-60 min. The AEC (3-Amino-9-ethylcarbazole) staining Kit is 
used for staining peroxidase labelled compounds in immunohistochemistry or 
immunoblotting techniques. AEC produces an insoluble end-product which has a red 
colour. Red stained foci were observed under microscope, wells were washed with 
normal water to remove the rest of salts and air dried at room temperature. After 
drying, the plates were scanned using the Canon scan 9900F (Canon) at 1600 dpi 
and virus foci counted. The viral titre was determined as follows: 
 
FFU/ml = number of foci x volume factor x dilution factor 
 
Volume factor: FFU (Foci forming unit) is related to 1 ml. If a dish was infected with 
50 μl viral dilution solution, the factor is 20.  
One foci was considered when more than 3-5 adjacent cells were stained in one 
particular area, as opposed to single cell staining which would probably mean, that 
the cell had not produced an infectious virus. 
2.2.7.3 Influenza virus plaque purification 
MDCK cells were seeded on 3.5 cm dishes one day before and grew to 100% 
confluence. The cells were washed once with 1X PBS++, then 100 µl of virus dilution 
(10 time serial dilute) was laid on the cells. The cells were incubated at RT for 1 h. 
During the incubation, 2 ml Oxoid (2%) agar was melted and incubated alongside at 
42°C in a water bath. DMEM medium was also incubated in a 37°C water bath. After 
one hour, the inoculum was removed from the dishes, 2 ml Oxoid (2%) agar was 
mixed with DMEM (and the other solutions, as describe in section 2.1.9.). 2 ml 
mixture was given immediately to every plate using a sterile plastic pipette. When the 
agar became solid, the dishes were inversely laid in a 37°C, 5% CO2 humidified 
incubator. After 2 days plaques were seen on the dishes. A single plaque was picked 
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using a sterile Pasteur pipette. The plug was incubated overnight in SM buffer to 
release the viral particles from the agarose.  
 
2.2.8 Haemagglutination (HA) Assay  
Red blood cells should be taken from Specific Pathogen Free (SPF) chickens. If SPF 
chickens are not available, blood may be taken from normal chickens that are shown 
to be free from antibodies to (avian) influenza viruses. Firstly about 20-30 ml fresh 
chicken blood was transferred to a 50 ml sterilized falcon centrifugation tube 
containing 10 ml of 3.7% sodium citric acid. The RBCs was washed by filling the tube 
to 50 ml with cooled 1X PBS++ and centrifuged at 1,500 rpm (Megafuge 1.0R, 700 g) 
at 4°C for 10 min. The supernatant above the RBC-fraction containing serum, white 
blood cells and fat was carefully removed by aspiration, and then RBCs pellet was 
washed again with cooled 1X PBS++ and centrifuged as mentioned above. This 
washing step was repeated twice. Finally the pellet of RBCs was diluted to 0.5% (v/v) 
with cooled 1X PBS++ for haemagglutination assay. 50 µl 1X PBS++ was dispensed 
into each well of a plastic V-bottomed microliter plate (96 wells), then 50 µl virus 
suspension (for example cell culture supernatant) was placed in the first well. Two-
fold dilutions of 50 µl volumes of the virus suspension were made from well #1-#12 in 
each row (left to right), subsequently 50 µl of 0.5% chicken RBCs was dispensed to 
each well. The mixture of every well was mixed by tapping the plate gently and then 
the RBCs were allowed to settle for about 30-60 min at 4°C. The Haemagglutinating 
Units (HAU) are: 2x, where X is the number of the last well without tear-shaped 
streaming. 
 
2.2.9 Confocal laser scanning microscopy and immunofluorescence assay 
(IFA) 
Confluent cells were trypsinized by 1X trypsin-EDTA, reseeded in the 3.5 cm dish 
containing sterile glass cover-slips (12 mm) and incubated at 37°C with 5% CO2. On 
the next day, the cells were confluent. After infection or transfection, the growth 
medium was removed from the culture dish at the indicated time points, and the cells 
were washed once with 1X PBS++, then the cells were fixed with 1 ml 4% PFA in 1X 
PBS++ over night at 4°C. After fixation, cells were washed twice with 1X PBS++ and 
subsequently incubated with 1 ml 1% Triton X-100 for 45 min. Cells were then 
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washed 3X with 1X PBS++  and incubated with 20 µl of the primary mouse anti-Flu A 
NP mouse (clone 1331) (1:200 dilution in PBS++/3% BSA) or rabbit anti-GST-NS1 
polyclonal antibody (1:1000 in PBS/3% bovine serum albumin), kindly provided by T. 
Wolff, (Berlin, Germany) for each cover-slip for 1 h at room temperature. Afterwards 
cells were washed three times as before, and further incubated with 20 µl of the 
secondary Alexa 594 goat anti-mouse IgG (1:200 diluted in PBS++/3% BSA) or goat 
anti-rabbit IgG (1:200 diluted in PBS++/3% BSA)  for 1 h at room temperature. The 
cells were then washed again three times and incubated with 20 µl DAPI (10 mg/ml 
in PBS/3% bovine serum albumin, Roth) for 5 minutes. After a further three washes 
(as above) and an extra wash with ddH2O, the glass cover slip was fixed on a glass 
slide with Mowiol/DABCO overnight. Fluorescence was visualised using a TCS-SP5 
confocal laser-scanning microscope (Leica). 
2.2.9.1 Mowiol/DABCO mounting medium 
Add 2.4 g of Mowiol 4-88 to 6 g of glycerol. Stir to mix. Add 6 ml of H2O and leave for 
several hours at room temperature. Add 12 ml of 0.2 M Tris-HCl (pH 8.5) and heat to 
50°C for 10 min with occasional mixing. After the Mowiol dissolves, clarify by 
centrifugation at 5,000 g for 15 min. For fluorescence detection, add DABCO to 2.5% 
to reduce fading. Aliquot in airtight containers and store at −20°C. Stock is stable at 
room temperature for several weeks after thawing.  
 
2.2.10 Western blotting (Semi-dry) 
2.2.10.1 Measurement of protein concentration (Bio-Rad protein assay) 
The Bio-Rad protein assay is based on the observation that when Coomassie 
Brilliant Blue G250 binds to the protein the absorbency maximum shifts from 450 nm 
to 595 nm. 5 µl of cell lysate (as described in 2.2.4. section) was added into diluted 
Bio-Rad Dye Reagent (1:5 dilution of Dye Reagent concentrate in ddH2O). Mix well 
and after a period of 10 min, the relative protein content was determined by 
measuring the absorption at wavelength 595 versus reagent blank (containing the 
lysis buffer only). This was done to apply an equal protein amount of all samples onto 
the SDS-PAGE gel. 
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2.2.10.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) 
The electrophoresis apparatus was assembled according to manufacturer's (Bio-
Rad) instruction, and the resolving gel was poured in between the two glass plates. 
Leave a space about 1 cm plus the length of the teeth of the comb. Isopropanol or 
100% ethanol was added to the surface of the gel for an even distribution along the 
gel surface. After the resolving gel was polymerized, isopropanol was removed and 
the stacking gel was poured on top of the resolving gel. Insert the comb and let the 
gel polymerise. Mixed 75 µl total of containing protein sample (after determining the 
protein concentration) with 35 µl laemlli buffer containing 10% β-mercaptoethanol to 
reduce disulphide bonds were incubated for 5 min at 95°C  and cooled on ice for 1 
min, then shortly centrifuged and the calculated sample amount was loaded into 
wells of gel. Rainbow protein marker (Roche, 2 µl marker + 8 µl laemlli buffer) was 
loaded as control. After running buffer was added to the chamber, a cover was 
placed over the gel chamber. Gels should be run at about 20 V/cm gel length. The 
negatively charged SDS-proteins complexes migrate in the direction of the anode at 
the bottom of the gel. Small proteins move rapidly through the gel, whereas large 
ones stay at the top. Proteins that differ in mass by about 2% can be distinguished 
with this method. The electrophoretic mobility of many proteins in SDS-
polyacrylamide gels is proportional to the logarithm of their mass. 
2.2.10.3 Transfer membrane in "Semi-dry" electroblotter  
After the cell extracts were subjected to SDS-PAGE, the proteins were transferred by 
electroblotting onto a PVDF-Membrane, which was incubated before in 100% 
Methanol for 2-3 min, and washed three times (5 min each) in ddH2O, then 
equilibrated in the transfer buffer for 2-3 min. On a layer of 2 blotting papers soaked 
with transfer buffer the PVDF-Membrane was laid. The polyacrylamide gel and again 
2 blotting papers soaked with transfer buffer were then placed on the PVDF-
Membrane, making a "sandwich" (without any bubbles), and laid in "Semi-dry" 
electroblotter. The current was set to 0.8 mA/cm2 for 90 min for transfer. 
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2.2.10.4 Immunodetection of proteins 
After transferring the proteins, the PVDF-Membrane was washed for 5 min in 1X 
TBS-T buffer, then the membrane was blocked in blocking buffer (5% non-fat milk in 
TBS-T) for 1 h at room temperature or overnight at 4°C. There after the membrane 
was washed for 5 min in 1X TBS-T buffer, then incubated with the primary antibody 
(e.g. anti-Flu A-NP monoclonal antibody, 1:500 dilution in blocking buffer or anti-NS1 
monoclonal antibody) for 1 h at room temperature or overnight at 4°C. After washing 
three times (5 min each) in 1X TBS-T buffer, the membrane was incubated with the 
secondary antibody solution (e.g.: HRP-conjugated anti mouse monoclonal antibody, 
1:1000 dilution in blocking buffer) for 1 h at room temperature. 
2.2.10.5 Enhanced chemiluminescence (ECL) reaction 
As mentioned above the membrane was washed three times (5 min each) in 1X 
TBS-T buffer and once in 1X TBS, then incubated for 1 min in ECL (enhanced 
chemiluminescence) solution, which was prepared according to the manufacture 
(Amersham) between a glass plate and a clear plastic membrane. After 1 min, 
everything was laid into a photo cassette, and then a light sensitive film was placed 
on top of the membrane and exposed for 1.5-5 min or longer. The film was then 
developed. 
In order to detect the beta-actin protein (as a loading control), the attached antibody 
was stripped from membrane by incubating the membrane in a 1:10 diluted “strong 
stripping solution” (Re-Blot Plus Western Blot Recycling Kit, Chemicon) for 45-60 min 
at 37°C. After washing with 1X TBS-T buffer for 5 min, the membrane was incubated 
in blocking buffer for 1 h at room temperature. Then it was washed for 5 min in 1X 
TBS-T buffer and incubated with the anti-beta-actin monoclonal antibody (1:10000 
dilution in blocking buffer) solution for 1 h at room temperature. Subsequently the 
membrane was washed three times in 1X TBS-T buffer and washed once in 1XTBS, 
then incubated for 1 min in ECL solution and proceeded as mentioned above. 
2.2.10.6 Quantification of protein bands 
Protein bands exposed on the film were scanned (Canon scan LiDE 30/N1240U) at 
800 dpi, and the picture was saved in grey scales as TIFF file. The intensity of 
protein bands was densitometrically determined by means of PC-BAS software. 
These steps were done for the specific bands of the protein to be detected (e.g. NP 
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or NS1) as well as beta-actin bands. The lowest value of beta-actin band, which was 
set to one, was divided by each value of beta-actin bands to get a factor for each 
according specific protein band value. This calculation was done to normalize the 
amount of specific protein by the amount of beta actin protein loaded. 
 
2.2.11 Primer extension 
2.2.11.1 Isolating RNA (Trizol Method) 
To isolated  total RNA from infected cells, confluent MDCK cells in 35 mm dishes 
were infected with different recombinant virus at MOI=2 in triplicates. The total 
cellular RNA was extracted with Trizol reagent (Invitrogen) at different time point post 
infection (2 h p.i., 4 h p.i., 6 h p.i. and 8 h p.i.) as followed: The medium from 
transfected or infected cells in 35 mm dishes was aspirated and 1 ml of Trizol was 
added into the dishes, after 5 min incubation at room temperature, Trizol was stirred 
with P1000 tip until all the cells are suspended. Then the solution was transferred 
into an reaction tube and was incubated at room temperature for 10 min. To each 
reaction tube 200 μl of chloroform was added and mixed properly and incubate for 5 
min at room temperature with occasional shaking. Later the tubes were centrifuged 
for 20 min at 4°C at 13,000 rpm. The upper phase (app. 0.6 ml) was transferred later 
into fresh RNAase free reaction cup. 0.5 ml isopropanol was added to this upper 
phase supernatant and mixed properly and incubated at room temperature for 10 
min. Afterwards centrifuge at 13,000 rpm for 20 min at 4°C. The supernatant was 
removed carefully and 1 ml of ethanol was added to the pellet and centrifuged at 
13000 rpm for 5-10 min at 4°C. Without dislodging the pellet, alcohol content was 
discarded and pellet was air dried for 5-10 min and dissolved in 30 μl of RNAase free 
H2O (Life Technologies) and used directly for the experiment or frozen at -70°C. 
2.2.11.2 Primer labeling 
The gene-specific primers used were as followed: NP mRNA and cRNA 5ʹ- 
ACCATTCTCCCAACAGATGC 3' (expected size of cRNA 121 nt and mRNA, 135 nt). 
NP vRNA: 5ʹ ATGATGGAGAGTGCCAGACC 3' (expected size of band 181 nt.  On 
receiving, the primers should be diluted into the concentration of 10 pmol/µl in 
RNAase free ddH2O. Mixed well with other components of labeling reaction and 
incubated at 37°C for 1 h in PCR thermoblock. 
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Labeling reaction:           Primer 10 pmol/µl           1  µl 
DPEC H2O                                  6  µl 
10X PNK Buffer (Roche)          1  µl 
[γ-32P]ATP (6000 Ci/mmol, 10 µCi/µl)             1 µl 
PNK (T4 polynucleotide kinase, 10 U/µl)          1  µl 
              ------------------ 
                         10  µl 
After 1 h incubation, This 10 μl mixture was transferred into new 1.5 ml RNAase-free 
reaction cup and further 450 μl PN-buffer (Qiagen Nucleotide removal Kit) was 
added, mixed well and placed over the Qiagen Nucleotide removal column with the 
help of a pipette. The column was spin for 1 min at 6,000 rpm and the collection was 
discarded. The column was washed 2 times with 500 μl PE-buffer. Further spin down 
for 1 min at 6000 rpm and the collection was discarded followed by one more time 
spinning down for one minute at 13,000 rpm to remove residual alcohol content in the 
column. Fresh 1.5 ml RNAase free eppendorf tube was labelled clearly and the 
column was placed onto it. 40 μl EB-buffer or RNAase free H2O was added on the 
column and incubated for 2 min at room temperature. Finally the tube was 
centrifuged for 1 min at 13000 rpm and eluted (40 μl) was collected in the eppendorf. 
This can be stored at -20°C in isotope room. 
2.2.11.3 DNA-marker labelling 
 
Labeling reaction:           autoclaved ddH2O        6.0  µl 
1 Kb DNA Ladder (Roche marker IV)     1.0  µl 
10X PNK Buffer (Roche)       1.0  µl 
[γ-32P]ATP (6000 Ci/mmol, 10 µCi/µl)               1.0  µl
 PNK (T4 polynucleotide kinase, 10 U/µl)     1.0  µl 
                                                                     ------------------ 
                       10  µl 
Mixed well and incubated at 37°C for 1h in PCR thermoblock. After 1 h incubation, 
This 10 μl mixture was transferred into new 1.5 ml RNAase-free eppendorf tube and 
further proceeded with Qiagen Nucleotide removal Kit as mention above and stored 
at -20°C in isotope room. Before gel loading, add the phosphorylated markers directly 
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to the Loading Dye, heat at 95°C for 10 minutes and then immediately load the 
markers onto the denature running gel. 
2.2.11.4 Reverse transcriptase 
Labelled primer-mix: mix the primers as follows according to the no. of samples to be 
analyzed and always make surplus than the need. 
For one sample:  
32P labelled  Primer for vRNA (10 mmol/µl)   0.25 µl 
32P labelled primer for cRNA and mRNA (10 mmol/µl) 0.25 µl 
32P labelled primer for 5s rRNA100  (10 mmol/µl) 0.25 µl 
Primer for 5s rRNA100 (cold) (10 mmol/µl) 0.25 µl 
DEPC ddH2O 3 µl 
Total                 4 µl 
For one reaction, 1.0 µl (10 µg) of Trizol-purified RNA was mixed with 4.0 µl of primer 
mixture. After 3 min running at 95°C in PCR block, the tubes were placed on ice for 5 
min. During 5 min incubation time, the superscript mixture was prepared as followed: 
 
For one sample : 
5X RT buffer (Invitrogen) 2.0 µl 
100 mM DTT (Invitrogen)  1.0 µl 
10 mM dNTP (sigma) 0.5 µl 
DEPC ddH2O 1.25 µl 
Superscript  II (Invitrogen, 10 U/µl ) 0.25 µl 
Total 5 µl 
Superscript master mix was prepared as mentioned above, and then pre-incubated 
at 45°C alongside with the primer-RNA mixture in a PCR block. When the RNA-
primer samples reached to 45°C, 5 μl of the Superscript mix was aliquoted into the 
RNA mix, then incubated for 1 h at 45°C (for reverse transcriptase reaction), followed 
by incubation at 70°C for 10 min (to inactivate the Superscript) and cooled to 4°C. 
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2.2.11.5 Running the 6% 7M urea polyacrylamide gel  
During reverse transcriptase reaction, the 6% 7M urea polyacrylamide gel should be 
prepared as follows: 
 
                                        Urea                             21.0   g 
10X TBE                  5. 0 ml 
40% acrylamide                 7. 5 ml 
                                                                      ------------------
Autoclaved ion free water to                              50 ml 
 
The above solution was mixed very well until the powder is dissolved. When the gel 
apparatus is ready, 0.5 ml 10% APS and 0.05 ml TEMED is added to the falcon tube 
and mixed quickly. The gel mixture was poured into the apparatus followed by 1 h 
incubation at RT and was fixed in the gel tank. Then pre-run at 50W for 1 h until the 
temperature of gel rise to 50°C. 8 μl of formamide mix (10 mM EDTA, xylene cyanol 
(Sigma No: X-2751XC), Bromophenol blue (Sigma, sodium salt), ACS reagent, No: 
B-7021BPB)) was added to each samples and mixed, and heated to 95°C. 10 μl of 
each sample was loaded on the gel. The gel was run at 50 W until the blue dye is 
approximately 3 cm away from the bottom of the plate. When the gel run was 
finished, the glass plates were separated very carefully and the gel should stick to 
one of the glasses. The gel on the glass plates was transferred to wattman-paper 
and was wrapped in Clingfilm (plastic foil side at the top). Then the gel was dried in 
vacuum drier for 60 min. When the gel was dried, it was placed in the screen 
cassettes together with a image plate phosphor (Fuji Photo Film Co. Ltd. ) the gel 
side should be facing towards the white side of screen) overnight. Next day the 
screen was scanned on a typhoon 9200 (GE Healthcare) and the bands were 
quantified using the “Quantity One” software package (BioRad). The Increases of 
vRNA, mRNA and cRNA level were compared to the strain-specific RNA level at 2 h 
p.i.. 
 
2.2.12 Tunel assay (in situ cell death detection Kit)  
Extensive DNA degradation is a characteristic event which occurs in the late stages 
of apoptosis. Cleavage of the DNA may yield double-stranded, low molecular weight 
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DNA fragments (mono- and oligo-nucleosomes) as well as single strand breaks 
(“nicks”) in high molecular weight DNA. Those DNA strand breaks can be detected by 
enzymatic labeling of the free 3’-OH termini with modified nucleotides (X-dUTP, X = 
biotin, DIG or fluorescein). This method is called “Terminal deoxynucleotidyl 
transferase dUTP nick end labeling” (Tunel).  
  
A549 cells grown on 6 well plate were infected with recombinant viruses at MOI=1 for 
10 h. Cells were washed with 1X PBS, then cells were trypsinized and transferred to 
eppendorf tube. Afterward cells were fixed with 4% paraformaldehyde (PFA) in 1X 
PBS (pH 7.4) over night at 4°C.  The samples were then washed twice with 1X PBS, 
centrifuge at 6,000 rpm for 5 min.  Cell pallets were permeabilized with 1% Triton X-
100 in 0.1% sodium citrate on ice for 20 min. Cells were washed and incubated with 
50 µl reaction mixture (provided in in situ cell death detection Kit, Invitrogen) or the 
"no enzyme" control in 50 µl label solution (provided in in situ cell death detection Kit, 
Invitrogen) for 1 h in the dark. After 3 washes with 1X PBS, cells were incubated with 
DAPI (10 mg/ml in 1X PBS containing 3% bovine serum albumin) for 10 min in the 
dark. Finally, cells were washed twice and were fixed in 3.7% formaldehyde in 1X 
PBS. Fluorescence was visualised using FAC analysis. 
 
2.2.13 IFN-beta enzyme linked immunosorbent assay (ELISA) 
IFN-beta concentrations were assessed using the human IFN-beta ELISA Kit (PBL) 
according to the manufacturer’s protocol. Briefly, confluent A549 cells in 3.5 cm 
dishes were infected with the different recombinant virus at an MOI of 0.01, and at 24 
h p.i., 36 h p.i. and 48 h p.i. 100 μl of supernatant was taken and added into 96-well 
plates coated with human IFN-beta IgG Fab fragments, together with standards, and 
incubated for 1 h with shaking at RT. After 2 times washes with washing solution 
(human IFN-beta ELISA Kit), the human HRP-labelled IFN-beta antibody (human 
IFN-beta ELISA Kit) was added and incubated for 1 h with shaking at room 
temperature. After 3 times washes, the substrate solution (human IFN-beta ELISA 
Kit) was added to develop the colour, followed by the stop solution (0.5 M H2SO4) 
and the OD at 450 nm was measured. 
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2.2.14 Microarray  
The microarray experiment were performed to compare the mRNA expression 
profiles of A549 cells infected which variant Influenza virus FPV-NS (MOI=2, 6 h p.i.) 
to A549 cells mock-infected with 1X PBS with 2 biological replicates. Six hours after 
infection, total RNA was isolated using the RNeasy mini Kit (QIAGEN, Hilden) 
following the manufacturer’s protocol. Quality control and quantification of total RNA 
was assessed using a NanoDrop1000 UV-Visspectrophotometer (Kisker) and an 
Agilent 2100 Bioanalyzer (Agilent Technologies). The microarray analysis was 
performed using single-color hybridizations. RNA labeling was done with the Low 
RNA Input Linear Amplification Kit PLUS (Agilent Technologies). In brief, mRNA was 
reverse transcribed and amplified using an oligo-dT-T7 promoter primer, and cyanin-
3 labelled cRNA was subsequently generated by T7 RNA-polymerase. After 
precipitation and purification, 1.25 µg of of each labelled cRNA was fragmented and 
hybridized to AgilentSurePrint G3 Human GE v2 8x60K Microarrays (Agilent Design 
ID 039494) according to the supplier’s protocol. Microarrays were scanned with 2 μm 
resolution using an Innoscan 900 scanner (Innopsys) and images were gridded with 
Mapix 6.5.0. Data were analyzed in R using limma. Signal intensities were quantified. 
Normalized log signal intensities of replicated spots were averaged before further 
processing. Genes were considered as up or down regulated relative to mock 
infected cells if they showed more than 2-fold different in average signal intensities 
and were statistically significant at the p≤0.01 level using ANOVA.  Gene set tests 
were performed for the KEGG pathways and Gene Ontologies using the gene Set 
Test function from limma on the moderated t-statistics. (According to Microarray 
Service by Dr. J. Wilhelm, ECCPS, Giessen). 
 
2.2.15 RNA analysis by qRT-PCR 
A549 cells were infected with recombinant viruses at MOI of 3. To analyze the 
primary viral transcription, cycloheximide (100 µg/ml) was added to the infection 
media. At 6 h p.i., cells were collected in Trizol and RNA was purified according to 
the manufacturer’s protocol. To measure the accumulation levels of viral mRNA and 
vRNA, quantitative RT-PCR (qRT-PCR) was performed. Total RNAs were subjected 
to reverse transcription using SuperScript III reverse transcriptase (Invitrogen) with 
either oligo-dT (50 pmol) or 5'-GACGATGCAACGGCTGGTCTG-3' (10 pmol) primer 
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for synthesizing cDNA from segment 5 (NP) mRNA, or vRNA, respectively. The 
synthesized single-stranded cDNA were subjected to real-time quantitative PCR 
analysis (MX3000P; Stratagene) using Power SYBR® Green PCR Master Mix 
(Invitrogen) and a set of specific primers (NP) (see below). The levels of these RNAs 
were normalized by the amount of cellular beta-actin mRNA measured using specific 
primers (see below). The results shown are averages from three independent 
experiments with standard deviations. The level of significance was determined by 
Student's t-test (unpaired). 
 
2.2.16 Mice infections 
C57BL/6J mice were obtained from Janvier, France and maintained under specific 
pathogen free conditions in a BSL3 facility at the Helmholtz Centre for Infection 
Research, Braunschweig, according to the German animal welfare law. The protocol 
used in these experiments has been approved by an ethics committee (Permit 
Number: 33.9.42502-04-051/09). Female mice (10-12 weeks of age) were 
anaesthetized by intra-peritoneal injection with ketamin-xylazines olution (85% NaCl 
(0.9%), 10% ketamine, 5% xylazine; 200 µl per 20 g body weight) and then infected 
intra-nasally with a dose of 2X104PFU of the respective virus in 20 µl sterile 1X PBS. 
Body weight was monitored every day. Mice showing more than 30% of body weight 
loss were euthanized. 
 
2.2.17 In silico analysis of NS1 protein flexibility at different temperatures 
3D models for NS1 of GD, MA and MA mutant were generated using Phyre2 Protein 
structure prediction on the web: a case study using the Phyre server [145], based on 
PDB structure 3F5T [X-ray structure of NS1 from a highly pathogenic H5N1 influenza 
virus [146]. The molecules were minimized and solvated in a neutralized water box of 
14x14 Å using NAMD [147-150]. Scalable molecular dynamics with NAMD [150] and 
vmd [151]. After equilibration and heating to the target temperature for ~0.7 
beta-actin-F GACGATGCAACGGCTGGTCTG 
beta-actin-R GGTCATCTTCTCGCGGTT 
NP-F GACGATGCAACGGCTGGTCTG 
NP-R AGCATTGTTCCAACTCCTTT 
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nanoseconds, the molecular dynamics simulations were performed using the 
CHARMM22 force-field [152] for 20 nanoseconds. 
 
2.2.18 Statistical analysis 
Each point corresponds to the mean +/- S.D. of the indicated experiments. The 
statistical significance of differences between the indicated groups was tested using 
the unpaired Student’s t test with a threshold of p: significant * < 0.5; very significant 
** <0.01 and very very significant *** < 0.001. 
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Chapter 3 
Results 
In order to cross the species barrier to mammals, AIV must gain adaptive mutations 
to overcome host specific restrictions for an efficient viral replication in the new host 
[89]. Beside amino acid (aa) changes in viral hemagglutinin (HA) to overcome the 
poor HA-binding to the cellular receptors of the new host [71, 74, 76, 77, 153, 154] 
and adaptations of the NS1 to escape the host immune response [155-157], the viral 
RNA-dependent RNA polymerase (RdRp) plays a central role in IAV replication and 
is known to undergo adaptive changes when IAV transmits between species. It was 
reported that the change E627K in PB2 of AIV is responsible for enhancing viral 
polymerase activity in mammalian cells, but not in avian cells [158]. However, the 
E627K substitution is not the only mammalian-adaptive mutation that can arise in the 
polymerase. Indeed, a large proportion of H5N1-type AIV strains isolated from 
humans possess a PB2:627E, suggesting that other adaptive aa substitutions must 
exist in order to counterbalance the generally low polymerase activity in human cells. 
Along this line, it was also reported that PB2:591K/R and PB2:701N can compensate 
for a lack of PB2:627K, thereby ensuring efficient polymerase activity in mammalian 
cells [90, 92]. Furthermore, there is evidence that the PB1 gene from an avian source 
promotes polymerase activity of human IAV in mammalian cells [87]. Two aa in an 
AIV PB1 (473V and 598P) were identified to further increase the polymerase activity 
of human IAV carrying PB2:627E in mammalian cells [88]. Besides adaptive 
mutations in the polymerase subunits PB1, PB2, and PA and the nucleoprotein (NP) 
also changes in the nuclear export protein (NEP) have been found to be involved in 
the viral host adaptation [89].  
 
In the recent years, it has become increasingly apparent that the NS1 gene is 
another factor likely to be responsible for enhancing IAV polymerase activity. NS1 
has been highlighted in an important interaction with the ribonucleoprotein (RNP) 
complex that regulates viral genome replication [56, 104, 117, 159].  In this respect it 
was shown that the NS1 protein interacts with the RNP complex in vivo [117] and 
that truncated NS1 affected the production of viral RNA (vRNA) but not of cRNA and 
mRNA in infected Madin-Darby canine kidney II (MDCK-II) cells, implicating a role of 
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NS1 in the regulation of viral genome replication [56]. Among many functions the 
NS1 protein of a human IAV was also shown to inhibit the activity of the cellular anti-
viral acting PKR and to regulate the time course of viral RNA synthesis during 
infection in mammalian cells for review [19] and  [104]. The NS segment of an H5N1-
type AIV could greatly improve the replication efficiency of the reassortant avian 
strain FPV (H7N1) in mammalian but not in avian cells by altering the production of 
viral RNA species [160]. NS1 also interacts with CPSF30, a host RNA polymerase II 
(Pol II)-associated factor involved in the 3’-end processing of host mRNAs, in a 
macromolecular complex also containing viral polymerase and NP [161]. In this 
regard, these findings provide substantial evidence that NS1 is capable to modulate 
viral genome replication and able to confer a significant replicative advantage during 
mammalian adaptation of AIV. However, it remains to be determined, which specific 
part and/or which aa of NS1 are involved in modulating viral polymerase activity, 
providing a rationale for this study. 
 
In this report, I demonstrate that the specific aa changes D74N and/or 
P3S+R41K+D74N in the NS1 protein are sufficient for mammalian adaption of AIV. I 
provide a detailed characterization of the phenotypic changes caused by these 
residues and I report the importance of these specific residues for strongly enhanced 
mRNA production as well as viral protein production in mammalian cells. At the same 
time these adaptive changes are not disadvantageous in avian cells. My study also 
suggest that the D74N and/or P3S+R41K+D74N substitutions are involved in the 
temperature adaptation of the AIV polymerase from birds to mammals, as the 
adaptive changes enhanced the production of viral RNAs synthesis at temperatures 
representative for the human upper respiratory tract (33-37°C), whereas no affect 
occurred at avian temperature (41°C). Furthermore, these substitutions enable a 
strictly AIV to replicate in mice and cause disease. Together, the adaptive mutation 
D74N and/or P3S+R41K+D74N in NS1 protein allow AIV to establish successful 
infections in mammalian cells.  
 
3.1 Identification mammalian adapted amino acid on NS1-GD 
A previous report by Wang and co-workers [160] has shown that different NS 
segments of highly pathogenic avian influenza virus (HPAIV) strains 
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A/Goose/Guandong/1/1996 (GD, H5N1) and A/Mallard/NL/12/2000 (MA, H7N3) in 
the genetic background of the HAPIV strain A/FPV/Rostock/34 (FPV, H7N1), resulted 
in altered viral replication characteristics including alteration of the RdRp activity. The 
reassortant virus FPV-NSGD replicates to high titer, while FPV-NSMA replication 
efficiency was impaired in mammalian cells [160]. However, in avian cell culture 
systems, both reassortant viruses replicate to similar extent. These results suggested 
that the NS1-GD contributes to mammalian adaptation. The two different NS 
segments of strain GD and MA belong to the same NS allele (allele A). These differ 
by only eight amino acids (Fig. 3.1A). In order to determine specific aa or aa 
combinations in the NS1-GD that might be responsible for improved replication of 
FPV-NSGD in mammalian cells, I utilize two chimera NS segments cloned into an 
according vRNA expression vector provided by our collaboration (Kalle Saksela, 
Finland). The first one, containing the N-terminal half of the NS-GD fused with the C-
terminal half of NS-MA (NS-GD/MA). The second one, containing the N-terminal half 
of NS-MA fused with the C-terminal half of NS-GD (NS-MA/GD) (Fig. 3.1B). 
 
To investigate the effect of mutations on viral replication, both vRNA expressing 
vectors for both NS chimeras were used to generate recombinant reassortant viruses 
in the backbone of a FPV by reverse genetics. The identity of the viruses was 
confirmed by RT-PCR and sequences analysis. I then determined the replicative 
properties of these reassortant viruses. For this I infected cells at a MOI of 0.01 and 
examined the kinetics of viral growth (Fig. 3.2A). The obtained results show that the 
reassortant virus harboring NS-GD/MA, grew similar to FPV-NSGD. In contrast, the 
reassortant virus harboring NS-MA/GD showed impaired replication in mammalian 
cells similar to FPV-NSMA. This result is reflected in the individual plaque size of the 
according viruses. I found that the reassortant virus harboring NS-GD/MA yielded 
large plaques (Fig. 3.2B), comparable to FPV-NSGD, while the reassortant virus 
harboring NS-MA/GD yielded small plaques. These results indicate that the residue 
difference between NS1-GD and NS1-MA of S3, K41, N74, V98 and S153, which are 
located in N-terminal part of NS1-GD, are contributing to the mammalian adaption of 
the respective reassortant virus in my experimental setting. However, its NS1 protein 
did not have any known high pathogenicity-associated determinants 
[90,156,162,163]. 
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Fig. 3.1 Structural and functional comparison of NS-MA and NS1-GD protein. (A) Comparison of the NS1 
amino acid sequences of A/Goose/Guangdong/1/1996 (GD) to A/Mallard/NL/12/2000 (MA). Sequences were 
aligned with CLUSTAL W. The different amino acid positon among of them are indicated, blue; GD and red, MA. 
(B) Schematic representation of chimeric NS1 containing the N-terminal sequence of 
A/Goose/Guangdong/1/1996 (GD) and the C-terminal sequence of A/Mallard/NL/12/2000 (MA) “GD/MA” and the 
chimeric NS1 containing the N-terminal sequence of A/Mallard/NL/12/2000 (MA) and the C-terminal sequence of 
A/Goose/Guangdong/1/1996 (GD) “MA/GD”. 
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Fig. 3.2 Growth kinetic of virus infected cells. (A) Replication kinetic, A549 cells were infected with wild type 
and mutant virus containing chimeric NS1 expression plasmid at MOI of 0.001. Supernatant of cells inoculated at 
a MOI of 0.001 were harvested at 12 h interval until 48 h post infection. The virus titers were determined by foci 
assay on MDCK cells. (B) Plaque assay, MDCK cells were inoculated with wild type and mutant virus expressing 
chimeric NS1. At 48 h p.i., cells were washed, fixed with 3.7% formaldehyde and stained with 1.25% Coomassie 
blue in 0.25% methanol. Error bars represent standard deviation (n=3). 
 
To further confirm the relevance of the five aa of NS1-GD (S3, K41, N74, V98 and 
S153) for mammalian adaptation, the codon of each of these aa was introduced into 
NS1-MA sequence in the corresponding vRNA expressing vector by site directed 
mutagenesis, replacing those found in the NS1-MA gene to yield five different 
mutated NS1-MA segments. In addition the codons for the aa combinations 
P3S+R41K, P3S+R41K+D74N, P3S+R41K+D74N+I98V and 
P3S+R41K+D74N+I98V+D153S were introduced in the same way. To investigate the 
effect of the adaptive mutations on viral replication, FPV-NSMA virus variants 
expressing the different NS1-MA proteins were generated by reverse genetics. As 
mentioned in section 2.2.7, 293T cells were transfected with 4 plasmids expressing 
polymerase proteins, NP and 7 plasmids expressing vRNA of FPV-PB1, FPV-PB2, 
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FPV-PA, FPV-NP, FPV-HA, FPV-NA, FPV-M, together with plasmids expressing 
vRNA of FPV-NS of the wild type A/chicken/FPV/Rostock/34 (FPV-WT, H7N1) or 
with other NS segments from A/Goose/Guangdong/1/96 (GD, H5N1), 
A/Mallard/NL/12/2000 (Ma, H7N3) and NS-MA mutants. At 24 h after transfection of 
293T cells, the harvested medium from transfected dishes was screened for rescued 
influenza virus by observation of liquid CPE and plaque assay on MDCK cells. After 
three rounds of plaque purification, the recombinant viruses were confirmed by 
restriction enzyme digestion of RT-PCR products obtained from the NS vRNA. 
Additionally, the NS, HA, NA and PB2 segments from different recombinant viruses 
were amplified by RT-PCR and sequenced by GATC corp. The results showed that 
after three passages, the NS, HA, NA and PB2 were not changed (data not show).  
 
After generation by reverse genetics, all nine possible FPV-NSMA variants were 
characterized. The replication kinetics were studied and compared to FPV-NSGD and 
FPV-NSMA in different host cell species: human A549 and avian QT6 cells. Given the 
titres achieved for each reassortant in human A549 cells (Fig. 3.3) the recombinants 
containing either the single substitution in NS1-MA (FPV-NSMA_D74N) (Fig. 3.3iv) or 
the triple substitutions in NS1-MA (FPV-NSMA_P3S+R41K+D74N) (Fig. 3.3viii) show similar 
or even higher virus replication compared to FPV-NSGD, respectively. Interestingly, 
FPV-NSMA_D74N and FPV-NSMA_P3S+R41K+D74N show comparable replication efficiency 
on avian QT6 cells (Fig. 3.4). This result revealed that the single substitution D74N 
and the triple substitutions P3S+R41K+D74N in NS1-MA protein implicated an 
important functional role for enhanced replication of an AIV in mammalian cells.  
 
I further asked the question whether P3S plus D74N or R41K plus D74N is needed 
for mammalian adapted virus strain. Results are presented in Fig 3.5. The growth 
kinetic (Fig. 3.5A) and plaque size (Fig. 3.5B) confirmed that the substitution P3S, 
R41K together with D74N or D74N alone can improve virus replication 
independently. Nevertheless, only the triple combination shows an optimal result. 
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Fig. 3.3 Growth kinetic of viruses in infected A549 cells. A549 cells were infected with wild type or different 
mutant virus at MOI of 0.001. Supernatant were harvested at 12 h interval until 48 h post infection. The virus 
titrations were determined by foci assay on MDCK cells. Error bars represent standard deviation (n=3). 
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Fig. 3.4 Growth kinetic of viruses in infected QT6 cells. QT6 cells were infected with wild type or different 
mutant virus at MOI of 0.001. Supernatant were harvested at 12 h interval until 48 h post infection. The virus 
titrations were determined by foci assay on MDCK cells. Error bars represent standard deviation (n=3). 
. 
 
                                                                                                                                                       Results 
 
80 
 
 
Fig. 3.5 Replication kinetics and plaque analysis. (A) A549 cells were infected with FPV-NSGD, FPV-NSMA or 
different mutant virus at MOI of 0.001. Supernatant were harvested at 12 h interval until 48 h post infection. The 
virus titrations were determined by foci assay on MDCK cells. (B) Plaque assay, MDCK cells were inoculated with 
FPV-NSGD, FPV-NSMA or different mutant. After 48 h p.i., cell were washed, fixed with 3.7% formaldehyde and 
stained with 1.25% Coomassie blue in 0.25% methanol. The diameters of plaques were measured in total 50 
plaques. The results represent the averages from three independent experiments. 
 
3.2 Specific effect of the amino acid substitutions in the NSMA on the plaque 
phenotype of reassortant FPV viruses  
In order to investigate whether the specific amino acid substitutions in the NSMA 
altered the replication speed of the wt FPV virus, I performed in vitro replication of the 
recombinant FPV-NS variants with harboring adaptive mammalian mutation by 
measuring plaque size upon infection of MDCK cells. At 48 h post infection, cells 
A 
B 
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were fixed and stained with 1.25% comases blue in methanol and acetic acid and the 
diameter of 50 plaques in duplicates was quantified. The results are presented in Fig. 
3.6. The MDCK cells infected with FPV-NSMA_P3S+R41K+D74N yielded plaques that were 
comparable to those observed for FPV-NSGD. However, plaques of cells infected with 
FPV-NSMA_D74N resulted in slightly increased size compared to FPV-NSMA, but the 
FPV-NSMA_D74N yielded plaques smaller than those observed for FPV-NSGD and FPV-
NSMA_P3S+R41K+D74N. This suggests that the adaptive mammalian substitutions 
P3S+R41K+D74N in the NS1 protein contribute to enhanced speed of virus 
replication in mammalian cells as shown by big plaque size, but it is not the case for 
single substitution D74N 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.6 Plaque assay. MDCK cells were inoculated with FPV-NSGD, FPV-NSMA as control and FPV-NSMA 
containing the indicated substitutions. At 48 h p.i., cell were washed, fixed and stained. The diameters of the 
plaques were measured (total 50 plaques in duplicates) (left panel). The size of individual plaques was plotted 
using boxplots indicating the median value and quartiles (right panel). Differences between individual groups 
were significant (p<0.01) in Student’s t-test.  
 
3.3 Substitution D74N and P3S+R41K+D74N in the MA-NS1 protein alters RNP 
export in mammalian cells 
Efficient nuclear export of RNPs is important for the production of infectious virus 
[164,165]. In order to investigate whether the substitution D74N and 
P3S+R41K+D74N in the NS1-MA protein affected viral RNP export patterns, NP 
localization was analyzed by immunofluorescence using an anti-NP antibody (Fig. 
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3.7). At 6h p.i., A549 cells infected with recombinant FPV-NSGD showed most NP 
protein predominantly in the cytoplasm, while FPV-NSMA showed a more nuclear 
localization. However, in cells infected with FPV-NSMA_D74N and FPV-
NSMA_P3S+R41K+D74N most NP protein was located in the cytoplasm in similar pattern as 
FPV-NSGD, indicating that the substitution D74N and P3S+R41K+D74N in the MA-
NS1 protein can alter RNP export dynamic. Interestingly, QT6 cells infected with 
different recombinant viruses showed analogues viral RNP export patterns. This 
indicates that the substitution D74N and P3S+R41K+D74N in the MA-NS1 protein do 
not influence RNP export dynamics in avian cell. It seems possible that the 
substitution D74N and P3S+R41K+D74N in the MA-NS1 protein contribute to rapid 
RNP export and higher infectious virus titres in mammalian host. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.7 RNP localization in infected cells. Immunofluorescence showing RNP export of the different 
recombinant viruses. A549 and QT6 cells were infected with recombinant viruses at an MOI of 3 and at 6 h p.i. 
stained with an anti-NP antibody (green) and DAPI (blue) for the nuclei. The results represent one out of three 
independent experiments. 
 
3.4 Substitutions D74N and P3S+R41K+D74N in the NS1-MA protein do not 
alter NS1 protein localization and do not correlate with infectious viral titre 
NS1 contains two nuclear localization signals (NLS) and one nuclear export signal 
(NES), which are responsible for the bi-directional transport of the protein between 
the nucleus and the cytoplasm. The NS1 protein can therefore localizes either in the 
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nucleus or in the cytoplasm or in both compartments [166, 167]. The aa sequence 
comparison showed that the sequence of both, the NLS1 (34-39 aa) and NLS2 (216-
220 aa) are conserved between the two NS1 proteins of GD and MA. However, the 
mammalian adaptive substitutions D74N and P3S+R41K+D74N in the NS1-MA 
protein are located close to the NLS1 region, possibly influencing its intra-cellular 
localization. Therefore, I investigated the localization of the NS1 proteins of the 
different reassortant viruses (FPV-NSGD, FPV-NSMA, FPV-NSMA_D74N, FPV-
NSMA_P3S+R41K+D74N) in infected A549 and QT6 cells. At all times points of the infection 
I found that the NS1 proteins of all viruses were predominantly cytoplasmic in A549 
infected cells (Fig. 3.8A), while all viruses infected QT6 cells showed a cytoplasmic 
and nuclear NS1 localization (Fig. 3.8B). Hence, the substitutions in the NS1-MA 
protein do not alter its intra-cellular localization, and therefore the infectious titre of 
the respective FPV-NSMA variants in A549 cells does not correlate with intra-cellular 
localization of the different NS1 proteins. 
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Fig. 3.8 The NS1 localization in infected cells. A549 (A) and QT6 (B) cells were infected with wild type and 
mutant virus at MOI of 3. At the indicated time points post infection, cells were fixed and stained using a rabbit 
polyclonal anti-NS1 primary, and Alexa 594 anti-rabbit (red) as well as DAPI (blue) to localize NS1 and the 
nucleus, respectively. Representative images are shown (taken using a 63x oil immersion objective). The results 
represent one out of three independent experiments. 
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3.5 The contribution of D74N and P3S+R41K+D74N in the MA-NS1 protein 
enhances viral protein synthesis in mammalian cells 
To determine the consequences of the aa substitutions in the NS1-MA at the level of 
the viral protein production, cells were infected with either FPV-NSGD or the mutant 
FPV-NSMA viruses and viral protein production was determined during a single-
infection cycle. For this, infected A549 cells (MOI=2) were lysed at the indicated time 
points p.i. and the viral proteins were detected after SDS-PAGE by Western blot 
using NS1- and NP-specific antibodies. The results are presented in Fig. 3.9A.  
Apparently, NS1 and NP synthesis in human A549 cells was strong over the entire 
time course of the FPV-NSGD infection. In contrast, I observed a delay in the 
synthesis as well as a low overall amount of these viral proteins during FPV-NSMA 
infection. However, compared to viral protein production in cells infected with FPV-
NSMA, I observed a higher accumulation of the viral proteins over the entire time 
course of the infection in cells infected with FPV-NSMA_D74N and FPV-
NSMA_P3S+R41K+D74N. Here, the amounts of NS1 and NP were comparable to those of 
the FPV-NSGD (Fig. 3.9A). The delay in viral protein synthesis as well as the low level 
of viral protein production observed for FPV-NSMA could be due to slower kinetics of 
viral RNA replication, viral transcription, or both. However, this defect was rescued in 
FPV-NSMA_D74N and FPV-NSMA_P3S+R41K+D74N virus-infected cells, suggesting that 
these substitutions in the NS1-MA protein might contribute to kinetics of viral RNA 
replication, viral transcription or both. The situation in avian QT6 cells was different 
(Fig. 3.9B). I found that the kinetic and also the amount of viral protein synthesis are 
undistinguishable between the different viruses in all infections. This could be due to 
equal mRNA or vRNA accumulation in these avian cells, and might be a possible 
explanation for the high production of viral proteins in the QT6 cells. To investigate 
these assumptions, I next set out to determine the accumulation of viral vRNA, 
mRNA and cRNA in cells infected with the different viruses.  
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Fig. 3.9 Viral protein synthesis in infected cells. A549 (A) and QT6 (B) cells were infected with wild type and 
mutant viruses at MOI of 3. Cells were lysed at the indicated time points, and the lysates were analyzed for the 
viral proteins NS1 and NP by immunoblotting under identical conditions. Cellular actin was detected as a loading 
control. The results represent one out of three independent experiments. 
 
3.6 Substitutions D74N and P3S+R41K+D74N in the MA-NS1 protein enhanced 
viral polymerase activity in a RNP reconstitution assay 
The NS1 protein has been shown to be involved in viral RNA replication [16, 56, 160, 
168], translation of viral mRNA [57, 169] and also the temporal regulation of vRNA 
synthesis was affected in NS1 mutant viruses [104]. Furthermore, the NS1 protein 
has been shown to interact directly with the viral polymerase complex [159]. In 
addition, NS1 also seems to interact with the 5′ untranslated region (5′-UTR) of viral 
mRNAs, enhancing their translation [57].  
 
To test the hypothesis that the single substitution D74N or the combination of 
P3S+R41K+D74N in the MA-NS1 protein might affect the viral polymerase activity, I 
utilized a RNP reconstitution assay that recreates functional influenza virus RNPs by 
transfecting cells with plasmids that separately express the three polymerase 
proteins PB1, PB2, PA, NP and NS1 and a (-) vRNA segment encoding a CAT gene. 
To determine polymerase complex function, CAT activity [22] was used as a marker 
of mRNA transcription. The principle of the in vitro RNP reconstitution assay is shown 
in Fig. 3.10. The results are presented in Fig. 3.11. In 293T cells, the polymerase 
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complex of FPV co-transfected with NS1-GD was significantly more active than that 
of wild-type NS1-FPV or NS1-MA (P<0.001, Student’s t-test). However, when the 
FPV polymerase complexes were co-transfected with NS1-MAD74N or NS1-
MAP3S+R41K+D74N, the reverse pattern was observed. The substitutions D74N in NS1-
MA resulted in a 2.5-fold increase in CAT activity as compared to the NS1-MA and 2-
fold compared to the wild-type NS1-FPV. Whereas, substitutions P3S+R41K+D74N 
in NS1-MA yielded a 4.5-fold increase in CAT accumulation compared to those 
induced by the NS1-MA and 4-fold compared to the wild-type NS1-FPV. Remarkably, 
the triple substitutions P3S+R41K+D74N in NS1-MA resulted even in a 1.5-fold 
increases as compared to NS1-GD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.10 Principle of RNP reconstitution assay (CAT assay). The plasmid pPOLI-CAT-RT contains the CAT 
open reading frame in minus sense flanked by the noncoding regions of the NS RNA segment of influenza 
A/WSN/33. Expression of the influenza virus-like RNA is driven by a truncated human RNA pol-I promoter and 
ended by a sequence derived from the hepatitis delta virus genomic ribozyme (R). The other four plasmids 
express viral PB1, PB2, PA, and NP proteins with a CMV promoter. These proteins are able to amplify and 
transcribe the influenza virus-like RNA expressed by pPOLI-CAT-RT into mRNA, resulting in the detection of CAT 
activity in transfected human 293 cells. The represented regions in the plasmid constructs are not drawn to scale 
[22]. 
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My data thus show that the different NS1 proteins can affect the viral polymerase 
activity of avian FPV virus, and that this effect is greater in mammalian cells when 
NS1 possess amino acid residues D74N and P3S+R41K+D74N. This observation 
raises the possibility that yet unknown molecular features in the NS1 contribute to 
high level of polymerase activity of avian FPV virus in mammalian cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.11 Effects of the substitutions in the NS1-MA protein on viral polymerase activity using RNP 
reconstitution assay. Relative CAT activity (normalized against FPV 3PNP+NSWT) after reconstitution of the 
avian FPV polymerase (FPV+3PNP) in 293T cells and co-transfection of plasmids encoding the different MA-NS1 
variants (NSGD, NSMA, NSMA_D74N and NSMA_P3S+R41K+D74N) or empty plasmid vector (control). Error bars represent 
standard deviation (n=3). 
 
3.7 Substitutions D74N and P3S+R41K+D74N in NS1 protein enhances viral 
genome synthesis 
To study the activity of the viral polymerase in more detail I investigated the amount 
of vRNA, cRNA and mRNA produced during the time course of a viral infection, by 
primer extension assays (The principle of primer extension is shown in the Fig 3.12) 
using total cellular RNA isolated from virus infected A549 and QT6 cells. At various 
time points after infection with MOI=2 using FPV-NSGD, FPV-NSMA, FPV-NSMA_D74N, 
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and FPV-NSMA_P3S+R41K+D74N viruses, all three RNAs species were detected and 
quantified.  
 
 
Fig. 3.12 Primer extension for detection of viral replication and transcription. As mentioned before, viral 
vRNA is replicated by a cRNA (full length copy) into more vRNA (replication) and transcribed into viral mRNA 
primed by cellular 5’ cap primer from vRNA (transcription). These three viral RNAs are different in their ends. If 
two radioactivity labelled primers are used for reverse transcription (RT) reaction to detect vRNA and 
cRNA/mRNA, they will give products of different length. After separation on the 7M urea 6% PAGE sequence gel, 
the RT products can be quantified to show the amount of viral RNA species.  
 
The results are presented in Fig 3.13A. Compared to FPV-NSGD, FPV-NSMA 
synthesized apparently lower amounts of all viral species in A549 cells. However, in 
infection with FPV-NSMA_D74N and FPV-NSMA_P3S+R41K+D74N virus infected cells led to 
elevated levels of all three viral RNA species similar to FPV-NSGD, predominantly 
increasing the amount of vRNA and cRNA, while marginally changing the mRNA 
quantity. Notably, infection with FPV-NSMA_D74N resulted in a minor increase in the 
level of vRNA and cRNA, while in a significant increase of the mRNA levels at early 
time points (2-4 h p.i.), but then significantly decreasing at late time points of infection 
(6-8 h p.i.). These results are compatible with the data obtained by in vitro 
reconstitution of recombinant RNPs (Fig 3.11). In contrast, in all virus-infected QT6 
cells no difference in the amounts of viral RNAs (Fig. 3.13) was observed. Here, 
production of all RNA species showed similar kinetics over the entire course of the 
infection, suggesting that the efficiency of polymerase activity of FPV-NSGD, FPV-
NSMA and FPV-NSMA mutants remained constant. From these results, I conclude that 
the single substitution D74N and the triple substitution P3S+R41K+D74N in MA-NS1 
increases mRNA production is based on transcription activity (mRNA levels) only or 
also in part on replication activity of the RdRp (vRNA, cRNA-level). 
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Fig. 3.13 Effects of the mutations in the NS1-MA protein on viral RNA synthesis. A549 (A) and QT6 (B) cells 
were infected (MOI of 2) with FPV-NSGD, FPV-NSMA, FPV-NSMA_D74N and FPV-NSMA_P3S+R41K+D74N. At the indicated 
time p.i. the accumulation levels of vRNA, cRNA and viral mRNA were determined by primer extension (shown in 
the upper panels), and the amount of these RNAs were normalized to that of cellular 5S rRNA (shown in the lower 
panels). Increase in the levels of vRNA, cRNA and mRNA at 4, 6, 8 h p.i. of each viruses were set in relation to 
the strain-specific RNA levels at 2 h p.i.. This experiment is represent one out of at least three independent 
experiments. 
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3.8 Viral transcription are affected by the substitutions D74N and 
P3S+R41K+D74N  
Based on the results mentioned above the level of viral RNA synthesis and the 
increase of virus protein synthesis in the presence of MA-NS1 with either the single 
substitution D74N or the triple substitution P3S+R41K+D74N (Fig. 3.13) could be 
caused by the viral genome amplification and/or the viral genome transcription.  
 
To elucidate whether the substitutions affect genome replication (cRNA and vRNA 
synthesis) and/or transcription (viral mRNA synthesis) activities, I measured the 
primary transcription activity, i.e. transcription directed by the incoming parental 
RNPs in the absence of viral RNA amplification using cycloheximide (CHX), a potent 
inhibitor of protein synthesis. It was previously shown that CHX suppresses (viral) 
protein synthesis and thereby leads to the degradation of newly replicated viral 
genomic RNA, but not of viral mRNA since formation of new vRNPs was repressed 
[170-172]. I utilized this method to measure the primary transcription activity that 
depends only on the incoming vRNPs excluding effects of the secondary genome 
replication process. Therefore, the levels of viral mRNA and vRNA in the absence or 
presence of CHX were determined after cells were transfected with different plasmid 
encoding NS1 and superinfect with different viruses. As the primer extension 
technique showed not to be suitable for this purpose, probably due to the overall low 
levels of viral RNAs in the infected cells, I performed qRT-PCR and the viral 
transcription activity was calculated as the ratio of viral mRNA/vRNA (Fig. 3.14). The 
results show that the difference of the mRNA/vRNA ratio for the NP segment of the 
FPV-NSGD is significantly higher than in the FPV-NSMA infected cells in the absence 
or presence of CHX (Fig. 3.14A and 3.14B). Interestingly, the difference of the 
mRNA/vRNA ratio between cells infected with FPV-NSMA_D74N or FPV-
NSMA_P3S+R41K+D74N compared to cells infected with FPV-NSMA is also higher in the 
absence and presence of CHX (Fig. 3.14A and 3.14B). These data indicate that 
either D74N alone or the combined P3S+R41K+D74N substitutions in the NS1-MA 
protein has an affect on transcription activity. 
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Fig. 3.14 Primary transcription activity of NS1 mutant influenza A viruses containing amino acids specific 
for mammalian adapted virus strains. A549 cells were infected with different viruses at MOI of 3 and incubated 
in the absence (A) or presence (B) of 100 µg/ml of CHX (right panel). At 4 h p.i., the accumulation levels of mRNA 
and vRNA were measured by qRT-PCR, and the amounts of these RNAs were normalized by that of cellular actin 
mRNA. The transcription activity is represented as a ratio of the amount of mRNA to that vRNA. Error bars 
represent standard deviation (n=3). 
 
3.9 Substitutions D74N and P3S+R41K+D74N in NS1-MA result in a replication 
advantage at lower temperature  
It has long been hypothesized that something as simple as the temperature at the 
site of replication could influence the host and tissue tropism of the virus [173-175]. 
Human-tropic influenza viruses are considered to replicate in the upper respiratory 
tract at 33–37°C, while AIV replicate in the gut of the birds at around 41°C [174]. The 
polymerase is an important determinant of influenza virus host range and 
pathogenicity [156,176,177] that is likely to be influenced by temperature. In our 
study, we could demonstrated that the substitution D74N and/or P3S+R41K+D74N in 
the NS1-MA protein contribute to enhanced polymerase activity, regulate viral 
genome synthesis, and thus increase the poor propagation of an avian virus in 
mammalian cell culture, thereby impeding the host restriction. To this point, I next 
asked, whether these substitutions would also result in a replication advantage at a 
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temperature comparable to the upper respiratory tract of mammals (e.g. humans). 
Since one of the substitution D74N is situated in the linker region (LR) of the NS1 
protein, I reasoned that this substitution might influence in flexibility of the NS1 
protein. Because of the inherent flexibility in the LR [178], a particular NS1 could 
acquire alternative conformational states allowing the RNA binding domain (RD) or 
the effector domain (ED) to engage in different quaternary interactions that 
participate in specific protein/protein or protein/RNA interactions. I therefore 
proposed that the ambient temperature might influence the flexibility of the NS1 
protein. To this end, I applied temperature dependent in silico structure simulation 
(data provided by M. Lechner, Marburg) to investigate the flexibility of NS1 at 33°C 
and 41°C. The results are presented in Fig. 3.15. At 33°C, the D74N change in NS1-
MA introduces significantly more flexibility compared to wild-type NS1-MA. 
Interestingly, this effect cannot be reproduced at 41°C. Here, the mutation does not 
apparently change the protein's flexibility, which remains similar to that of the wild-
type NS1-MA. Notably, NS-GD is most flexible at 33°C as well as at 41°C. 
 
 
Fig. 3.15 Flexibility of the NS1 mutant protein. Distance of the geometric centers of both NS1 subunits 
connected by the linker (positions 5-70 and 106-225) over the course of 20 nanoseconds (ns) in a virtual 
molecular dynamics simulation using namd (http://www.ks.uiuc.edu/Research/namd/) at 33°C and 41°C. Boxplots 
summarize the distances of the last 12 ns (to mask border effects of the simulation in the first 8 ns).  
 
 
Next I analyzed, whether the in silico-predicted increased flexibility given by D74N 
substitution would also affect viral replication at low (33°C) or elevated (41°C) 
temperatures in vitro. To study this in the context of a viral infection, A549 cells were 
infected with FPV-NSGD, FPV-NSMA, FPV-NSMA_D74N, and FPV-NSMA_P3S+R41K+D74N 
viruses as indicated in Fig 3.16. Multiple-cycle growth curves show that FPV-NSGD, 
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FPV-NSMA_D74N, and FPV-NSMA_P3S+R41K+D74N viruses replicate efficiently at 33°C, and 
41°C, whereas, FPV-NSMA was restricted at 33°C. However, at 41°C it replicated as 
efficiently as all the other variants. The comparable replication efficiency of the 
viruses tested at elevated temperature equivalent to the avian gut could be due to the 
fact that all viruses tested have an avian (FPV) background. Nevertheless, the data 
indicate that avian viruses with increased replication ability in mammals can arise in 
birds without any replication disadvantage in birds. 
 
 
 
 
 
 
Fig. 3.16 Effect of temperature on virus replication. Comparison of the growth kinetic of NS1 mutant influenza 
A viruses containing amino acids specific to mammalian adapted virus strain by multi-cycle assay. A549 cells 
were infected at MOI of 0.001 and incubated at either 33°C or 41°C. Virus titers at indicated time points were 
determined by foci assay. Error bars represent standard deviation (n=3). 
 
To further determine the influence of the incubation temperature on viral RNA 
synthesis in the context of an infection, cells were inoculated with the four different 
viruses (FPV-NSGD, FPV-NSMA, FPV-NSMA_D74N, and FPV-NSMA_P3S+R41K+D74N) and 
incubated at 33°C or 41°C. Lysates of infected cells were harvested every two hours 
until eight hours p.i., and total cellular RNA was isolated. Primer extension was 
performed for the simultaneous detection and quantification of v-, c- and mRNA from  
segment 5 (NP). The results are presented in Fig. 3.17. Compared to FPV-NSGD 
infected cells, the vRNA accumulation from FPV-NSMA infected cells showed similar 
kinetics at 41°C, but two to threefold decreased accumulation rates at 33°C. 
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However, this reduction was partially rescued in FPV-NSMA_D74N and fully 
compensated in FPV-NSMA_P3S+R41K+D74N infected cells. To analyze whether the 
reduction of vRNA obtained by FPV-NSMA was a consequence of a decreased cRNA 
production, the accumulation of NP cRNA was also determined at both temperatures. 
The result is presented in Fig. 3.17. Here, I could not observe a temperature-
dependent effect on the cRNA accumulation of the different viruses. These results 
indicated that the aa at position S3, K41 and N74 in the NS1-MA protein might affect 
the process of vRNA generation rather than cRNA production and demonstrate that 
the functional disadvantage of the NS1-MA at lowered temperature can partially be 
rescued by the D74N substitution and fully compensated by the triple change 
(P3S+R41K+D74N), suggesting that the aa S3+K41+N74 in the NS1-MA contribute 
to the temperature-sensitive phenotype observed for FPV-NSMA. 
 
To elucidate whether the reduction in vRNA accumulation of FPV-NSMA at the 33°C 
would be reflected in viral transcription, the accumulation of the various mRNAs was 
analyzed. The results obtained for NP mRNA are presented in Fig 3.17. Similar to the 
effect on vRNA accumulation, NP mRNA accumulation was significantly reduced at 
33°C in FPV-NSMA infected cells, but was comparable to the amount of the other 
mRNAs at 41°C. Again, this difference in the levels of the specific mRNAs was 
equilibrated in FPV-NSMA_D74N and FPV-NSMA_P3S+R41K+D74N infected cells. These 
results are fully compatible to the growth kinetic of the viruses-infected cells. In 
summary, these data support the concept that the substitutions in NS1-MA 
significantly contribute to overcome the notable physiological difference between 
avian and mammalian host systems.  
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Fig. 3.17 Effect of temperature on viral RNA synthesis. A549 cells were infected at MOI of 3 and incubated at 
either 33°C or 41°C. After the indicated time points post infection, cells were lysed and RNAs accumulation levels 
were determined by primer extension analysis using primer specific for segment 5 (NP). The accumulation levels 
of viral mRNA and vRNA were measured by primer extension, and the amount of these RNAs were normalized by 
that of cellular actin mRNA. Increase in the levels of vRNA, cRNA and mRNA at 4, 6, 8 h p.i. of each viruses were 
set in relation to the strain-specific RNA levels at 2 h p.i. This experiment is represented one out of at least three 
independent experiments. 
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3.10 Substitutions P3S+R41K+D74N in the NS1-MA contributed to pathogenic 
in mice 
In cell culture I have identified adaptive changes in the NS1, which contribute to the 
ability of avian viruses to overcome host range restrictions and to replicate efficiently 
in mammalian cells. To evaluate the effect of the adaptive changes P3S, R41K and 
D74N in the NS1 of avian virus on the virulence and replication in a mammalian 
model, I infected C57BL/6J mice with 2x104 PFU of FPV-NSGD, FPV-NSMA, FPV-
NSMA_D74N and FPV-NSMA_P3S+R41K+D74N by intranasal infection. It was previously 
shown that FPV wild-type is not pathogenic for mice [179]. I then monitored body 
weight and survival rate. In my experiments, mice either succumbed to the infection 
or were euthanized when they had lost more than 30% of their initial body weight. 
FPV-NSGD and FPV-NSMA viruses showed similar levels of virulence in mice (Fig. 
3.18). Mice that were infected with these two viruses showed a slight loss of body 
weight (10-15%) up to day 5 p.i.. First mice started to die at day 9 p.i.. Surprisingly, 
no major differences in overall mortality caused by the two viruses were observed. In 
contrast, mice infected with FPV-NSMA_P3S+R41K+D74N succumbed to infection even 
more rapidly, and there was a dramatically loss of body weight up to 17% at day 2 
p.i. and up to 30% at day 3 and no mouse survived beyond day 5 p.i.. In contrast, 
only one mouse infected with FPV-NSMA_D74N succumbed to the infection (Fig. 
3.18B). These results strongly suggest that the adaptive substitutions 
P3S+R41K+D74N in the NS1-MA protein resulted in severe pathogenicity in mice. 
However, the single change D74N (FPV-NSMA_D74N) had no appreciable effect on the 
virulence of FPV-NSMA, but in contrast to the in vitro experiment did not show strong 
pathogenicity for mice. 
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Fig. 3.18 Pathogenicity of NS1 mutant viruses in mice. Female mice (10-12 weeks of age) C57BL/6J mice 
were inoculated intranasal with the recombinant FPV-NS variant viruses. The percentages of surviving mice and 
weight loss during the course of the experiment are given. (A) The body weights of infected mice were recorded 
up to 14 days p.i.. Error bars indicate standard deviations. Mice had to be euthanized when they lost more than 
30% of their initial body weight (B). Morbidity and mortality were analyzed for mice intranasal infected with 2x104 
PFU of the virus. 
 
3.11 Prevalence of D74N and/or P3S+R41K+D74N in the NS1 of IAV 
To assess the prevalence of the aa S3, K41 and N74 in the NS1 protein of IAV, I 
determined the frequency of these residues from NS sequences (31,237 sequences) 
that were obtained from the NCBI’s Influenza Virus Resource database [180]. I found 
that the pathogenicity marker, the aa N74 and the combination S3+K41+N74 
represents only 0.1-2% of the available human-, avian-, and other-isolates except for 
swine viruses where it is represented around 10% (Fig. 3.19). Although the pool of 
viruses encoding the N74 and/or S3+K41+N74 in the NS1 gene was small, a pattern 
emerged that associated this substitutions with adaptation to host-switching (Table 
3.1). P3S+R41K+D74N was found in swine isolates from 1976-1979 of H1N1 virus 
that switched from avian to swine hosts (Table 3.1) P3S+R41K+D74N was also 
independently observed in two case of the 1997 H5N1 virus (A/Hong Kong/481/97-
H5N1 and A/Hong Kong/437-6/1997-H5N1) that switched from avian to human host, 
in one case of the 2013 H7N9 virus A/Fujian/1/2013 (H7N9) that also switched from 
avian to human host and was also found in the pandemic 2009 H1N1 virus that 
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switched from swine to human host (Table 3.1). Interestingly, the aa 3S+41K are 
already highly conserved in human, avian, swine, and other IAV (Fig. 3.19) resulting 
in a significant percentage of around 94-96% of all virus isolates (Fig. 3.19). I 
therefore asked next what function (s) are affected by Asparagine (N) at position 74 
in an NS1, which already possesses S3+K41.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.19 Percentage of viruses encoding NS1 protein with adaptive residues (S, K, N) at aa position 3, 41 
and 74. Amino acid sequences of the NS1 proteins (Human: 11,152, Avian: 10,678, H5N1: 2,715, Swine: 3,085, 
and other: 851 sequences) of influenza A viruses obtained from the NCBI’s Influenza Virus Resource database 
were analyzed (accessed: 20 October 2014). The percentages of isolated virus of human, avian, swine and other 
origin containing the indicated aa S3, K41, N74 alone or in combination, S3+K41 and S3+K41+N74 in their NS1 
are shown. 
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Table 3.1 List of represent virus containing the 3S+41K+74N in NS1 protein 
 
 
3.12 Asparagine at position 74 of the NS1 enhances viral RNA synthesis also in 
the FPV wild type 
I could show that either the single D74N or the triple P3S+R41K+D74N substitution in 
the NS1-MA protein, placed in the FPV background, enhanced viral genome 
replication and transcription in mammalian cells. To now determine whether this 
effect would only occur in this specific genetic constellation or whether this would 
also apply for NS1 proteins belonging to allele A and to a wild type avian IAV, I 
changed D74 to N in the NS1 protein of FPV-WT, which already carries S and K at 
position 3 and 41. I hypothesized that this virus would show a similar phenotype as 
Accession 
number 
Name subtype Origin Host Amino acids 
 
ACZ47203 A/Hong Kong/437-6/1997 H5N1 Avian Human S3+K41+N74  
AF084285 A/Hong Kong/482/97 H5N1 Avian Human S3+K41+N74  
AGK82162 A/Fujian/1/2013 H7N9 Avian Human S3+K41+N74  
AEL89636 A/Bangkok/INS481/2010 H1N1 Avian Human S3+K41+N74  
ACZ96032 A/Texas/45104048/2009 H1N1 Swine Human S3+K41+N74  
ADG42288 A/Hvidovre/INS141/2009 H1N1 Swine Human S3+K41+N74  
ACY30105 A/Niigata/749/2009 H1N1 Swine Human S3+K41+N74  
ADM33114 A/Lagos/WRAIR1984T/2009 H1N1 Swine Human S3+K41+N74  
ADM86424 A/Copenhagen/INS434/2009 H1N1 Swine Human S3+K41+N74  
ADM33094 A/Lagos/WRAIR1982N/2009 H1N1 Swine Human S3+K41+N74  
ABQ45419 A/swine/Tennessee/3/1976 H1N1 Avian Swine S3+K41+N74  
ABQ45430 A/swine/Tennessee/7/1976 H1N1 Avian Swine S3+K41+N74  
ABQ45441 A/swine/Tennessee/15/1976 H1N1 Avian Swine S3+K41+N74  
ABQ45452 A/swine/Tennessee/17/1976 H1N1 Avian Swine S3+K41+N74  
ABQ45463 A/swine/Iowa/1/1976 H1N1 Avian Swine S3+K41+N74  
ABQ45538 A/swine/Tennessee/19/1976 H1N1 Avian Swine S3+K41+N74  
ABR15824 A/swine/Iowa/4/1976 H1N1 Avian Swine S3+K41+N74  
ABD95717 A/swine/Tennessee/25/1977 H1N1 Avian Swine S3+K41+N74  
ABR15835 A/swine/Tennessee/19/1977 H1N1 Avian Swine S3+K41+N74  
ABR15846 A/swine/Tennessee/21/1977 H1N1 Avian Swine S3+K41+N74  
ABR15857 A/swine/Tennessee/31/1977 H1N1 Avian Swine S3+K41+N74  
ABR28641 A/swine/Minnesota/5892-7/1979 H1N1 Avian Swine S3+K41+N74  
CY037902 A/Swine/Belgium/WVL1/1979 H1N1 Avian Swine S3+K41+N74  
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FPV-NSMA_P3S+R41K+D74N. Following my hypothesis, I found that the FPV-NSWT_D74N 
was able to replicate in A549 to higher (1 log) titre than FPV-NSWT, whereas similar 
replication kinetics of both, FPV-NSWT and FPV-NSWT_D74N were observed after 
infection of QT6 cells (Fig. 3.20A). In agreement with my previous results from the 
primer extension assay for FPV-NSMA_P3S+R41K+D74N, infection of A549 cells with FPV-
NSWT_D74N resulted in significantly increased transcript levels of viral mRNA (Fig. 
3.20C) and thus in higher accumulation of viral protein (Fig. 3.20B), while both 
viruses showed similar protein production in QT6 cells (Fig. 3.20B). I also confirmed 
that this single adaptive mutation has the potential to contribute significantly in 
overcoming the temperature restriction that avian viruses are faced in the upper 
respiratory tract of humans, leading to strongly increased virus titers at 33°C (Fig 
3.21A). In agreement with primer extension result (Fig. 3.20C), A549 infected with 
FPV-NSWT_D74N at 33°C resulted in increased transcription levels of mainly vRNA and 
mRNA compared to cells infected with FPV-NSWT. However, similar differences in 
transcript levels were observed after infection at 41°C (Fig. 3.21B). 
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Fig. 3.20 General effect of amino acids in the NS1 for the mammalian adaptation of avian virus strain. (A) 
Comparison of the growth kinetic of avian FPV wild-type and FPV NS1 mutant containing amino acids specific to 
mammalian adapted virus strain (FPV-NSWT_D74N) on A549 and QT6 cells by multi-cycle assay. Error bars 
represent standard deviation (n=3). (B) A549 and QT6 cells were infected with FPV wild-type or FPV-NSWT at 
MOI of 3. Cells were lysed at the indicated time points, and the lysates were analyzed for the viral proteins NS1 
and NP by immunoblotting under identical conditions. Cellular actin was detected as a loading control. A549 cells 
were infected with FPV wild-type or FPV-NSWT_D74N at MOI of 3 and incubated at 37°C. This experiment is 
represent one out of at least three independent experiment. (C) A549 cells were infected with FPV wild-type or 
FPV-NSWT at MOI of 3. After the indicated time points post infection, cell were lysed and RNAs accumulation 
levels were determined by primer extension analysis using primer specific for segment 6. The accumulation levels 
of viral mRNA and vRNA were measured by primer extension. This experiment is represent one out of at least 
three independent experiments. 
 
Finally, the pathogenic potential of the adaptive changes P3S+R41K+D74N for mice 
was further demonstrated by mice infection with FPV wild-type and FPV-NSWT_D74N. 
FPV wild-type is known to be apathogenic for mice [179], but already carries S3 and 
K41 presented in its NS1 protein. By introduction of D74N into NS1 of FPV wild-type. 
I mimicked a FPV-NSMA_P3S+41K+74N phenotype. Following my hypothesis, mice 
infected with FPV-NSWT_D74N showed a dramatic decrease in body weight of up to 
30% at day 8.5 p.i. and beyond day 9 p.i. only one mouse out of ten survived 
infection, while FPV-NSWT only caused a slight loss of body weight up to 20% and 
mice that recovered (9/10) regained 100% (Fig. 3.22). These results strongly 
confirmed the effect on pathogenicity of the adaptive substitutions P3S+R41K+D74N 
in mice. 
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Fig. 3.21 General effect of amino acids in the NS1 for the mammalian adaptation of avian virus strain at 
different temperatures. (A) Comparison of the growth kinetic of avian FPV wild-type and FPV NS1 mutant 
containing amino acids specific to mammalian adapted virus strain (FPV-NSWT_D74N) on A549 and QT6 cells by 
multi-cycle assay at 33°C and 41°C. Error bars represent standard deviation (n=3). (B) A549 cells were infected 
with FPV wild-type or FPV-NSWT_D74N at MOI of 3 and incubated at 33°C or 41°C. After the indicated time points 
post infection, cells were lysed and RNAs accumulation levels were determined by primer extension analysis 
using primer specific for segment 6. The accumulation levels of viral mRNA and vRNA were measured by primer 
extension. This experiment is represent one out of at least three independent experiments. 
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Fig. 3.22 Pathogenicity of FPV-NS1 mutant viruses in mice. Female C57BL/6J mice (10-12 weeks of age) 
(n=10) were inoculated intranasal with the recombinant FPV-NS variant viruses. The percentages of surviving 
mice and weight loss during the course of the experiment are given. (A) The body weights of infected mice were 
recorded up to 14 days p.i.. Error bars indicate standard deviations. Mice had to be euthanized when they lost 
more than 30% of their initial body weight (B). Morbidity and mortality were analyzed for mice intranasal infected 
with 2x104 PFU of the virus. 
 
3.13 Asparagine at position 74 of the NS1 enhances viral replication also in the 
broad spectrum of influenza virus 
In an alternative attempt to confirm my finding that the collectively residues S3, K41 
and N74 in the NS1 significantly contribute to the adaption of avian IAV towards 
mammalian cells, I introduced aa 74N into the NS1 protein (carrying S3+K41) of 
another avian IAV, which basic replication in mammalian cells is impaired. For this I 
selected a pair of viruses SC35 and SC35M.  
 
SC35 was originally derived from A/Seal/Massachusetts/1/80 (H7N7) by serial 
passages in chicken embryo cells, thereby acquiring a multi-basic cleavage site in its 
Haemagglutinin (HA) [181] becoming 100% lethal for chickens, but being low-
pathogenic for mice. Passaging SC35 in mouse lung, resulted in the mouse-adapted 
variant SC35M [163]. In contrast to SC35, SC35M is highly pathogenic for both mice 
and chickens. Both viruses differ mainly by mutations in their polymerase proteins 
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(PB2, PB1, and PA) and in the nucleoprotein (NP). SC35M has a considerably higher 
polymerase activity in mammalian cells than SC35, which correlates with increased 
virulence in mice. Similar polymerase mutations were found in unrelated strains, 
especially H5N1 HPAIV and human isolates [92]. 
 
I determined the viral genome replication and transcription kinetic by primer 
extension. For this, A549 cells were infected with the mutant SC35NS_D74N (NS allele 
A) and compared it to SC35WT and SC35M. The replication of SC35NS_D74N resulted in 
virus titers that were higher than those of SC35WT, but lower than those of SC35M for 
entire time course of infection (Fig. 3.23A). Consistently, determination of viral RNA 
species accumulation by primer extension (Fig. 3.23B) showed a strong increase for 
all viral RNA species in SC35NS_D74N compared to SC35WT infected A549 cells. Again, 
the values for SC35M remained higher, indicating an optimized adaptation. 
Nevertheless, this result demonstrates that one single D74N substitution in NS1 
protein can strongly alter the viral genome replication and transcription, thus 
contributing to improved virus replication in a mammalian host.  
 
Moreover, the introduction of this single mutation N74 into the NS1 of the 2009 
pandemic influenza virus A/Gießen/6/2009 (S-OIV-H1N1) and a A/Thailand/1(KAN-
1/2004 (H5N1) HPAIV both already possessing S3+K41 demonstrated that now 
these mutant viruses show significantly increased replication in human A549 cells 
compared to wild-type viruses (Fig. 3.24). This finding suggest that the acquisition of 
N74 for the AIV that already possess S3+K41 in their NS1, may create viruses with 
improved replication ability in mammalians, including humans. 
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Fig. 3.23 Replication kinetics and viral RNA synthesis of SC35 and SC35-NSG74N on A549 cells. (A) Cells 
were infected with viruses at MOI of 0.001. Supernatant of inoculated cells were harvested at 12 h interval until 48 
h post infection. The virus titrations were determined by foci assay on MDCK cells. (B) Cells were infected with 
viruses at MOI of 2 and incubated for the indicated time post infection. The accumulation levels of viral mRNA and 
vRNA were measured by primer extension, and the amount of these RNAs were normalized by that of cellular 
actin mRNA. Increase in the levels of vRNA, cRNA and mRNA at 4, 6, 8 h p.i. of each viruses were set in relative 
to the strain-specific RNA levels at 2 h p.i. This experiment is represent one out of at least three independent 
experiments. 
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Fig. 3.24 Replication kinetic of (A) A/Thailand/1(KAN-1/2004) (H5N1) and (B) A/Gießen/6/2009 (S-OIV-H1N1) 
harboring specific amino acid N74 in their NS1 segment compared to its wild-type viruses on A549 cells. 
Cells were infected with viruses at MOI of 0.001. Supernatant of inoculated cells were harvested at 12 h interval 
until 48 h post infection. The virus titrations were determined by foci assay on MDCK cells. Error bars represent 
standard deviation (n=3). 
 
Cellular transcription profile response to infection of different NS Gene 
reassortant avian influenza viruses in human host 
To optimize virus production, virus is expected to direct cellular machinery for its 
replication and interfere with cellular pathways that inhibit virus replication. Most 
viruses have evolved countermeasures to limit or delay the cellular innate immunity 
by blocking the activation or signaling of pattern recognition receptors (PRRs), 
inhibiting interferon (IFN) signaling from the IFN receptor or directly inhibiting the 
activity of one or several Interferon-stimulated genes (ISGs) (reviewed in [182]). In 
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addition, many viruses down-regulate transcription and/or translation of cellular 
genes and hence indirectly inhibit the induction of IFNs and ISGs. In the case of 
influenza A viruses, the non-structural NS1 protein is a major molecular determinant 
of virus virulence and contributes significantly in disease progression by modulating a 
number of virus and host cell processes [19, 183, 184]. NS1 is highly multifunctional, 
NS1 can bind many proteins and RNAs, and although it is non-essential for virus 
replication, it has roles in viral protein synthesis, viral RNA replication, virion 
production and can modulate cellular post-transcriptional RNA processing and 
transport [56, 58, 118, 185]. The anti-IFN action of NS1 is exerted through a 
combination of several possible NS1-host cell interactions, such as: (i) down-
regulation of new cellular transcription elongation and post-transcriptional RNA 
processing after infection [186, 187], (ii) inhibition of RIG-I activation [188-190], (iii) 
interference with the IFN signaling [191, 192] and (iv) direct inhibition of specific 
ISGs, like PKR and RNAse L [142, 143, 193]. 
 
Another important function of NS1 protein is to regulate host apoptotic mechanism. 
Apoptosis was initially thought to be a host cellular mechanism to restrict virus 
replication however, there are evidences now that it can be triggered by viral factors 
and can be used by the virus for its own benefit [135, 194]. Both induction as well as 
suppression of apoptosis has been shown to be associated with NS1 protein [138, 
140, 195]. Some studies have shown that NS1 protein specifically derived from H5 
subtypes can induce apoptosis in human cells [138, 140, 196-198] however 
contrasting to that, other studies have shown suppression of apoptotic events by NS1 
protein specifically derived from H1 subtypes in mammalian hosts [140, 195]. Clearly, 
these observations were dependent on virus strain and cellular host system used for 
the study.  
 
In this report, I compared the ability of NS1 proteins of two distinctly different 
subtypes NS-GD (H5N1) and NS-MA (H7N3) in genetic backbone of avian influenza 
viruses FPV (H7N1) to induce host cellular responses. The recombinant virus FPV-
NSGD shows increased replication, whereas the FPV-NSMA replication ability is 
impaired in mammalian cell [160, 179]. However, the global effects of viral infection 
on host cell gene expression profile are largely unknown. Indeed, the understanding 
of host protection at the organism level must take into account factors that are 
                                                                                                                                                       Results 
 
109 
 
beyond cell-intrinsic viral control. A comprehensive analysis of the global host 
response is essential for the development of a complete understanding of the factors 
following infection that might be involved in the adaptation of avian influenza virus to 
the mammalian (human) cell. Microarray analysis, are well suited for this purpose in 
order to have an insight into a role of the NS1 protein in modulating host cellular 
environment. 
 
3.14 The global transcriptomic response to influenza viruses infected A549 
cells 
To assess the whole transcriptomic cellular response to IAV infection, I used 
hierarchical clustering (Fig. 3.25A) to visualize “Euclidian” distances between each 
transcriptomic profile of A549 cells infected with FPV-NSGD, FPV-NSMA, FPV-
NSMA_D74N and FPV-NSMA_P3S+R41K+D74N. This analysis shows that FPV-
NSMA_P3S+R41K+D74N was mostly closer to FPV-NSGD virus strain than FPV-NSMA_D74N. 
The FPV-NSMA was the most distinct. Of note, the response to FPV-NSMA was 
different from mock infected samples. To study the specificity in the host response 
and to detect significant changes in the transcription of the cells infected with the four 
different of IAV, I identified the differentially expression (DE) between IAV-infected 
samples and mock-infected samples at 6 h p.i. using the following criteria: a q value 
of <0.01, as determined by Limma’s empirical Bayes moderated t-test, and a log1.5 
fold change (log1.5 FC) (Fig. 3.25B, 3.25C). Consistent with transcriptomic distance 
analysis, IAVs induced transcriptomic change at 6 h p.i.. The cellular response to 
avian FPV-NSMA infection was significant robust, with 62 DE genes, while there were 
only 39, 47, and 45 DE genes after infection of FPV-NSGD, FPV-NSMA_D74N and FPV-
NSMA_P3S+R41K+D74N, respectively. Altogether, these results show that the host 
response to FPV-NSMA_D74N and FPV-NSMA_P3S+R41K+D74N which harbour the specific 
amino acids D74N alone (FPV-NSMA_D74N) and/or combined P3S+R41K+D74N (FPV-
NSMA_P3S+R41K+D74N) in the NS1-MA segment render the FPV-NSMA virus affected 
globally gene expression more similar to that of the mammalian adapted reassortant 
FPV-NSGD, which is also reflected in the viral properties as mention in the previous 
results.  
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3.15 Functional characterization of host responses specific to FPV-NSGD, FPV-
NSMA, FPV-NSMA_D74N and FPV-NSMA_P3S+R41K+D74N viruses 
In the further study of the specificities in the host response to each of the four IAV 
using the following criteria: a q value of <0.01, as determined by Limma’s empirical 
Bayes moderated t-test, and a log2 fold change (log1.5 FC) (Fig. 3.25C). I found that 
the FPV-NSMA infected cells show highest number up-regulated genes; 50 genes 
were up-regulated whereas FPV-NSGD, FPV-NSMA_D74N and FPV-NSMA_P3S+R41K+D74N 
up-regulated 31, 35 and 38, respectively (Fig. 3.25C). Interestingly, the 31 common 
genes among the virus infected cells show that the majority of the up-regulated 
genes upon virus infection are ISG genes. The ISG RNA expression patterns show 
similarity, however contrasts in the levels of up-regulation (Table 3.2). For four 
recombinant IAV at the log1.5 FC cut-off selected genes belong to early innate 
immune response pathways. A complete list of genes is provided in Table 3.2. For all 
four recombinant IAVs the largest category of up-regulated genes was the ISGs (e.g. 
IFIT2, IFI44L, IFIT3, OAS2, OASL, MX1, RSAD2). Other genes up-regulated by all 
four isolated included interferon-induced chemokines (e.g., CCL5), type III-IFN (e.g., 
IL28A, IL28B and IL29), PRRs (e.g., DDX58, IFIH1, IRF7, IRF3) and other apoptosis 
signaling (e.g. BATF2). Surprisingly, when a log2 FC cut-off with a significance of 
p<0.01 was applied there was unique to FPV-NSMA infected cells (Table 3.27A, Fig. 
3.26A) 12 genes which are not up-regulate in FPV-NSGD, FPV-NSMA_D74N and FPV-
NSMA_P3S+R41K+D74N infected cells. Also there are three genes up-regulate in FPV-
NSMA_D74N but not in NSMA_P3S+R41K+D74N (Table 3.3, Fig. 3.26B). Altogether the results 
indicate that FPV-NSMA carrying amino acid change D74N and combined 
P3S+R41K+D74N in the NS1-MA segment affected the expression of lower number 
of genes than in FPV-NSMA infected cells. Interestingly, all genes that were up-
regulate to FPV-NSMA infected cells are involved in interferon-stimulated genes (e.g. 
poly(ADP-Ribose) polymerases; PARP9, PARP10, OAS1, IDO), involved in antiviral 
activities (e.g.TRIM14, TRIM21, ZC3HAV1) and in the innate immune response 
(IER5L). However, the fact that these genes were not up-regulate in FPV-NSMA_D74N 
and  FPV-NSMA_P3S+R41K+D74N infection, indicates that the amino acid changes D74N 
and combined P3S+R41K+D74N in NS1-MA are prevent interferon-stimulated 
activity, antiviral activity and also innate immune responses of the cells against these 
viruses. 
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Table 3.2 Notable common genes up-regulated and down-regulated in A549 cells 
infected with different recombinant FPV viruses at 6 h p.i. 
 
Gene 
Symbol FPV-NSGD FPV-NSMA FPV-NSMA_D74N FPV-NSMA_P3S+R41K+D74N 
IFIT1 8.5 9.7 8.6 8.8 
IFIT3 8.2 9.5 8.4 8.5 
OASL 8.1 9.3 8.2 8.4 
IFIT2 7.7 9.0 7.9 8.0 
MX1 7.6 8.7 7.7 7.9 
PRIC285 7.2 8.4 7.4 7.5 
BATF2 7.2 8.6 7.5 7.5 
CCL5 6.2 8.6 7.5 6.5 
IL28A 7.0 8.5 7.4 7.4 
IFI6 6.6 7.8 6.9 6.7 
IFITM1 6.5 7.8 6.8 6.7 
IRF7 6.5 7.6 6.7 6.8 
IFI44 6.4 7.4 6.1 6.5 
IFIH1 5.4 7.1 5.5 5.4 
RSAD2 5.2 7.3 6.1 4.4 
OAS2 4.7 5.1 5.0 4.7 
TNFSF10 4.7 6.4 5.4 4.4 
DDX58 4.6 6.4 5.4 5.1 
ISG15 4.6 5.6 4.8 4.9 
IRF1 4.2 6.4 5.1 3.4 
IFIT5 4.2 5.7 4.7 4.5 
SAMD9L 4.1 5.1 4.5 3.9 
IL28B 4.0 6.0 5.3 3.9 
CMPK2 3.9 4.9 4.1 3.4 
IL29 3.8 5.9 4.5 3.2 
MYH9 -1.8 -1.6 -1.5 -1.7 
HERC5 2.8 4.9 3.8 2.8 
IRF9 2.6 3.2 2.7 2.5 
REC8 2.4 3.6 3.3 3.4 
LMO2 2.4 3.9 2.9 2.2 
IFI27 2.3 4.3 3.0 3.3 
SPTAN1 -1.8 -1.9 -1.7 -1.8 
FLNA -1.3 -1.3 -1.2 -1.4 
PLEKHA4 1.8 3.4 2.6 2.5 
FLNB -1.2 -1.3 -1.3 -1.3 
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Table 3.3 List of up-regulated genes in unique response to FPV-NSMA infection 
 
Gene Gene description Log1.5 FC 
TRIM14 tripartite motif containing 14 1.5 
ZC3HAV1 zinc finger CCCH-type, antiviral 1 1.5 
FBXW10 F-box and WD repeat domain containing 10 1.6 
IER5L immediate early response 5-like 1.7 
MME membrane metallo-endopeptidase 2.6 
DTX3L deltex 3-like (Drosophila) 2.3 
SLC6A13 solute carrier family 6 (neurotransmitter transporter, GABA), member 13 2.2 
PARP9 poly (ADP-ribose) polymerase family, member 9 2.9 
IDO1 indoleamine 2,3-dioxygenase 1 3 
UBE2L6 ubiquitin-conjugating enzyme E2L 6 1.6 
OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa 1.3 
PCF11  cleavage and polyadenylation factor subunit, homolog (S. cerevisiae) 1.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                       Results 
 
113 
 
A                                                               B                                                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.25 Number of up-regulated and down-regulated differentially expressed (DE) gene after infection 
with reassortant viruses compared to time matched mock infection. (A) Hierarchical clustering by average 
linkage of reassortant viruses- and mock-infected samples at 6 h p.i. based on their gene expression profiles. 
Distances were calculated using Peason correlation distance. (B) Heat map showing microarray gene profiles of 
reassortant viruses infected A549 cells at 6 h p.i.. Expression of genes with p-value <0.01 and fold change ≥ 1.5. 
For each viral condition, DE genes were classified as up- or down-regulated across infection. Genes were 
clustered in 25 clusters by a constant height cut of the hierarchical clustering dendrogram of Euclidean distance of 
DE profiles. (C) Genes up-regulation and down-regulation in A549 cells infected with recombinant FPV viruses at 
6 h p.i.: Criteria used for differential expression analysis are a q value of < 0.01 as determined by student t-test 
and (log1.5 FC). 
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Table 3.4 List of differentially up-regulated genes between FPV-NSMA_D74N and FPV-
NSMA_P3S+R41K+D74N in infected cells 
 
Gene Gene description Log1.5 FC 
APOL2 apolipoprotein L, 2 2.3 
PARP10 poly (ADP-ribose) polymerase family, member 10 3.6 
TRIM21 tripartite motif containing 21 3.2 
 
 
 
 
 
 
 
 
 
 
              
 
 
 
 
 
 
 
 
 
 
Fig. 3.26 Global analysis of DE genes distinguishing IAV infected A549 cells relative to mock. Venn 
diagram representing the agreement between the lists of DE genes by microarray of IAV viruses relative to mock 
infection at 6 h p.i.. 
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3.16 Pathway enrichment analysis 
I further conducted pathway analyses using the Ingenuity Pathway Analysis (IPA) to 
identify the intracellular signaling pathways that were most significantly represented 
in FPV-NSGD, FPV-NSMA, FPV-NSMA_D74N and FPV-NSMA_P3S+R41K+D74N infected cells 
using Fisher's Exact Test (Table 3.6). The five ranking pathways for all four viruses 
were the same; IFN signaling, chemokine signaling, role of PRRs in recognition virus, 
communication between immune cells and apoptosis signaling. Interestingly, the role 
of five pathways were shared but greatest for FPV-NSMA. This suggests an 
importance of the IFN signaling and apoptosis for FPV-NSMA, while an importance of 
apoptosis also suggested for FPV-NSMA_P3S+R41K+D74N. A role of PRRs in recognition 
virus and communication between immune cells is suggested for all viruses. 
Interestingly, FPV-NSMA_P3S+R41K+D74N stronger affects the apoptosis pathway than 
FPV-NSMA_D74N, suggesting that apoptosis might have an important but different role 
between FPV-NSMA_P3S+R41K+D74N and FPV-NSMA_D74N infected cells. Combined with 
the individual gene analysis, the pathway analysis underscores important similarities 
but also gene specific differences. 
 
Table 3.5 Top five significant canonical pathways affected in IAV-infected A549 cells 
at 6 h p.i. relative to mock 
 
Pathway FPV-NSGD FPV-NSMA FPV-NSMA_M74 
FPV-
NSMA_P3S+R41K+D74N 
IFN signaling 6.50E-07 6.50E-12 6.50E-09 6.50E-08 
Chemokine signaling 3.70E-06 7.70E-10 1.20E-08 5.50E-06 
Role of PRRs in recognition virus 7.50E-06 5.40E-06 5.70E-05 8.30E-05 
Communication between immune 
cells 
3.07E-05 4.70E-06 6.51E-05 4.12E-05 
Apoptosis signaling 7.14E-04 5.17E-08 5.35E-05 5.17E-08 
 
For each canonical pathway we report the p-value of Fisher’s exact test to measure significance in the pathway 
 
 
 
 
 
 
                                                                                                                                                       Results 
 
116 
 
3.17 Reassortant IAV infected A549 cells affects IFN-beta levels  
The difference in the up-regulation of genes, which are mostly interferon-stimulated 
genes (Table 3.2, 3.3) prompted me to ask whether differences occur in the amount 
of interferon secreted from infected A549. IFN-beta levels were measured by ELISA 
in A549 cells infected with recombinant viruses at an MOI of 0.01 at various time 
points (24 h, 36 h and 48 h p.i.). I found that FPV-NSMA induced the highest IFN-beta 
response at all-time points compared to the other three viruses, followed by FPV-
NSMA_D74N at 24 and 36 h p.i. (Fig. 3.27).  This result is well in agreement with the 
result that the highest number and greatest degree of expressed interferon-
stimulated gens are found in FPV-NSMA infected A549 cells (Table 3.2, 3.3, Fig. 3.25) 
great interferon secretion. When these results are compared to the titres of the 
various viruses (Fig. 3.3) it can be concluded that in general the more IFN-beta is 
induced, the lower the virus titre is. 
 
Fig. 3.27 Recombinant viruses induce different levels of IFN-beta.  A549 cells were infected with the 
recombinant viruses at an MOI of 0.01. Supernatants were harvested at 24, 36 and 48 h p.i. and measurements 
were taken using an IFN-beta ELISA Kit. Results represent the average of three independent experiments. 
 
3.18 Recombinant viruses induce different levels of apoptosis 
During the course of my experiments I observed that the FPV-NSMA and FPV-
NSMA_P3S+R41K+D74N viruses appeared to cause cell death in a different way than the 
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FPV-NSMA_D74N, and FPV-NSGD viruses in A549 cells. Cells infected with FPV-NSMA 
and FPV-NSMA_P3S+R41K+D74N rounded-up but did not detach from the dishes, while 
infection with the other two viruses resulted in the cells becoming detached. I 
hypothesized that the FPV-NSMA and FPV-NSMA_P3S+R41K+D74N viruses were inducing a 
different level of apoptosis compared to the other viruses. This would be in well 
agreement with the microarray results, FPV-NSMA and FPV-NSMA_P3S+R41K+D74N 
prominent apoptosis signaling than FPV-NSGD and FPV-NSMA_D74N in infected A549 
cells (Table 3.3). In order to determine the extent of apoptosis induced in cells 
infected with the different viruses. A casespase-3 activity was analyzed as a marker 
for cellular apoptosis and an additional alternative assay (Tunel assay) was used in 
which A549 cells were infected and examined by FACs analysis. I observed that the 
FPV-NSMA and FPV-NSMA_P3S+R41K+D74N viruses induced the highest casespase-3 
activity as well as highest DNA-fragmentation shown by Tunel assay, followed by 
FPV-NSMA_D74N and FPV-NSGD (Fig. 3.28).  Reassortant viruses containing different 
NS segments therefore differ in their abilities to induce cell death. When the extent of 
apoptosis is compared to the infectious titres of the various viruses no correlation 
between levels of apoptosis and virus titres. 
 
      A                                                        B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.28 Levels of apoptosis induced by the recombinant viruses. (A) Caspase-3 activity, A549 cells were 
infected with recombinant viruses at an MOI of 1 and at 10 h p.i. the cells were lysed and being processed using 
Caspase-3 assay Kit (colorimetric, Abcam) according to the manufacturer’s instructions. (B) Detect fragmented 
DNA by Tunnel assay, A549 cells were infected with recombinant viruses at an MOI of 1 and at 10 h p.i. the cells 
were harvested and being processed using the In-Situ Cell Death Detection Kit (Roche). The specimens were 
then examined by FACs analysis.  Results represent the average of three independent experiments. 
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Chapter 4 
Discussion 
In my thesis work I have demonstrate that the specific aa changes D74N and/or 
P3S+R41K+D74N in the NS1 protein are sufficient for mammalian adaption of AIV. I 
provide a detailed characterization of the phenotypic changes caused by these 
residues and I found the importance of these specific residues for strongly enhanced 
mRNA production as well as viral protein production in mammalian cells. At the same 
time these adaptive changes are not disadvantageous in avian cells. My study also 
suggest that the D74N and/or P3S+R41K+D74N substitutions are involved in the 
temperature adaptation of the AIV polymerase from birds to mammals, as the 
adaptive changes enhanced the production of viral RNAs synthesis at temperatures 
representative for the human upper respiratory tract (33-37°C), whereas no affect 
occurred at avian temperature (41°C). Furthermore, these substitutions enable a 
strictly avian influenza virus to replicate in mice and cause disease. Together, the 
adaptive mutations D74N and/or P3S+R41K+D74N in NS1 protein allow AIV to 
establish successful infections in mammalian cells. 
 
4.1 The effect of different NS segments on the replication of a recombinant 
HPAIV FPV is independent of the NS allele, the virus subtype and the year of 
the virus isolation, but depends on host factors and the genetic background 
It was previously shown that replacement of the NS segment of the avian influenza 
virus A/FPV/Rostock/34 (H7N1, FPV) by NS segments from the avian strains 
A/Goose/Guangdong/1/1996 (GD, H5N1) and A/Mallard/NL/12/2000 (MA, H7N3) 
resulted in changes of the viral replication characteristics in mammalian cell culture. 
In my work I show that the replication differences of the reassortant viruses in 
mammalian and avian cells based on the specific NS segments should depend on 
specific host factors. In avian cells, FPV-NSGD and FPV-NSMA had similar titers, 
whereas in mammalian cells FPV-NSGD replicated to titers almost 2 logs higher than 
that of FPV-NSMA (Fig. 3.3 and Fig. 3.4). The NS segments of GD and MA originated 
from avian viruses, and therefore it is plausible to speculate that in the genetic 
background of the avian FPV they should not confer a replication disadvantage in 
avian cells. In this context, it should be noted that in a previous study, the NS 
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segment of the 1918 IAV (H1N1) was set in the genetic background of A/WSN/33 
(H1N1). The virus replicated well in tissue culture (MDCK cells), but was attenuated 
in mice compared to the A/WSN/33 wild type [199]. It was suggested that the 
attenuation in mice may be related to the human origin of the 1918 NS1 gene and 
that interaction of the NS1 protein with host-cell factors might play a significant role in 
viral pathogenesis. Taken together, for the effects exerted by the NS segment 
exchange, it seems to be relevant from which host the donor strain was isolated and 
in which host the recipient is tested. 
 
In an overall comparison of the different NS proteins, I found that the NS1-GD protein 
sequence is similar to that of NS1-MA, differing by only eight amino acids (see 
Fig.3.1A). Using site direct mutagenesis and reverse genetic, I was able to identify of 
key NS1 residues responsible for the adaptation and the virulence in a mammalian 
host namely, S3, K41 and N74. Here I show that avian FPV virus harboring the single 
mutation N74 alone or combined S3+K41+N74 in the NS1 increased viral replication 
in mammalian A549 cells indicating that the mutations demonstrated adaptive 
properties. Increased replicative fitness in mammalian cells was seen at the levels or 
rate of virus propagation as well as viral gene expression (at both the mRNA and/or 
protein level) (see Fig. 3.3, 3.9).  
 
4.2 NS1 localization and expression level are not correlated to the alteration of 
viral propagation 
In order to investigate whether the effect of NS mutants on the propagation of the 
recombinant viruses was caused by differences in the NS1 protein expression levels, 
the individual expression rate was investigated (Fig. 3.8). I found that early in 
infection the FPV-NSGD virus had higher levels of NS1 protein expression than the 
other viruses, however by later time points there were no significant differences. The 
different properties of the recombinant viruses could therefore not be explained by 
different NS1 expression levels. In theory, newly synthesized NS1 is present in the 
cytoplasm, where it may be involved in inhibiting the type 1 interferon expression by 
binding to dsRNA or pppRNA, or inducing a pro-apoptotic or anti-apoptotic pathway. 
After synthesis, the protein is also transported into the nucleus where it interferes 
with the processing and export of cellular mRNAs [105,114,125,200,201].  Later, 
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some of the NS1 will be re-exported into the cytoplasm, where it may play a role in 
the regulation of the host anti-viral response. The NS1 protein has many diverse 
roles in both the cytoplasm and nucleus of infected cells, and therefore at this stage I 
cannot exclude the possibility that the different localizations of the NS1 proteins 
studied may play a role in the downstream effects observed. 
 
Another report showed that all NS1 is located in the nucleus of cells transfected with 
plasmids expressing NS1 protein. It was suggested that the NES of the NS1 was 
specifically inhibited by the adjacent aa sequence in the effecter domain [109]. In 
contrast, in IV-infected cells the NES of the NS1 protein molecules was unmasked, 
and a substantial amount of the NS1 protein is exported in the cytoplasm. Since this 
unmasking only happened in infected cells but not in uninfected cells, it was 
concluded in the report that it is more likely that this unmasking resulted from specific 
interaction between another virus-specific protein or host factors induced/altered by 
infection and the NS1 protein. Here, in A549 infected cells, NS1-GD, NS1-MA-D74N 
and NS1-MA-P3S+R41K+D74N showed the tendency that an increased proportion of 
the NS1 protein resides in the cytoplasm. I assume that the four different NS1 may 
have extended functions in the cytoplasm, which may lead to stronger limitation of 
host antiviral response, including IFN response and apoptosis in the cytoplasm. NS1 
contains two nuclear localization signals and one nuclear export signal responsible 
for their transport between nucleus and cytoplasm. Therefore NS1 can be present in 
the nucleus or the cytoplasm or both [119,166,200-203]. The aa sequence 
comparison between my four NS1 (Fig 3.1A) showed that the NLS1 (34aa-39aa) and 
NLS2 (216aa-220aa) are identical between the four NS1. Maybe this is the reason 
for the similar localization of the four NS1. 
 
NS1 accumulation in the nucleus has been reported to help the replication of IV 
[204]. Here, although NS1-GD, NS1-MA, NS1-MA-D74N, and NS1-MA-
P3S+R41K+D74N had the same NS1 localization patterns, they produced different 
virus titer. The results showed that there was no correlation between intra cellular 
NS1 localization and virus titres, which means they may have different functions even 
they are all localized in nucleus or cytoplasm.  
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4.3 NS exchange also changes the RNP export patterns and this is correlated 
to the virus titer 
The influenza virus genome is transcribed and replicated in the nucleus, where its 
eight segments of negative-sense RNA are encapsidated into ribonucleoproteins 
(RNPs) by the viral nucleoprotein [21]. Newly assembled RNPs are subsequently 
exported to the cytoplasm to be packaged into virus particles. Nuclear export of 
RNPs results from their sequential binding by the viral M1 and NS2/NEP proteins, 
followed by recognition of a nuclear export signal in NEP by the cellular nuclear 
export receptor CRM1 [205]. Accordingly, inactivation of CRM1 in infected fibroblasts 
by the toxin leptomycin B (LMB) causes nuclear retention of RNPs and also causes 
them to redistribute to the nuclear periphery [206, 207]. Here, I show that, in A549 
infected cells, RNP localization of the FPV-NSGD viruses had a mostly cytoplasmic 
distribution, while FPV-NSMA showed a more nuclear RNP localization. This suggests 
that transport of the viral genome out of the nucleus was reduced for these viruses 
(Fig. 3.7). However, FPV-NSMA_D74N and FPV-NSMA_P3S+R41K+D74N had a cytoplasmic 
distribution similar to FPV-NSGD. This suggests this substitutions on the NS1-MA had 
an impact to RNP localization. The more rapid RNP export was found to correlate 
with higher virus titers, an explanation for this could be that less efficient RNP export 
should lead to lower infectious titres by limiting RNPs available for packaging [208]. It 
has recently been proposed that NS2 plays a major role in the transport of vRNPs 
out of the nucleus [209]. Although NS2 does not interact directly with RNPs, it binds 
to M1 associated with vRNPs [210]. Furthermore, NS2 contains a functional nuclear 
export signal (NES) and interacts with components of the nuclear pore complex 
(NPC) in a yeast two-hybrid system [209]. Accordingly, it has been suggested that 
NS2 acts as an adapter molecule that links M1-RNP complexes with the NPC, thus 
mediating their NS2 can mediate RNP export by interaction with M1 protein. The aa 
comparison of NS2/NEP [160] shows that there are only two aa differences between 
the GD and MA NS2/NEP protein sequences. Therefore, if NS2/NEP confers the 
demonstrated difference in RNP export, it should be based on this two aa difference, 
otherwise the RNP export of FPV-NS-GD should be similar to FPV-NS-MA, however, 
here data showed RNP export of FPV-NSMA_D74N and FPV-NSMA_P3S+R41K+D74N is 
stronger than FPV-NSMA without any changes in the NS2/NEP. I therefore unlikely 
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that NS2/NEP is responsible for the observed differences. Further experiments need 
to be performed to investigate this.  
 
4.4 Substitutions D74N and P3S+R41K+D74N in NS1-MA enhance viral 
polymerase activity and thus enhance viral RNA synthesis 
My results suggest that the major impairment of the polymerase of avian FPV-NSMA 
in mammalian cells is due to deficient viral genome replication and transcription, 
which seems to be affected by the NS1. I observed that the reassortment of the FPV-
NSGD and FPV-NSMA differently affected both, replication and transcription and 
thereby the accumulation of viral genomes in the infected cells (See Fig. 3.11 and 
3.13). FPV-NSMA displayed a lower accumulation as well as a delayed peak of viral 
mRNA accumulation compared to FPV-NSGD (See Fig. 3.13), suggesting that NS 
segments can influence the time course of RNA synthesis with is in line to previously 
study that the NS1 protein has been shown previously implicated in the regulation of 
viral RNA synthesis [56, 104, 160, 168, 211], possibly through interaction with the 
viral RNP complex. In addition, NS1 protein also exhibits binding to influenza virus 
RNA [113].  NS1 can be co-immunoprecipitated with the polymerase proteins and NP 
from infected cell lysates [117]. In addition, NS1 interacts with CPSF30, a host RNA 
polymerase II (Pol II)-associated factor involved in the 3′-end processing of host 
mRNAs, in a macromolecular complex also containing viral polymerase and NP 
[161]. I found that the polymerase activity of FPV virus could be increased to a very 
large extent by substituting of NS1-MA segment with NS1-MA segments harboring 
D74N and/or P3S+R41K+D74N. I found that avian FPV-NSMA confers an impaired 
rate of overall RNA synthesis in human cells most likely due to the low transcriptional 
activity of the RdRp and, consequently, the low protein levels expressed in cultured 
cells. FPV-NSMA_D74N and FPV-NSMA_P3S+R41K+D74N were found to increase viral 
polymerase activity in mammalian 293T cell as well as an increase viral mRNA 
synthesis in infected A549 cells, which correlates with increased viral protein 
synthesis compared to FPV-NSMA (See Fig. 3.9, 3.13). This indicates that the 
substitutions D74N and/or P3S+R41K+D74N in NS1-MA protein affect a functional 
interaction between the NS1 and polymerase activity due to direct or indirect 
interactions of the NS1 with viral polymerase components. This hypothesis is in line 
with numerous studies that have linked NS1 action with the ability of influenza virus 
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to synthesize viral RNA or associate with components of the polymerase complex 
[117, 159]. In addition to increased yields of viral mRNA and protein, I observed a 
differential regulation of NP and NS1 protein synthesis relative to FPV-NSMA infected 
cells. NS1-MA mutants D74N and/or P3S+R41K+D74N induced higher levels of NP 
and NS1 protein relative to FPV-NSMA infected cells. This is also demonstrated at the 
level of mRNA synthesis and probably efficiency in mRNA translation. Interestingly, 
other reports have shown that the N-terminal half of the NS1 protein is sufficient for 
nuclear retention of poly (A)-containing RNA and enhancement of viral mRNA 
translation [57]. And given the location of the substitution D74N and/or 
P3S+R41K+D74N within binding domains for cellular factors involved in translation 
(PABPI), I cannot rule out the possibility that enhanced interaction with this factor 
may also contribute to increase levels of virus protein synthesis. 
 
4.5 Substitutions D74N and P3S+R41K+D74N in NS1-MA result in a replication 
advantage at lower temperature 
This study examined the enhancing polymerase activity of the NS1 segment of avian 
virus. Interestingly, FPV-NSGD, FPV-NSMA_D74N and FPV-NSMA_P3S+R41K+D74N were well 
adapted to 33°C (See Fig. 3.16A), which is closer to the temperature of human upper 
airway, but the activity of FPV-NSMA was much lower at this temperature. This 
observation is in line with the fact that the avian FPV-NSMA viruses have limited 
replication in A549 human cells as well as human upper airway, and thus they have a 
lower efficiency in transmission from human to human. 
 
I found that the polymerase activity of FPV-NSMA could be increased to a very large 
extent by substituting the NS1-MA protein with a D74N and/or P3S+R41K+D74N 
which are corresponding to FPV-NSGD, and this effect was more pronounced at 33°C 
(See Fig. 3.16). This is an important concern as such reassortants may be able to 
adapt to the human upper airway and might show an increased human to human 
transmission efficiency. By contrast, at avian gut temperature (41°C), the polymerase 
activity of all viruses are similar. These results clearly demonstrated that optimal 
polymerase activity, due to a better compatibility, is probably required for efficient 
viral replication in given host [212]. Although the underlying mechanism of 
temperature dependency of the polymerase activity is not clear, NS1-MA harbouring 
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D74N and/or P3S+R41K+D74N substitutions are likely to be important for host range 
restriction. The differential quantitative analysis of different viral RNA species (See 
Fig. 3.16B) revealed that substitutions D74N and/or P3S+R41K+D74N on the NS1-
MA enhanced both the transcription and replication activity of the viral polymerase. 
However, notable differences in the profile of transcriptive (mRNA) and replicative 
(vRNA and cRNA) intermediates were observed between 33°C and 37°C. Similar to 
an earlier study showing that mutant influenza viruses encoding C-terminally deleted 
NS1 are thermosensitive and are defective in virus RNA replication and translation of 
late virus mRNAs at 33°C [56]. My results show that at 41°C, all three substitutions 
only resulted in the elevation of vRNA level but not mRNA and cRNA levels, 
suggesting that these substitutions may only enhance the polymerase activity of 
cRNA-dependent vRNA synthesis but not the activity of vRNA-dependent mRNA and 
cRNA synthesis. In contrast, at 33°C, the effect on transcription was stronger than on 
replication. Of note, the substitution D74N in the NS1-MA showed a dramatically 
increase in the mRNA level at 33°C, whereas the increase in levels of cRNA and 
vRNA was less pronounced. Interestingly, P3S+R41K+D74N substitution on the 
NS1-MA showed a dramatically increase in all RNA species level at 33°C. 
 
4.6 What function(s) are affected by the substitutions at position 3, 41, and 74 
of NS1-MA? 
An X-ray crystallographic model shows that the residue at position K41 is located 
within the second-helix spanning amino acids 30 to 50 of the RNA-binding domain 
(RBD) of the NS1 protein [112]. The basic amino acid K41, in this same region has 
previously been reported to be important for inhibiting host IFN induction and 
virulence of influenza A viruses in mice [213]. K41 is also reported to be a part of 
NLS1 [110], and comprises an ISG15 acceptor site, which is also involved in IFN 
production [214]. A recent study reported that the NS1 protein interacts specifically 
with NP and not with the polymerase subunits and amino acid K41 is part of a 
binding site directly involved in the NP interaction. This might be a reason for 
changing in the polymerase activity [159]. Moreover, the N-terminal domain of NS1 
can bind to the host DDX21 RNA helicase. This leads to free PB1, thus inducing 
higher viral RNA and viral protein synthesis [215].  The amino acid N74 is located in 
a linker region (LR) of NS1 and is implicated in replication, pathogenesis, and host 
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range [157, 216-218] probably due to the result of the altered structural flexibility that 
may exists among NS1s due to sequence variations, particularly in the regions close 
to the LR. No biological function is available for residue S3 of NS1. However, it is 
located in the RBD, and it is tempting to speculate that it might influence RNA binding 
of NS1. Taken together, the exact answer to the above question and the exact 
mechanism by which the aa at position 3, 41 and 74 of NS1 affect the adaptation of 
AIV to mammalian hosts currently remains elusive. Interestingly, I found that a high 
percentage of influenza viruses encode S3+K41 in the NS1 in nature, resulting in a 
significant percentage around 94-96% (See Fig. 3.19), which were associated with 
increased polymerase activity and virulence in this study. My data represented the 
fact that just only single mutation (D74N) occur in such virus which already 
possessing 3S+41K in NS1 protein can affect the adaptation of avian influenza 
viruses to mammalian hosts (See Fig. 3.20 and Fig. 3.23). Moreover, introduced 
these single mutation N74 into NS1 of pandemic influenza virus (SOIV-H1N1) and 
H5N1 (A/Thailand/1(KAN-1)/2004), with already possess NS1-S3+K41 and respect 
to high replication in human. We found that these mutant viruses highly replicate in 
human A549 cells compared to wild-type viruses (See Fig. 3.24). This findings 
suggest that acquisition of NS1-N74 for the viruses that already possess NS1-S3+ 
K41, may create viruses with high replicative ability in mammalian, including humans.  
 
 4.7 Pathogenicity of NS1 mutant viruses in mice 
In contrast to cell culture, the reassortant FPV-NSGD and FPV-NSMA viruses show 
similar levels of virulence in mice, with only minor differences. The FPV-NSGD virus 
was slightly more virulent than the FPV-NSMA, as judged by faster weight loss and 
shorter average survival time. However, I demonstrate that S3, K41 and N74 (FPV-
NSMA_P3S+R41K+D74N) act together to affect FPV-NSMA virus virulence. Specifically, I 
found that the overall effect on the virulence on mice of the three combined mutations 
is greater than that of FPV-NSMA and even greater than that of FPV-NSGD. As 
demonstrate by body weight and survival rate (See Fig. 3.18A and 3.18B), FPV-
NSMA_P3S+R41K+D74N infected mice show faster weight loss (weight loss up to 20% at 2 
day post infection) and shorter time until the mice died (all mice succumbed to dead 
at 5 day post infection) compared to FPV-NSGD and FPV-NSMA mice infected that 
succumbed to death at 8 day post infection. My findings emphasize that multiple 
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genetic constellations exist (such as NS1-N74 and NS1-S3+K41) that may render the 
virus highly virulent as demonstrate in mice infected with FPV-NSWT_D74N (already 
possessing NS1-S3+K41) showing high pathogenicity in mice in contrast to wild type 
FPV, which is apathogenic for mice (See Fig. 3.22A and 3.22B). Furthermore, these 
substitutions not only render avian viruses highly virulent in mammalians but also 
render human virus more virulent in mammalian cells as demonstrated in the case of 
SOIV-H1N1 (A/Gießen/6/2009) and H5N1 (A/Thailand/1(KAN-1)/2004) (See Fig. 
3.24). Moreover, functional interactions among genetic constellations as described 
here add significantly to the potential to predict virulence-enhancing mutations. All 
viruses that I studied here, possessed S3+K41 in the NS1 segment, 
A/FPV/Rostock/1934 (H7N1) isolated in 1934, A/Thailand/1(KAN-1)/2004 (H5N1) 
isolated in 2004 and A/Gießen/6/2009 (H1N1) isolated in 2009, are genetically not 
closely related as shown by phylogenetic tree analysis (data not shown) yet, the 
introduction of the N74 into their NS1 protein made them highly pathogenic. Therefor 
my findings indicate that these amino acids in the NS1 are likely to have a broad 
effect on viral replication and virulence. 
 
4.8 Type I IFN response is enhanced in response to FPV-NSMA infection 
Pathogenesis of influenza A viruses is a multigenic trait, which involves the 
interaction of different viral proteins in host cells. NS1 works as a primary host 
defending factor by inhibiting IFN induction, which is considered as the most powerful 
innate defenses to limit viral replication [19, 219]. Many reports are available to 
demonstrate how NS1 works in host cells to limit the production of IFN. NS1 inhibition 
of antiviral responses is strain-specific and it is likely that certain viruses have 
evolved distinct mechanisms to counter host defences [121, 122]. 
 
In this study, I found that 31 of the common genes that were up-regulated in all 
viruses infected cells are IFN-stimulated genes and these were expressed to the 
highest degree in response to FPV-NSMA infection (Table 3.2, Fig. 3.25). However, 
when D74N (FPV-NSMA_D74N) or P3S+R41K+D74N (FPV-NSMA_ P3S+R41K+D74N) were 
introduced into NS1-MA segment they resulted in a lower number of IFN-related 
gens as well as lower degree of gene expression. For instance, the gene expression 
data indicates an increased expression of IL29 at 6 h following infection with all 
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viruses, but with the highest expression induced by FPV-NSMA infection. IL29 was 
recently recognized as a type III IFN, which signals through a similar JAK-STAT 
pathway as type I IFNs [220]. Type I and III IFN bind to the IFNAR1/IFNAR2 and 
IL10R2/IFNλR1 receptors respectively. Upon binding of IFNs, the corresponding 
receptor subunits dimerize to form the receptor complex and activate JAK-STAT 
signaling, which then results in downstream induction of a range of genes through 
ISGF3, a trimeric transcription factor complex of signal transducer and activator of 
transcription 1 and 2 (STAT1 and STAT2) and IRF9. Downstream genes regulated 
by ISGF3 include viral sensors, antiviral effector molecules, inhibitors of IFN signaling 
and viral sensing, and a range of other IFN-stimulated genes (ISGs). 
 
Amongst the IFN-stimulated genes, I found both positive and negative effectors. A 
number of genes implicated in the antiviral response are up-regulated, many to a 
much higher degree in FPV-NSMA infection. For instance the 2′-5′-oligoadenylate 
synthetases OASL, OAS2, as well as OAS1 were only expressed after FPV-NSMA 
infection, but not other virus infection. OAS is activated by dsRNA, a putative by-
product of viral replication, and polymerizes ATP into 29-59 oligoadenylate chains. 
These chains cause dimerization and activation of the latent RNase, RNase L, which 
inhibits virus replication by degradation of RNA [221]. Data indicate that a 
predominant function of the NS1 RNA-binding domain is to out-compete OAS for 
interaction with dsRNA, thereby inhibiting this host antiviral strategy [143]. Given the 
role of RNase L in augmenting the production of IFN-β [221], it is possible that NS1-
mediated OAS inactivation also contributes to suppression of IFN-β synthesis [203, 
213]. 
 
Several guanylate binding proteins, myxovirus resistance protein 1 (MX1), radical S-
adenosyl methionine domain containing protein 2 (RSAD2), pentraxin related protein 
PTX3, IFN-induced protein with tetratricopeptide repeats 1 (IFIT1) were up-regulated 
to the highest degree in FPV-NSMA infected cells and Zinc finger CCCH-type antiviral 
protein 1 (ZC3HAV1) was only expressed in FPV-NSMA infection. However, as above 
all these genes were down regulated when the substitutions D74N or 
P3S+R41K+D74N were introduced into the NS1-MA. This result strongly supports 
the idea that this substitutions regulate the IFN pathway.  
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4.9 Activation of the poly(ADP-ribose) polymerase IFN response in FPV-NSMA 
infected cells 
In parallel with the type I IFN-mediated activation of the JAK-STAT pathway, FPV-
NSMA also causes the poly(ADP-ribose) polymerase, PARP9 and PARP9 genes 
(Table 3.3), which have been identified as potent inhibitors of replication of a variety 
of alphaviruses and other RNA viruses [222], suggesting a broad-spectrum antiviral 
function via interference with common cellular processes is involved in virus 
replication. PARP9, PARP10 were found to be very potent regulators of cellular 
translation [223]. Their effect on translation was shown to be stronger than that 
described for a well-characterized ISG, the double-stranded RNA (dsRNA)-activated 
protein kinase PKR. PKR was one of the first antiviral proteins described. It interacts 
with virus-specific dsRNA, and this in turn leads to autophosphorylation and 
dimerization of PKR, making it capable of phosphorylating the α-subunit of eukaryotic 
initiation factor 2 (eIF-2α) and thus inducing translation inhibition. Furthermore, the 
inhibitory functions of PARP9 and PARP10 are determined by more than a single 
mechanism, and one of them is based on the ability of these proteins to regulate 
cellular translation. Interference with the cellular translational machinery depends on 
the integrity of both the amino-terminal domain, containing a number of putative 
RNA-binding motifs, and the catalytic function of the carboxy-terminal PARP domain. 
The PARP-induced changes in translation efficiency appear to have a more potent 
effect on the synthesis of virus-specific proteins than on that of cellular proteins, thus 
making PARP-specific translational down-regulation an important contributor to the 
overall development of the antiviral response [222]. Therefore this mechanism could 
be one of the reasons that restrict FPV-NSMA replication in mammalian cells, which is 
not the case in FPV-NSGD, FPV-NSMA_D74N and FPV-NSMA_P3S+R41K+D74N infected cells. 
 
4.10 Apoptosis 
From the microarray data in the present study, I have used the Ingenuity Pathway 
Analysis (IPA) (QIAGEN) to identify the intracellular signaling pathways that were 
most significantly represented in FPV-NSGD, FPV-NSMA, FPV-NSMA_D74N and FPV-
NSMA_P3S+R41K+D74N infected cells using, Fisher's Exact Test (Table 3.6). Apoptosis 
signaling was a suggested response to FPV-NSMA and FPV-NSMA_P3S+R41K+D74N 
infection. Microarray data is in well agreement with the caspase-3 activity and DNA 
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degradation (Tunel assay) (Fig. 3.29) of FPV-NSMA and FPV-NSMA_P3S+R41K+D74N 
infected cells. When the extent of apoptosis is compared to the infectious titres of the 
various viruses it can be concluded that there is no correlation between degree of 
apoptosis and virus titres. 
 
The role of apoptosis in viral replication may vary with different viruses. For example, 
in certain acute viral infections, lytic viruses can utilize host apoptotic cascades to aid 
in cell lysis and virus dissemination [224]. In such cases, the infected cell releases 
the infectious viral particles as well as the immature unpacked viral material including 
dsRNA to the micro-environment. The dsRNA can trigger innate sensing receptors of 
neighbouring cells and trigger apoptosis in these cells which otherwise may have 
hosted additional cycles of virus replication. This is an example of the host initiating 
“altruistic” apoptosis in bystander cells which can lead to limiting viral spread [225]. 
Taken together, further investigation of the pathogenic significance of the early 
expression factors involved in apoptosis signaling in response to FPV-NSMA and 
FPV-NSMA_P3S+R41K+D74N infection observed in my microarray data is necessary. The 
role of apoptosis, as well as whether apoptosis or delayed apoptosis contributes to 
FPV-NSMA and FPV-NSMA_P3S+R41K+D74N pathogenesis through its positive or negative 
effects on viral replication, remain to be determined. Nevertheless, I have shown that 
compared with FPV-NSGD and FPV-NSMA_D74N viruses, FPV-NSMA and FPV-
NSMA_P3S+R41K+D74N infected A549 cells were found to have highest production of 
apoptosis related factor. 
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Chapter 5 
Conclusions 
Zoonotic transmissions of avian influenza viruses pose a constant threat to the 
human population and can cause severe pandemics associated with high fatality. 
Due to effective species barriers, avian influenza virus can establish a new lineage in 
humans only in rare cases. To overcome these species barriers avian influenza virus 
require adaptive mutations in order to achieve high-level replication in the new host. 
Here, I demonstrate that three amino acid substitutions P3S+R41K+D74N in the viral 
NS1 protein prove to be sufficient for a strictly avian influenza virus to achieve high-
level replication in human cell culture and mice. I demonstrate that these adaptive 
substitutions enhanced viral genome replication and transcription, thus contributing to 
the overall viral protein production. This observation raises the possibility that as yet 
unknown molecular features in NS1 could affect the level of polymerase activity. 
Furthermore, the viral polymerase activity is increased at the temperature of the 
human upper respiratory tract. Remarkably, these substitutions do not impair 
replication in avian cells, indicating that such viruses with enhanced replication 
efficiency in mammalian host could be generated in avian hosts. Thus, monitoring for 
these amino acids in avian influenza viruses is important to assess their potential 
zoonotic risk.  
 
The frequency of the amino acids N74 alone or in combination with S3+K41 in the 
NS1 protein sequence was found to be only 0.1-2% available in IAV. Interestingly, 
the aa S3+K41 are already highly conserved in human, avian, swine, and other IAV 
with 94-96% of all virus isolates. My data present here shows that such viruses 
already possess S3+K41 in the NS1 protein, just one further single substitution (N74) 
must occur to gain the combination S3+K41+N74 that could greatly affect the 
adaptive ability of AIV to mammalian hosts. The acquisition of N74 for AIV that 
already possess S3+K41 in their NS1, may create viruses with improved replication 
ability in mammalians, including humans.  
 
My results demonstrate gene expression analysis of A549 cells infected with 
comparable virus doses of the FPV-NSGD, FPV-NSMA, FPV-NSMA_D74N and FPV-
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NSMA_P3S+R41K+D74N viruses, reveals differences at the quantitative rather than at the 
qualitative protein levels. An up-regulation of pathway ligands rather than signaling 
intermediaries appears to be the driving force behind pathway activation in the 
response to FPV-NSGD, FPV-NSMA, FPV-NSMA_D74N and FPV-NSMA_P3S+R41K+D74N. 
However, a role for differential phosphorylation of signaling intermediaries and other 
regulatory mechanisms, such as post-transcriptional regulation by microRNAs, 
cannot be excluded as a contributing mechanism for the activation of host responses. 
Integration of data from complementary approaches will be required in the future to 
further understand the molecular events that lead to viral pathogenesis. 
 
The FPV-NSMA induced hyper-activation of IFN-β, IFN-γ and TNF-α pathways 
synergize to generate a highly pro-inflammatory cytokine/chemokine response that is 
markedly elevated compared to FPV-NSMA_D74N and FPV-NSMA_P3S+R41K+D74N infection 
which harbour amino acids changes in the NS1-MA segment which are likely to 
balance the innate immune system to prevent inflammation, contributing to tissue 
damage. I also observed an increase in inhibitors of certain pathways (e.g. OASL1), 
which may reflect the cell's attempt to shut off IFN and IFN-related pathways that 
have been over-activated in response to FPV-NSMA, but this attempt may themselves 
result in a skew of the innate immune response to one of an increased pro-
inflammatory nature. 
 
It may eventually be possible to exploit these quantitative differences in host 
pathways activated by FPV-NSMA for therapeutic purposes through the use of the 
appropriate inhibitors. Further investigation into the nature of these inhibitors and 
their specific targeting mechanisms is a challenging but critical task, and may 
ultimately result in novel therapeutic strategies that are capable of restoring the 
equilibrium of the host response and minimizing the impact of highly pathogenic 
influenza virus infection on the host. 
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